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1CHAPTER 1: INTRODUCTION
The proliferation of high-throughput genomics technologies has resulted in an abun-
dance of data, for many different biomedical conditions. However, real progress in under-
standing biological mechanisms of disease states still lags far behind the data gathering.
Due to noise, study bias, or too small changes in biological signals between disease and
healthy, individual studies or assays often fail to identify the true phenomenon. This em-
phasizes the need for data integration, as demonstrated by a wave of important discoveries
reported recently in top-notch discovery journals, such as Nature [1–5], Cancer Cell [6–8],
and Cell [9–11], when multiple sources of data are analyzed together.
Given the high demand of computational methods for data integration, my most sig-
nificant research involved developing new methods for horizontal and vertical integration
of large-scale bio-molecular data [12–26]. The former is meta-analysis of independent but
related studies, while the latter is the integration of heterogenous types of data. Each of
the developed techniques was validated using both simulation and real-world data obtained
from thousands of patients. To further assess their practicality, I also applied some of these
techniques in the AstraZeneca-Sanger Drug Combination Prediction DREAM Challenge,
which was jointly organized by AstraZeneca, the European Bioinformatic Institute, Sage
Bionetworks, Sanger Institute, IBM Research, and RWTH Aachen University. Out of more
than 70 teams world-wide, our team was a very close runner-up to the first prize in predicting
synergistic effects of drug combinations on cancer cell lines.
This dissertation is organized as follows. Chapter 2 focuses on horizontal meta-analysis,
introduced in the context of pathway analysis. We discuss the limitations of classical meta-
analyses and then introduce new approaches that offer practical improvements over existing
methods. The proposed techniques are compared with 25 existing meta-analysis approaches
using thousands of real samples obtained from independent studies related to three human
diseases, Alzheimer’s disease, acute myeloid leukemia, and type II diabetes mellitus. Our
frameworks greatly outperform their competitors to consistently identify pathways that are
2relevant to the given phenotypes. Via extensive simulation studies, we also demonstrate that
these methods are sufficiently general to be applied outside the scope of pathway analysis and
biomedical research. The manuscripts describing these horizontal meta-analysis techniques
were published in Bioinformatics [13] and the Proceedings of the IEEE [14].
Chapter 3 focuses on vertical integrative analysis, where multiple types of biomedical
data are integrated for the goal of disease subtyping. We now know that there is no such
thing as “breast cancer” (BC), but rather a multitude of very different BC subtypes, such
as those over-expressing HER2 (HER2+), estrogen receptor (ER+), etc. The treatment
options, as well as the ultimate treatment success, are highly dependent on the specific
tumor subtype, for any given stage. Furthermore, even patients with the same tumor type
may respond very differently to the same treatment, indicating that patients themselves
may fall into different subgroups. The currently unmet challenge is to discover the molecular
subtypes of disease and subgroups of patients in an unbiased way. Many attempts to achieve
this based solely on gene expression have been undertaken but yielded only modest success
so far (very few gene expression tests are FDA approved so far).
We propose a new algorithm, called PINS, that is able to subtype diseases using either
a single or multiple types of data. The framework has been validated on thousands of cancer
samples, using gene expression, DNA methylation, and microRNA data available from the
Gene Expression Omnibus, the Broad Institute, and The Cancer Genome Atlas (TCGA).
This simultaneous subtyping approach accurately identifies known cancer subtypes and novel
subgroups of patients with significantly different survival profiles. The manuscript describing
this work is under peer review by the time this dissertation is being prepared [15, 16].
Chapter 4 focuses on orthogonal meta-analysis that serves as a bridge between the two
orthogonal types of data integration: horizontal and vertical analysis. One bottleneck in
multi-omics data integration is that samples run on different platforms should come from
the same set of patients. This is referred to as the “sample-matched data bottleneck”. This
is an important problem because performing many different assays on the same samples
3is often impractical, as well as very expensive. Furthermore, since the existing approaches
cannot integrate heterogeneous information available across independent experiments, they
neither account for bias inherent in individual studies, nor do they benefit from increased
sample size of the merged data. We proposed a general framework that is able to integrate
unmatched omics data obtained from independent laboratories. The result is to break
the sample-matched data bottleneck, by successfully integrating datasets of different types
generated in independent laboratories from different sets of patients. The paper describing
this work was published in Nature Scientific Reports [12].
Finally, chapter 5 concludes the dissertation by proposing future work and possible
research directions. With the vast amount of biological data of all kinds being generated
everyday, data integration is the key to obtain the power needed to pinpoint the biological
mechanisms of the underlying disease. This document describes important limitations of
current integrative approaches, and provides general statistical approaches to increase the
power of analysis methods. We expect the proposed frameworks to be of interest to a large
spectrum of scientists working in bio-medical research and drug development.
I would also like to note that the work presented in this document is largely derived
from one US patent [15] and four journal articles [12–14, 16], for which I am the first author.
4CHAPTER 2: HORIZONTAL META-ANALYSIS –
APPLIED TO PATHWAY ANALYSIS
2.1 Introduction to pathway analysis
With rapid advances in high-throughput technologies, the generation of various kinds
of high-throughput genomic data is prevalent in most biomedical research. Advanced tech-
niques in sequencing and microarray assays have transformed biological research by enabling
comprehensive monitoring of biological systems. Vast amounts of data of all types have ac-
cumulated in many public repositories, such as Gene Expression Omnibus (GEO) [27], Ar-
ray Express [28], Therapeutically Applicable Research to Generate Effective Treatments
(http://ocg.cancer.gov/programs/target), and The Cancer Genome Atlas (TCGA)
(http://cancergenome.nih.gov). Gene expression data, as measured by microarray and
high-throughput sequencing, are particularly abundant in public repositories, such that
many diseases are represented by a dozen studies or more.
A typical comparative analysis of high-throughput expression data, e.g. patients versus
healthy samples, generally yields a set of genes that are differentially expressed (DE) between
the conditions. These sets of DE genes contains the genes that are likely to be involved in
the biological processes responsible for the underlying disease. However, such sets of genes
are usually insufficient to reveal the underlying biological mechanisms. In addition, due to
inherent bias and batch effects present in individual studies, independent studies of the same
disease often yield completely different sets of DE genes, making interpretation extremely
difficult [29–31].
In order to translate these lists of DE genes into a better understanding of biological
phenomena, researchers have developed a variety of knowledge bases that map genes to func-
tional modules. Depending on the amount of information that one wishes to include, these
modules can be described as simple gene sets based on a function, process or component
(e.g., the Molecular Signatures Database MSigDB [32]), organized in a hierarchical struc-
ture that contains information about the relationship between the various modules, as found
5in the Gene Ontology [33], or organized into pathways that describe in details all known
interactions between the various genes that are involved in a certain phenomenon. Path-
way databases include: the Kyoto Encyclopedia of Genes and Genomes (KEGG) [34, 35],
Reactome [36], and Biocarta (www.biocarta.com).
Analysis techniques have been developed to help interpret such sets of DE genes. The
earliest approaches use Over-Representation Analysis (ORA) [37, 38] to identify gene sets
that have more DE genes than expected by chance. The drawbacks of this type of approach
include that: i) it only considers the number of DE genes and completely ignores expression
changes; ii) it assumes that genes are independent, which they are not; and iii) it ignores
the interactions between various modules. Functional Class Scoring (FCS) approaches,
such as Gene Set Enrichment Analysis (GSEA) [39] and Gene Set Analysis (GSA) [40],
have been developed to address some of the issues raised by ORA approaches. The main
improvement of FCS is the observation that small but coordinated changes in expression of
functionally related genes can have significant impact on pathways. Both FCS and ORA
approaches can be used with gene sets, ontologies, or pathways. However, these approaches
do not account for the hierarchical structure of pathways or interactions between genes.
Topology-based approaches, which fully exploit all the knowledge about how gene interact
as described by pathways, have been developed more recently. The first such techniques
were ScorePAGE [41] for metabolic pathways and the Impact Analysis [42] for signaling
pathways.
2.2 Meta-analysis and limitations
It would be tremendously beneficial if all datasets associated with a given condition
could be analyzed together because of the increase in power expected to be associated
with the much larger number of measurements in the combined dataset. However, batch
effects, patient heterogeneity, and disease complexity all complicate the integration of data
from different sources. Indeed, for the same disease, different studies produce different sets
of differentially expressed (DE) genes [29–31], and we will show that this problem is not
6resolved at the systems level, as pathway analysis results are often inconsistent as well.
To demonstrate the inconsistency of pathway analysis across independent studies, we
downloaded 7 Alzheimer’s datasets from Gene Expression Omnibus: GSE28146 (hippocam-
pus), GSE5281_EC (entorhinal cortex), GSE5281_HIP (hippocampus), GSE5281_MTG
(medial temporal gyrus), GSE5281_PC (posterior cingulate), GSE5281_VCX (primary vi-
sual cortex), and GSE5281_SFG (superior frontal gyrus). These datasets were chosen for
several reasons. First, all the 7 datasets were assayed using the same platform (Affymetrix
Human Genome U133 Plus 2.0). This would limit the heterogeneity of the data. Second,
there is a dedicated pathway in KEGG that was created in order to describe the known
mechanisms involved in Alzheimer’s disease. We expect pathway analysis methods to iden-
tify the target pathway, Alzheimer’s disease, to be the most significant one.
We use 4 pathway analysis methods to process the expression data in each study. Gene
Set Enrichment Analysis (GSEA) [39] and Gene Set Analysis (GSA) [40] are Functional
Class Scoring methods [39, 40, 43, 44], Down-weighting of Overlapping Genes (PADOG)
[43] is an enrichment method [37, 45, 46], and Signaling Pathway Impact Analysis (SPIA)
[47, 48] is a topology-aware method [42, 47]. These methods together have accumulated
tens of thousands of citation (according to Google Scholar). We will demonstrate that the
results vary greatly across different datasets and methods, making the interpretation of the
results very difficult.
For each dataset, each method produces a list of pathways ranked according to their
p-values. For each of these list, we adjust the p-values for multiple comparisons using
FDR [49]. The rankings and FDR-corrected p-values of the pathway Alzheimer’s disease
for the 7 Alzheimer’s datasets are displayed in Figure 2.1. The graphs demonstrate that
the adjusted p-values and rankings of the target pathway vary substantially between the 4
methods for a given study, and from one study to the next. Furthermore, both GSA and
PADOG report the target pathway Alzheimer’s disease as not significant in all 7 studies.
This demonstrates that individual studies fail to shed light on the underlying mechanisms
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Figure 2.1: Ranks (panel A) and p-values (panel B) of the KEGG target pathway, Alzheimer’s disease, for 7 Alzheimer’s
datasets, using the pathway analysis methods: Gene Set Enrichment Analysis (GSEA), Gene Set Analysis (GSA), Signaling
Pathway Impact Analysis (SPIA), and Down-weighting of Overlapping Genes (PADOG). The horizontal axes show the 7
Alzheimer’s datasets. The vertical axis in panel (A) shows the rankings of the target pathway for each dataset using the 4
methods. The vertical axis in panel (B) shows the FDR-corrected p-values of the target pathway. The red horizontal line in
(B) shows the threshold 0.01. Note how the rankings and p-values of the target pathway vary greatly across different datasets
and methods, making the interpretation of the results very difficult.
of diseases. This emphasizes the need of meta-analysis.
Meta-analysis of gene expression data has primarily been used for DE gene detec-
tion [50]. Early meta-analyses simply performed the intersection or union of DE gene lists
obtained from individual studies [51, 52]. Such approaches are useful for demonstrating
consistency when combining a few studies. However, when combining many studies, Venn
diagrams are either too conservative (for intersection) or too anti-conservative (for union),
while vote counting is statistically inefficient [50, 53, 54]. Rhodes et al. [55] were among the
earliest to apply sophisticated meta-analysis methods for DE gene detection. In their work,
p-values from multiple prostate cancer datasets were combined using Fisher’s method [56].
Since then, other p-value based meta-analysis methods have been applied, such as Stouf-
fer’s method [57], minP [58], maxP [59], weighted Fisher’s method [60], and latent variable
approaches [61]. A recent literature review [50] revealed that p-value based meta-analysis
for gene detection accounts for approximately twice as many studies as any other type of
meta-analysis, and is favored for its simplicity and extensibility. Therefore, we will focus on
this type of p-value based meta-analysis, investigate its limitations, and address them with
new approaches.
Recently, meta-analysis has also been used to combine multiple experiments at the
8pathway level [62, 63]. Kaever et al. [63] used classical methods, such as Fisher’s method
and Stouffer’s method, to combine p-values of pathways from independent studies. Shen et
al. [62] introduced a dedicated approach, named MetaPath, that performs meta-analysis at
both the gene and pathway level separately, and then combines the results to give the final
p-value and ranking of pathways. For gene level analysis, MetaPath calculates a t-statistic
for each gene in each study, then combines them using the maxP method [59]. A pathway
enrichment score is calculated using these genes, for each pathway, using a Kolmogorov-
Smirnov test, and assessed for significance with a sample-wise permutation test. At the
pathway level, MetaPath calculates pathway enrichment for each individual study, then
combines the p-values, again using the maxP method [59]. Finally, p-values from the gene
and pathway level are integrated using minP [58] to give the final p-value and ranking of
pathways.
One major limitation of the classical methods of combining p-values, including Fisher’s,
Stouffer’s, minP, and maxP, is that they are sensitive to outliers. For example, Fisher’s
method employs the log product of individual p-values and thus, a single p-value of zero in
one individual case will result in a combined p-value of zero regardless of the other p-values.
This can be a serious problem for pathway analysis methods that employ a finite number of
iterations to construct an empirical distribution of a statistic which is then used to calculate
an empirical p-value. If the observed value of the statistic is more extreme than any of the
values obtained by the iterations, such methods may report a p-value of zero, which will, in
turn, dramatically influence the meta p-value. The same is true for the minP, maxP, and
Stouffer’s method, where outliers greatly influence the combined p-values. In Section 2.3,
we provide a detailed discussion and how to address this limitation by utilizing the additive
method [64] and the Central Limit Theorem [65].
In addition, existing meta-analysis methods work under the assumption that the p-
values provided by the individual statistical tests follow a uniform distribution under the
null hypothesis. Previous reports describe non-uniform distributions of p-values under the
9null as due to specific factors such as improper normalization, cross-hybridization, poorly
characterized variance, and heteroskedasticity in microarray data analysis [66, 67], or even
due to properties of some more general distributions [68]. In Section 2.4, we show that this
assumption does not hold in the realm of pathway analysis methods, severely compromising
the reliability of the results. We also propose a new meta-analysis that learns from the
data under the null hypothesis and compensates for any bias potentially introduced by an
individual hypothesis testing methods.
Another drawback of existing p-value based meta-analysis approaches is that, because
they perform just one statistical test for each individual experiment, they may not fully
exploit the potentially large number of samples within each study. A statistical test which
is not powerful enough to reject the null hypothesis in one individual experiment can only
derive power by amassing a large number of experiments. Low power in the case of a single
experiment can be due in part to a mathematical design which favors a moderate number
of samples, but may fail to fully exploit large sample sizes. For example, the basic t-test is
designed to do well even with a small number of samples in each group. While the power
of the t-test increases as the number of samples increases, a set of 20 experiments with 5
samples each has more power than a single experiment comprised of the same 100 samples.
In Section 2.5, we propose a novel bi-level meta-analysis approach that makes better use of
the available number of samples within individual studies. We demonstrate the power of the
bi-level meta-analysis in the context of pathway analysis as well as in general applications.
2.3 Combining independent p-values
We first describe classical methods for combining p-values, such as Fisher’s method
and the additive method, then discuss some of their limitations. Subsequently, we introduce
our technique that is able to address the limitations.
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2.3.1 Fisher’s method
Fisher’s method [56] is one of the most widely used methods for combining independent
p-values. Considering a set of m independent significance tests, the resulting p-values P1,
P2, . . . , Pm are independent and uniformly distributed on the interval [0, 1] under the
null hypothesis. Denoting Xi = −2 lnPi (i ∈ {1, 2, . . . ,m}) as new random variables, the
cumulative distribution function of Xi can be calculated as follows:
Fi(x) = Pr(Xi ≤ x) = Pr(−2 lnPi ≤ x) = Pr(Pi ≥ ex2 )
=
∫ 1
e−
x
2
f(p)dp = 1− e−x2
The above function is the cumulative distribution function of a chi-squared distribution
with two degrees of freedom (χ22). Since the sum of chi-squared random variables is also
a chi-squared random variable, −2∑mi=1 ln(Pi) follows a chi-squared distribution with 2m
degrees of freedom (χ22m). In summary, the log product of m independent p-values follows
a chi-squared distribution with 2m degrees of freedom:
X = −2
m∑
i=1
ln(Pi) ∼ χ22m (2.1)
We note that if one of the individual p-values approaches zero, which is often the case
for empirical p-values, then the combined p-value approaches zero as well, regardless of
other individual p-values. For example, if P1 → 0, then X →∞ and therefore, Pr(X)→ 0
regardless of P2, P3, . . . , Pm. This can be a serious problem for methods in pathway analysis
and other biomedical research areas that employ a finite number of iterations to construct
an empirical distribution of a statistic which is then used to calculate an empirical p-value.
If the observed value of the statistic is more extreme than any of the values obtained by
the iterations, such methods may report a p-value of zero, which will, in turn, dramatically
influence the meta p-value. This limitation is also true for other classical methods, such as
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Stouffer’s method [57], maxP [59], and minP [58].
2.3.2 The additive method
The additive method [64] uses the sum of p-values as the summary statistic, instead of
the log product. Let us denote the p-values resulting from the m independent significance
tests as P1, P2, . . . , Pm. These p-values are independent and uniformly distributed between
zero and one under the null (i.e. all p-values between zero and one are equally probable when
the null hypothesis is true). Denote the sum of these p-values, X =
∑m
i=1 Pi (X ∈ [0,m]),
as the new random variable. X is known to follow the Irwin-Hall distribution [69, 70] with
the following probability density function (pdf):
f(x) =
1
(m− 1)!
bxc∑
i=0
(−1)i
(
m
i
)
(x− i)m−1 (2.2)
Unlike Fisher’s method, the additive method is not sensitive to small individual p-values.
However, we note that the additive method faces a different practical problem. For large
values of m, Equation (2.2) involves some intensive computation due to a sum of combi-
natorial and division by a factorial, the result of which can lead to arithmetic underflow
and overflow problems. In other words, the factors can be numbers smaller or bigger than
what a computer can actually store in memory. Panels a and b in Figure 2.2 display the
Irwin-Hall probability density function (pdf) and the area under the pdf curve (AUC) for
different m values. For each value of m, the area under the curve, F (X = m), should be
1 and therefore the log absolute value of F (X = m) should be 0. However, the calculation
is not accurate for large values of m and the area under the curve increases very rapidly
(panel b). The calculation of the additive method is not reliable when m > 30.
2.3.3 The application of the Central Limit Theorem: add-CLT
Here we describe an enhancement to the additive method that makes it more reliable
for larger values of m. First, we change the random variable from the sum of the p-values
to the average of the p-values. Second, when m is large, we replace the additive method
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Figure 2.2: Probability density functions (pdf) and the area under the pdf curve (AUC) of the Irwin-Hall and add-CLT
distributions. In (A), the left panel displays the pdf of the Irwin-Hall distribution for different values of m. The horizontal axis
displays the values of the random variable X ∈ [0,m] while the vertical axis displays the density of X. The right panel shows
the AUC calculated by a 64-bit implementation of R (version 3.1.1, 2014-Jul-10). The horizontal axis shows increasing values
of m while the vertical axis shows the log absolute value of F (X = m), i.e. the area under the entire pdf curve. For each value
of m, F (X = m) should be 1 and therefore the log absolute value of F (X = m) should be 0. However, due to the complexity
of the Irwin-Hall formula and arithmetic underflow, the calculation is completely unreliable when m > 30. Similarly, the left
panel in (B) displays the pdf for different values of m. The horizontal axis shows the random variable Y ∈ [0, 1] while the
vertical axis shows the density of Y . For m < 20, we use the linear transformation of the Irwin-Hall distribution to calculate
the pdf of Y . For m ≥ 20, we use the normal distribution with mean µ = 1
2
and variance σ2 = 1
12m
to calculate the pdf of
Y (Central Limit Theorem). The right panel shows the log absolute value of G(Y = 1), i.e. the area under the entire pdf
curve. For each value of m, G(Y = 1) should be 1 and therefore the log absolute value of G(Y = 1) should be 0. The right
panel shows that the add-CLT method overcomes the computational problem presented in the classical additive method using
Irwin-Hall distribution.
with the Central Limit Theorem (CLT). The reason for the modification is that the additive
method is accurate for small values of m, while the Central Limit Theorem is more accurate
for large values of m. We select m = 20 as a conservative cut-off. In other words, we will
use the additive method when m < 20, and the Central Limit Theorem when m ≥ 20.
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To show the validity of using the Central Limit Theorem for large m, we define a new
random variable Y =
∑m
i=1 Pi
m
(Y ∈ [0, 1]), which is the average of p-values. Since Y = X
m
,
we can derive the probability density function (pdf) of Y using a linear transformation of
X as follows:
g(y) =
m
(m− 1)!
bm·yc∑
i=0
(−1)i
(
m
i
)
(m · y − i)m−1 (2.3)
The corresponding cumulative distribution function (cdf) can be calculated as:
G(y) =
1
m!
bm·yc∑
i=0
(−1)i
(
m
i
)
(m · y − i)m (2.4)
The variable Y is the mean ofm independent and identically distributed (i.i.d.) random
variables (the p-values from each individual experiment), that follow a uniform distribution
with a mean of 1
2
and a variance of 1
12
. From the Central Limit Theorem [65], the average
of such m i.i.d. variables follows a normal distribution with mean µ = 1
2
and variance
σ2 = 1
12m
, i.e. Y ∼ N (1
2
, 1
12m
) for sufficiently large values of m.
In the rest of the document, we refer to our proposed combination of the Irwin-Hall
distribution and the Central Limit Theorem as “add-CLT”, for “additive-Central Limit The-
orem”, in order to distinguish it from the classical additive method. As noted above, the
transition from the additive method to the Central Limit Theorem takes place at them ≥ 20
threshold. The pdf of Y for different m values and the corresponding AUCs are displayed
in panels c and d in Figure 2.2. The data show that the AUC is 1 as it should be, for all
values of m. We can see that add-CLT overcomes the computational problem of the classical
additive method using the Irwin-Hall distribution. We favor add-CLT for several reasons.
First, it is robust against small p-values and against bias under the null. Second, it is more
powerful than Fisher’s method in detecting changes in signal as will demonstrate with the
simulation studies.
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2.3.4 Simulation studies: add-CLT versus Fisher’s method
Here we compare the add-CLT method with Fisher’s method, and show that the add-
CLT method is more powerful and more robust to bias and outliers. Both Fisher’s method
and add-CLT work under the assumption that the p-values provided by the individual statis-
tical tests follow a uniform distribution under the null hypothesis. Previous reports describe
non-uniform distributions of p-values under the null due to specific factors such as improper
normalization, cross-hybridization, poorly characterized variance, and heteroskedasticity in
microarray data analysis [66, 67], or even due to properties of some other more general dis-
tributions [68]. Therefore, we need to investigate how robust the two meta-analysis methods
are, Fisher’s method and add-CLT, against weak bias of p-values under the null.
Here we construct a distribution of 40, 000 p-values. This distribution is slightly bi-
ased towards zero with distribution mean 0.498. In Figure 2.3, the left panel shows the
distribution of the p-values under the null while the middle and right panels show the false
positive rate (FPR) of Fisher’s method and add-CLT. For a given value of m as the number
of studies, we calculate the FPR of a meta-analysis method as follows. We randomly pick
m p-values from the null distribution and then combine them into one combined p-value.
We repeat the process 1, 000 times to have 1, 000 combined p-values. We then calculate
the FPR of the meta-analysis method for the given value of m as the number of combined
p-values that are smaller than the threshold 0.01 divided by 1, 000. We calculate the FPR
of both meta-analysis methods for all values of m in the range between 1 and 50.
The middle panel of Figure 2.3 shows that the FPR of Fisher’s method increases linearly
with the number of studies. The FPR of Fisher’s method is at 1% with one study, and then
reaches 5% and 10% with 20 and 40 studies, respectively. This indicates that Fisher’s method
is sensitive to weak bias under the null. The right panel of Figure 2.3 shows that the FPR
of add-CLT constantly at 1 − 2% regardless of the number of studies to be combined. In
summary, add-CLT is robust against bias under the null.
Theoretically, when there are no disease effects, individual p-values are equally probable
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Figure 2.3: False positive rate (FPR) of Fisher’s and the add-CLT method. The method add-CLT is a combination of the
additive method and the Central Limit Theorem. The left panel shows a slightly biased distribution of 40, 000 p-values under
the null (with mean of 0.498). The horizontal axis displays the p-values while the vertical axis displays the density. The
middle and right panels display the FPR using Fisher’s method and add-CLT, respectively, varying the number of studies
to be combined. The horizontal axes display the number of studies to be combined while the vertical axes display the FPR.
Given m as the number of studies, we calculate the FPR of a meta-analysis method as follows. We randomly pick m p-values
from the distribution and then combine them to have one combined p-value. We repeat the process 1000 times to have 1000
combined p-values. We then compute the FPR as the number of combined p-values that are smaller than the significance
threshold (0.01) divided by 1000. The false positive rate of Fisher’s method increases linearly with the number of studies. The
FPR of Fisher’s method is around 1% with one study, and then reaches 5% and 10% with 20 and 40 studies, respectively. On
the contrary, the FPR of add-CLT is constantly near 1 − 2% regardless of the number of studies to be combined. The figure
shows that add-CLT is more robust against weak bias compared to Fisher’s method.
between zero and one. Let us now consider the distribution of the p-values for those pathways
(or genes) that are truly implicated in the condition over a number of datasets. Some of the
truly implicated pathways will have individual p-values that are smaller than the significance
threshold, will be identified as relevant and therefore will be true positives. Others, will
have p-values higher than the significance threshold, will not be identified as relevant and
therefore will be false negatives. Let us denote ξ as the empirical distribution of p-values
only for the truly implicated pathways. It is reasonable to assume that the mean of this
distribution is notably smaller than 0.5.
We simulate three cases of ξ as shown in Figure 2.4. The left-most panels show the
distribution of the p-values. Each distribution consists of 40, 000 p-values. In these panels,
the horizontal axes represent the p-values while the vertical axes represent the density of
p-values. The middle and right panels show the true positive rate of Fisher’s method and
add-CLT, varying the number of studies to be combined. Given m as the number of studies
to be combined, we calculate the TPR of a meta-analysis method as follows. We randomly
sample m p-values from ξ and then combine them into one combined p-value. We repeat
the process 1, 000 times to have 1, 000 combined p-values. We then compute the TPR for
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m as the number of combined p-values that are smaller than 0.01 divided by 1, 000.
In the first case (A), the p-values are highly concentrated near zero and are almost
uniformly distributed in the rest of the interval. In this case, Fisher’s method has a higher
true positive rate than add-CLT. With 20 studies to be combined, the TPR of Fisher’s
method is higher - about 40% compared to 20% for add-CLT. The advantage of Fisher’s is
due to the fact that it favors extremely small p-values. However, this kind of distribution
is not likely to represent the p-values of the truly implicated pathways. One would not
expect these p-values to be distributed uniformly on most of the interval [0, 1] as shown in
Figure 2.4A, but rather highly concentrated below the significance threshold.
In the second case (B), the density of the p-values linearly increases with the decreasing
p-value. In this case, add-CLT has more power than Fisher’s method. With 20 studies to be
combined, the TPR of add-CLT is 50% while the TPR of Fisher’s method is 30%. Although
the mean of the distribution in (B) is smaller than that in (A), Fisher’s method loses power
because the p-values are less concentrated near zero. On the contrary, add-CLT gains power
because the distribution mean decreases.
In the third case (C), the density of p-values peaks at 0.2 but the mean of the distribu-
tion is even smaller than in (A) and (B). In this case add-CLT is much more powerful than
Fisher’s method. One likely reason for the shift in power of the two meta-analysis methods
is that add-CLT’s power greatly improves when the distribution mean decreases. The sec-
ond reason is that Fisher’s method loses power because the p-values are less concentrated
near zero. With 20 studies, the TPR of add-CLT is 80% compared to less than 30% TPR
of Fisher’s method.
The three cases in Figure 2.4 are sorted with the decreasing order of distribution mean
of p-values. One would expect that a meta-analysis method would gain more power when
the distribution of p-values shifts towards zero. However, Fisher’s method loses power in
this scenario due to its sensitivity to extremely small p-values, which are less frequent in this
scenario. With 20 studies, the TPR of Fisher’s method decreases from 40% in (A) to less
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Figure 2.4: Comparison of true positive rates (TPR) obtained by applying Fisher’s and the add-CLT method to three simulated
data distributions. The left-most panels in each row show the simulated p-value distributions, ordered by decreasing mean.
The horizontal axes of these panels display the p-values while the vertical axes display the densities. The middle and right
panels display the TPR using Fisher’s method and add-CLT, respectively, with varying numbers of studies to be combined.
The horizontal axes display the number of studies to be combined while the vertical axes display the TPR. Given m as the
number of studies to be combined, we calculate the TPR of a meta-analysis method as follows. We randomly pick m p-values
from the corresponding distribution and then combine them to have one combined p-value. We repeat the process 1000 times
to have 1000 combined p-values. We then compute the TPR of the method as the number of combined p-values that are
smaller than the threshold 0.01 divided by 1000. In (A), we see that Fisher’s method has more power than add-CLT when
the p-values are highly concentrated near zero, and are almost uniformly distributed elsewhere. In (B), add-CLT is more
powerful than Fisher’s method when the density of p-values increases linearly with decreasing of p-values. In (C), add-CLT is
much more powerful than Fisher’s method when the density peaks at 0.2. Interestingly, Fisher’s method loses power when the
distribution mean decreases. This shows that Fisher’s method is highly sensitive to the shape of the distribution of p-values.
On the contrary, the power of add-CLT increases quickly when the distribution mean decreases, regardless of the shape of the
distribution.
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than 30% in (C). On the contrary, add-CLT’s power greatly increases when the distribution
mean decreases. For example, with 20 studies, the TPR of add-CLT increases from 20%
to 80% when the distribution mean decreases from 0.41 to 0.309. We conclude that add-
CLT has some advantage over Fisher’s method in terms of both false positive rate and true
positive rate.
2.4 DANUBE: Data-driven meta-ANalysis using UnBiased Em-
pirical distributions
We first describe the pitfalls of statistical methods applied in the context of pathway
analysis. We then propose DANUBE (Data-driven meta-ANalysis using UnBiased Empirical
distributions), a new meta-analysis framework which can combine the p-values of multiple
studies in a better way. Our simulation experiments demonstrate that both type I and type
II errors of DANUBE are better than those of classical meta-analysis approaches using both
parametric and non-parametric tests.
We apply DANUBE in the context of pathway analysis using 16 public gene expression
datasets from two biological conditions, and 4 different pathway analysis methods. Gene
Set Enrichment Analysis (GSEA) [39] and Gene Set Analysis (GSA) [40] are Functional
Class Scoring methods [39, 40, 43, 44], Down-weighting of Overlapping Genes (PADOG)
[43] is an enrichment method [37, 45, 46], and Signaling Pathway Impact Analysis (SPIA)
[47, 48] is a topology-aware method [42, 47]. These pathway analysis methods are applied
on the human signaling pathways from KEGG [34, 35].
We show that with the exception of GSEA, each of the other three methods GSA, SPIA,
and PADOG have different biases, leading to non-uniform distributions of p-values under
the null hypothesis. Not surprisingly, when combining p-values using classical methods such
as Fisher’s or the additive method, each of the three pathway analysis methods (GSA, SPIA,
and PADOG) yields a very different list of significantly impacted pathways. We then apply
the DANUBE framework using the empirical distributions characteristic to each of these
methods. The DANUBE results yield much more consistent lists of significant pathways
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that are also pertinent to the phenotypes.
2.4.1 Pitfalls of statistical methods
Null distributions are used to model populations so that statistical tests can determine
whether an observation is unlikely to occur by chance. The p-values produced by a sound
statistical test must be uniformly distributed in the interval [0,1] when the null hypothesis
is true [66–68, 71]. For example, the p-values that result from comparing two groups using
a t-test should be distributed uniformly if the data are normally distributed [68]. When
the assumptions of statistical models do not hold, the resulting p-values are not uniformly
distributed under the null hypothesis. We will demonstrate this fact using gene expression
data and pathway analysis.
Using 74 control samples from the 7 Alzheimer’s datasets (GSE28146, GSE5281_EC,
GSE5281_HIP, GSE5281_MTG, GSE5281_PC, GSE5281_SFG, and GSE5281_VCX), we
simulate 40, 000 datasets as follows. We randomly label 37 as “control” samples and the
remaining 37 as “disease” samples. We repeat this procedure 10, 000 times to generate
different groups of 37 control and 37 disease samples. To make the simulation more general,
we also create 10, 000 datasets consisting of 10 control and 10 disease samples, 10, 000
datasets consisting of 10 control and 20 disease samples, and 10, 000 datasets consisting of
20 control and 10 disease samples. We then calculate the p-values of the KEGG (version 65)
human signaling pathways using the following methods: GSEA [39], GSA [40], SPIA [47, 48],
and PADOG [43].
Figure 2.5 displays the empirical null distributions of p-values using GSA, SPIA, and
PADOG. The horizonal axes represent p-values while the vertical axes represent p-value
densities. Blue panels (A0–A6) show p-value distributions from GSA, while purple (B0–B6)
and green (C0–C6) panels show p-value distributions from SPIA and PADOG, respectively.
For each method, the larger panel (A0, B0, and C0) shows the cumulative p-values from all
KEGG signaling pathways. The small panels, 6 per method, display extreme examples of
non-uniform p-value distributions for specific pathways. For each method, we show three dis-
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tributions severely biased towards zero (eg. A1–A3), and three distributions severely biased
towards one (eg. A4–A6). The most extreme null distributions (for individual pathways)
that are biased toward zero are displayed in Figures 2.6, 2.7, and 2.8.
These results show that, contrary to generally accepted beliefs, the p-values are not
uniformly distributed for three out of the four methods considered. Therefore one should
expect a very strong and systematic bias in identifying significant pathways for each of these
methods. Pathways that have p-values biased towards zero will often be falsely identified
as significant (false positives). Likewise, pathways that have p-values biased towards one
are likely to rarely meet the significance requirements, even when they are truly implicated
in the given phenotype (false negatives). Systematic bias, due to non-uniformity of p-value
distributions, results in failure of the statistical methods to correctly identify the biological
pathways implicated in the condition, and also leads to inconsistent and incorrect results.
The effect of combining control (i.e. healthy) samples from different experiments is to
uniformly distribute all sources of bias among the random groups of samples. If we compare
groups of control samples based on experiments, there could be true differences due to batch
effects. By pooling them together, we form a population which is considered the reference
population. This approach is similar to selecting from a large group of people that may
contain different sub-groups (e.g. different ethnicities, gender, race, or living conditions).
When we randomly select samples (for the two random groups to be compared) from the
reference population, we expect all bias (e.g. ethnic subgroups) to be represented equally
in both random groups and therefore, we should see no difference between these random
groups, no matter how many distinct ethnic subgroups were present in the population at
large. Therefore, the p-values of a test for difference between the two randomly selected
groups should be equally probable between zero and one.
We apply this procedure for the popular Gene Set Enrichment Analysis (GSEA) [39] us-
ing the exact same 40, 000 datasets simulated from the pool of control samples of Alzheimer’s
data. The resulting p-value distributions are uniform, as displayed in panel A1 in Fig-
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ure 2.10, showing not only that our resampled data correctly models the null, but also that
GSEA is an unbiased test. This supports the idea that the non-uniformity of the distri-
butions is due to the methods rather than the data. We also plot the top 24 most biased
null distributions of GSEA (Figure 2.9) using the exact same data and exact same random
grouping of samples. In each figure, the panels are sorted by the distribution means. The
distributions of GSEA are uniform while those of GSA, SPIA, and PADOG are biased.
Therefore, the bias is indeed due to the methods and not to one specific pathway.
It is important to note that each pathway analysis method is applied as proposed by its
authors. In fact, each pathway analysis method builds its own null and tests it appropriately.
These nulls are constructed including both the disease control samples in each data set.
We capture the bias of each method by repeatedly analyzing the differences between two
groups drawn randomly from the same population. The subgroups that are included in
this population are not important since each subgroup will be sampled proportionally and
included in each of the two groups tested in each iteration. In order to demonstrate this,
we have reconstructed these distributions of the p-values produced by GSEA, GSA, SPIA,
and PADOG using all samples, including the disease samples from all experiments. The
distributions are shown in Figure 2.10. This figure shows that there is no difference between
the distributions of the p-values obtained from a reference population that included only
the controls from all experiments, versus a reference population that includes both controls
and diseases from all experiments.
2.4.2 The DANUBE framework
We propose a new framework for meta-analysis that makes no assumptions on the data
and is therefore expected to perform much better than any of the classical methods when the
individual p-values are not distributed uniformly, as we have shown that it is the case for the
pathway analysis methods. Figure 2.11 displays a flowchart comparison between classical
meta-analysis and DANUBE. Both approaches take m independent studies as input. The
pipeline marked by blue arrows (I–II) shows the classical meta-analysis, and the one marked
22
Cumulative distributions Examples of individual pathways
Distribution of p−values for all pathways (GSA)
p−values
D
en
si
ty
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
1.
2
(A0) Prostate cancer (GSA)
0.0 0.2 0.4 0.6 0.8 1.0
0
1
2
3
4
5
(A1) Adherens junction (GSA)
0.0 0.2 0.4 0.6 0.8 1.0
0
1
2
3
4
(A2) Pathways in cancer (GSA)
0.0 0.2 0.4 0.6 0.8 1.0
0
1
2
3
4
5
(A3)
Ribosome biogenesis in eukaryotes (GSA)
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
1.
2
1.
4
(A4) African trypanosomiasis (GSA)
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
1.
2
1.
4
(A5) Pertussis (GSA)
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
5
1.
0
(A6)
Distribution of p−values for all pathways (SPIA)
p−values
D
en
si
ty
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
5
1.
0
1.
5
2.
0
(B0) Synaptic vesicle cycle (SPIA)
0.0 0.2 0.4 0.6 0.8 1.0
0
1
2
3
4
5
6
7
(B1) Amphetamine addiction (SPIA)
0.0 0.2 0.4 0.6 0.8 1.0
0
1
2
3
4
5
(B2) Pathogenic Escherichia coli infection (SPIA)
0.0 0.2 0.4 0.6 0.8 1.0
0
1
2
3
4
5
6
7
(B3)
Influenza A (SPIA)
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
5
1.
0
1.
5
(B4) Measles (SPIA)
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
5
1.
0
1.
5
(B5) Natural killer cell mediated cytotoxicity (SPIA)
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
(B6)
Distribution of p−values for all pathways (PADOG)
p−values
D
en
si
ty
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
(C0) Adherens junction (PADOG)
0.0 0.2 0.4 0.6 0.8 1.0
0
1
2
3
4
(C1) Prostate cancer (PADOG)
0.0 0.2 0.4 0.6 0.8 1.0
0
1
2
3
(C2) Renal cell carcinoma (PADOG)
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
5
1.
0
1.
5
2.
0
(C3)
African trypanosomiasis (PADOG)
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
(C4) Taste transduction (PADOG)
0.0 0.2 0.4 0.6 0.8 1.0
0
1
2
3
4
5
6
7
(C5) Systemic lupus erythematosus (PADOG)
0.0 0.2 0.4 0.6 0.8 1.0
0
1
2
3
4
5
6
(C6)
Figure 2.5: The empirical null distributions of p-values using: GSA - top, SPIA - middle, and PADOG - bottom. The
horizontal axes display the p-values while the vertical axes display the p-value densities. Panels A0-A6 (blue) show the
distributions of p-values from GSA; panels B0-B6 (purple) show the distribution of p-values from SPIA; panels C0-C6 (green)
show the distribution of p-values from PADOG. The large panels on the left, A0, B0, and C0, display the distributions of
p-values cumulated from all KEGG signaling pathways. The smaller panels on the right display the p-value distributions
of selected individual pathways, which are extreme cases. For each method, the upper three distributions, for example A1-
A3, are biased towards zero and the lower three distributions, for example A4-A6, are biased towards one. Since none of
these p-value distributions are uniform, there will be systematic bias in identifying significant pathways using any one of
the methods. Pathways that have p-values biased towards zero will often be falsely identified as significant (false positives).
Likewise, pathways that have p-values biased towards one are more likely to be among false negative results even if they may
be implicated in the given phenotype.
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Figure 2.6: The 24 most extreme null distributions of GSA generated from 74 control samples of 7 Alzheimer’s datasets. The
panels are sorted by the distribution means. The horizontal axes display the p-values while the vertical axes display the p-value
densities. The data show that GSA is biased towards generating lower p-values for these specific pathways.
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Figure 2.7: The 24 most extreme null distributions of SPIA generated from 74 control samples of 7 Alzheimer’s datasets. The
panels are sorted by the distribution means. The horizontal axes display the p-values while the vertical axes display the p-value
densities. The data show that SPIA is biased towards generating lower p-values for these specific pathways.
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Figure 2.8: The 24 most extreme null distributions of PADOG generated from 74 control samples of 7 Alzheimer’s datasets.
The panels are sorted by the distribution means. The horizontal axes display the p-values while the vertical axes display the
p-value densities. The data show that PADOG is biased towards generating lower p-values for these pathways.
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Figure 2.9: The top 24 most biased null distributions of GSEA generated from 74 control samples of 7 Alzheimer’s datasets.
The panels are sorted by the distribution means. The horizontal axes display the p-values while the vertical axes display the
p-value densities. This figure shows that distributions of the p-values produced by GSEA are reasonably uniform for each of
these pathways.
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Distribution of p−values using controls (PADOG)
p−values
D
en
si
ty
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
(D1)
Distribution of p−values using all samples (PADOG)
p−values
D
en
si
ty
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
(D2)
Figure 2.10: Comparison between the distribution of the p-values obtained from a reference population constructed using only
control samples (left column) and using all samples (right column) for GSEA (A1-A2), GSA (B1-B2), SPIA (C1-C2), and
PADOG (D1-D2). Each of the left panels show the empirical null distribution of p-values generated from 40, 000 simulated
datasets using control samples of Alzheimer’s datasets. Each of the right panels show the empirical null distribution of p-values
generated from 4, 000 simulated datasets using both control and disease of Alzheimer’s datasets. The figure shows that the bias
profiles are almost identical whether the reference population is constructed from controls alone or both controls and disease
samples.
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Figure 2.11: The DANUBE framework for meta-analysis. The blue arrows (I and II) show the classical meta-analysis pipeline
while black arrows (1-4) show the pipeline of DANUBE. The first step (I) of the classical approach is to perform a parametric
or non-parametric test for each study. This step provides individual p-values which are independent and identically distributed
(i.i.d.), but not necessarily uniformly distributed under the null, as shown in Figure 2.5. The second step (II) of the classical
approach is to use a classical method, such as Fisher’s, to combine the individual p-values, relying heavily on the assumption
of uniformity under the null. In step (1) of DANUBE, we choose the discriminating statistic and calculate the values of this
statistic in each study (t1, t2, . . . , tm). In step (2), we generate the empirical distribution ξT of the discriminating statistic
under the null hypothesis. In step (3), we calculate the probability of observing t1, t2, . . . , tm using ξT . In step (4), we combine
the m empirical p-values using the add-CLT method.
by black arrows (1–4) is DANUBE.
The classical approach first calculates a p-value for each study using a parametric or
non-parametric test, then it combines the individual p-values into one. The main limitation
of the classical approach is that it relies on the assumption of uniformity of the p-values
under the null hypothesis, which often does not hold true. As shown in Figure 2.5, this
assumption is not true for real transcriptomics data and KEGG pathways.
In the DANUBE framework, instead of modeling the data under a specific assumption,
we construct empirical distributions and use them to calculate empirical p-values. Following
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the black arrows (1–4) in Figure 2.11, we initially calculate the values t1, t2, . . . , tm of the
discriminating statistic for the m studies in step (1). For example, instead of using a
statistical test to directly calculate the p-values, we could calculate the means of the data
samples over the m studies. In step (2), we construct the empirical null distribution ξT for
the chosen statistic. In step (3), we calculate the empirical p-values ep1, ep2, . . . , epm for
the m studies with respect to the empirical null distribution ξT . For all i ∈ {1, 2, . . . ,m},
epi is calculated as the number of elements in ξT more extreme than ti, divided by the total
number of elements in ξT . We will prove that the resulting empirical p-values are uniformly
distributed under the null hypothesis.
Lemma 1. Let T be a random variable with the empirical distribution ξT and the cumulative
distribution function FT (T ). We define the new random variable X as follows:
X =
|{x : x ∈ ξT ∧ x ≤ T}|
|ξT | (2.5)
where the numerator represents the number of elements of ξT that are smaller than or equal
to T . If ξT consists of enough data points to be considered as continuous, then X is uniformly
distributed on the interval [0,1].
Proof. Denote FT (T ) as the cumulative distribution function of T. For any value t ∈ ξT ,
FT (t) can be calculated as follows:
FT (t) =
|{x : x ∈ ξT ∧ x ≤ t}|
|ξT | (2.6)
We can see that X = FT (T ). In addition, FT (t) is a strictly increasing function for all values
t ∈ ξT . Let FX(X) be the cumulative distribution function of X, we have the following
30
formula:
FX(x) = Pr(X ≤ x)
= Pr(FT (T ) ≤ FT (t))
= Pr(T ≤ t) = FT (t) = x
(2.7)
We note that FX(x) = x is the cumulative distribution function of the continuous uni-
form distribution on [0,1]. Therefore, if we have enough data for FT (T ) to be considered
continuous, then X will be a uniformly distributed random variable.
In step (4), we combine the empirical p-values using the add-CLT method. According
to Lemma 1, the resulting p-values after step (3) are now truly uniformly distributed under
the null hypothesis and thus can be combined using the new method add-CLT. However, the
additive method can be computationally intensive when m is large. For this reason, we use
the CLT to approximate the combined p-value [72]. The uniform distribution has mean and
variance of 1
2
and 1
12
, respectively. According to the CLT, the average of m independent and
identically distributed (i.i.d.) variables (with large m) follows a normal distribution with
mean µ = 1
2
and variance σ2 = 1
12m
. By default, we use this to approximate the combined
p-value when m ≥ 20. We note that the additive method of combining p-values in our
framework may be substituted by any other method of combining p-values.
2.4.3 The application of DANUBE in pathway analysis
Here we present the application of DANUBE in the context of pathway analysis (Figure
2.12). Let us consider a method M , which can be GSEA, GSA, SPIA, or PADOG, or any
other method that outputs a p-value for each pathway in the pathway database. We treat
this p-value as the discriminating statistic. In step (1), we calculate the p-values of the
pathways using the method M . A pathway i will have m p-values (pi1, pi2, . . . , pim) for
the m studies. The m p-values for a pathway are independent and identically distributed
(i.i.d.). However, these p-values are not necessarily uniformly distributed under the null
hypothesis (see Figure 2.5). Therefore, combining these p-values will lead to systematic
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bias in identifying significant pathways as shown in Section 2.4.1. Instead of combining
these p-values, we treat them as observed values of the discriminating statistic.
To calculate the probability of observing such values, we need to construct the empirical
distribution under the null hypothesis as described in steps (2-5) above. In step (2), we take
all of the control samples from the m studies to create a set of control samples as shown in
(C) in Figure 2.12. In step (3), we generate the k synthetic datasets by random sampling
from the pool of control samples. For example, for a simulation, we choose two groups of
samples from the pool and label them as controls and diseases. In our case study using the
Alzheimer’s datasets, as described in Section 2.4.1, we generated 10, 000 simulations of 10
control and 10 disease samples, 10, 000 simulations of 10 control and 20 disease samples,
10, 000 of 20 control and 10 disease samples, and 10, 000 of 37 control and 37 disease samples,
for a total of 40, 000 simulations.
After generating k simulations from the control samples, we proceed to calculate the
p-values for each pathway and each simulation using the same method M . For a pathway
i, we have a set of p-values spi1, spi2, . . . , spik. Since all of these p-values are calculated
from the real control samples (i.e. healthy people), they can be considered as p-values under
the null hypothesis. These p-values will be used to construct the empirical distribution ξi
in step (5). In summary, steps (2-5) produce an empirical distribution for each pathway,
resulting in a total of n empirical distributions for n pathways. These distributions will be
used to calculate the empirical p-values of the measurements done in step (1).
After steps (1–5), for a pathway i, we have m p-values pi1, pi2, . . . , pim and an empirical
distribution ξi. Using the formula described in Equation (2.3), we calculate the empirical
p-values epi1, epi2, . . . , epim. As we showed in the Methods section, these empirical p-
values are independent and uniformly distributed under the null hypothesis. In step (7),
we combine these empirical p-values using the add-CLT method to have a single p-value
pDANUBEi for pathway i.
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Figure 2.12: DANUBE’s application in pathway analysis. The input is m studies (datasets), and a pathway database. Step
(1): perform pathway analysis using a method M (eg. GSA, SPIA, or PADOG). For each pathway, the resulting m p-values
are independent and identically distributed (i.i.d.). However, these p-values are not uniformly distributed under the null
hypothesis (see Figure 2.5), and therefore combining them would result in systematic bias. Step (2): pool the control samples
from the m datasets to produce a large set of control samples. Step (3): generate k simulated datasets by randomly sampling
from the pool. Step (4): perform pathway analysis on the simulated data. Step (5): build an empirical distribution for each
pathway, which consists of k p-values obtained under the null hypothesis. Step (6): calculate an empirical p-value for each
p-value obtained from step (1). For example, using the empirical distribution ξ1, we calculate the empirical p-value ep11 as
the probability of observing a p-value more extreme than p1, i.e., ep11 = |{sp1i ≤ p11, i ∈ [1..k]}|. Step (7): combine the m
empirical p-values obtained for each pathway using the add-CLT method.
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2.4.4 Results and validation
In this section we illustrate the limitations of combining p-values using classical meta-
analysis approaches, and show that DANUBE overcomes these limitations. Sections 2.4.4.1
and 2.4.4.2 compare the classical approaches with DANUBE for the specific application
domain of pathway analysis. Sections 2.4.5.1 and 2.4.5.2 compare the classical meta-analysis
approaches with DANUBE in the general case, applicable to any meta-analysis.
For the pathway analysis applications, we compare DANUBE with 5 classical meta-
analysis methods: Stouffer’s, Z-method, Brown’s, Fisher’s, and the additive method [56, 57,
63, 73], each of them combined with each of the 4 pathway analysis methods (GSEA, GSA,
SPIA, and PADOG). We also compare these methods with a stand-alone meta-analysis
method, MetaPath. In total, we analyze the results of 25 approaches: 6 meta-analyses
combined with 4 pathway analysis methods, plus MetaPath [62, 74]. Each of these methods
is tested on two diseases, one is Alzheimer’s disease with 7 and the other is acute myeloid
leukemia (AML) with 9 datasets. These conditions were selected for two reasons. First,
there is a pathway in KEGG for each of the diseases. We refer to this as the target pathway,
and use it to validate the methods. Second, there are multiple experiments available in the
public domain for both of these diseases.
The platform for all of the datasets is the Affymetrix Human Genome U133 Plus 2.0
array. Affymetrix CEL files containing raw expression data were downloaded from GEO
for each dataset and processed using R and Bioconductor version 2.13. Quality control
was performed using the qc method from the package simpleaffy version 2.38.0 [75]. Ar-
rays were removed from the analysis if the scale factor was not in the 3-fold range of the
mean of all arrays. Pre-processing was performed on individual datasets using the threestep
function from the package affyPLM version 1.38.0 [76–78]. The parameters used for the
threestep function are: robust multi-array analysis (RMA) background adjustment, quantile
normalization, and median polish summarization.
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2.4.4.1 Pathway analysis applications: Alzheimer’s disease
The Alzheimer’s datasets are GSE28146 (hippocampus, 15 cases and 8 controls) and
GSE5281 (6 different tissues: entorhinal cortex (EC, 9 cases and 12 controls), hippocam-
pus (HIP, 10 cases and 13 controls), medial temporal gyrus (MTG, 16 cases and 11 controls),
posterior cingulate (PC, 6 cases and 13 controls), superior frontal gyrus (SFG, 22 cases and
7 controls), and primary visual cortex (VCX, 16 cases and 10 controls).
The 4 pathway analysis methods, GSEA, GSA, SPIA, and PADOG, were used to pro-
cess the expression data in each study and output a p-value for each study and for each
pathway. We combine the 4 pathway analysis methods with 6 meta-analyses: Stouffer’s,
Z-method, Brown’s, Fisher’s, the additive method, and DANUBE. Using a pathway analysis
methodM , each pathway has 7 p-values – one per study. These 7 p-values are combined us-
ing each of the 6 meta analysis methods Therefore, each pathway analysis method produces
6 lists of pathways. Each list has 150 pathways ranked according to the combined p-values.
We then adjusted the combined p-values for multiple comparisons in each list using FDR.
In order to run DANUBE, we generated the null distributions from control samples
as described in Section 2.4.3. We took the 74 control samples from the 7 Alzheimer’s
datasets, and randomly divided them into “control” and “disease” subgroups. We generated
10, 000 simulations of 10 controls and 10 diseases, 10, 000 simulations of 10 controls and 20
diseases, 10, 000 of 20 controls and 10 diseases, and 10, 000 of 37 controls and 37 diseases,
for a total of 40, 000 simulations. For each pathway analysis method, we constructed 150
empirical distributions for 150 KEGG signaling pathways (totally 600 empirical distributions
for the 4 methods GSEA, GSA, SPIA, and PADOG). We used these empirical distributions
to calculate the empirical p-values before applying the add-CLT method to combine the
empirical p-values for each pathway, resulting in 150 combined p-values. We then adjusted
the combined p-values for multiple comparisons using FDR.
Table 2.1 displays the results using GSA combined with the 6 meta-analysis methods.
The horizontal line across each list marks the 1% significance threshold. The pathway
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Table 2.1: The 17 top ranked pathways and FDR-corrected p-values obtained by combining the GSA p-values using 6 meta-
analysis methods for Alzheimer’s disease. Stouffer’s method, the additive method, and DANUBE, identify the target pathway
as significant and rank it in positions 11th, 6th, and 2nd, respectively. DANUBE yields the best ranking. The horizontal lines
show the 1% significance threshold. The target pathway Alzheimer’s disease is highlighted in green. Pathways highlighted
in red are examples of false positives. These pathways were expected to be reported as false positives because their null
distributions are very skewed toward zero (see Figure 2.5 panels A1-A3 and Figure 2.6). These include Adherens junction and
several cancer-related pathways, which are not considered to be implicated in Alzheimer’s disease.
GSA + Stouffer’s method GSA + Z-method GSA + Brown’s method
Pathway pvalue.fdr Pathway pvalue.fdr Pathway pvalue.fdr
1 Vasopressin-regulated
water reabsorption
< 10−4 Vasopressin-regulated
water reabsorption
< 10−4 Vasopressin-regulated
water reabsorption
< 10−4
2 Pathogenic Escherichia coli
infection
< 10−4 Pathogenic Escherichia coli
infection
< 10−4 Pathogenic Escherichia coli
infection
< 10−4
3 Prostate cancer < 10−4 Prostate cancer 0.0307 Prostate cancer 0.0418
4 Pathways in cancer 0.0003 Pathways in cancer 0.1352 Adherens junction 0.1722
5 Adherens junction 0.0003 Adherens junction 0.1352 Pathways in cancer 0.1722
6 Hippo signaling pathway 0.0004 Hippo signaling pathway 0.1352 Hippo signaling pathway 0.1765
7 Synaptic vesicle cycle 0.0032 Synaptic vesicle cycle 0.2443 Synaptic vesicle cycle 0.2625
8 Vibrio cholerae infection 0.0032 Vibrio cholerae infection 0.2443 Endocrine and other factor-
regulated calcium reabsorp-
tion
0.2625
9 Endocrine and other factor-
regulated calcium reabsorp-
tion
0.0032 Endocrine and other factor-
regulated calcium reabsorp-
tion
0.2443 Vibrio cholerae infection 0.2625
10 Shigellosis 0.0071 Shigellosis 0.2808 Pancreatic cancer 0.2625
11 Alzheimer’s disease 0.0073 Alzheimer’s disease 0.2808 Focal adhesion 0.2950
12 Bacterial invasion of epithe-
lial cells
0.0073 Bacterial invasion of epithe-
lial cells
0.2808 Shigellosis 0.3027
13 Pancreatic cancer 0.0095 Pancreatic cancer 0.2808 Bacterial invasion of epithe-
lial cells
0.3034
14 Focal adhesion 0.0112 Focal adhesion 0.2808 Notch signaling pathway 0.3254
15 Parkinson’s disease 0.0112 Parkinson’s disease 0.2808 Alzheimer’s disease 0.3254
16 Huntington’s disease 0.0112 Huntington’s disease 0.2808 HIF-1 signaling pathway 0.3274
17 Wnt signaling pathway 0.0112 Wnt signaling pathway 0.2808 SNARE interactions in
vesicular transport
0.3274
GSA + Fisher’s method GSA + Additive method GSA + DANUBE
Pathway pvalue.fdr Pathway pvalue.fdr Pathway pvalue.fdr
1 Vasopressin-regulated
water reabsorption
< 10−4 Prostate cancer < 10−4 Cardiac muscle contraction 0.0014
2 Pathogenic Escherichia coli
infection
< 10−4 Pathways in cancer 0.0002 Alzheimer’s disease 0.0014
3 Prostate cancer < 10−4 Hippo signaling pathway 0.0005 Huntington’s disease 0.0014
4 Adherens junction 0.0019 Adherens junction 0.0015 Parkinson’s disease 0.0014
5 Pathways in cancer 0.0023 Endocrine and other factor-
regulated calcium reabsorp-
tion
0.0042 Hippo signaling pathway 0.0025
6 Hippo signaling pathway 0.0030 Alzheimer’s disease 0.0042 Vibrio cholerae infection 0.0047
7 Synaptic vesicle cycle 0.0097 Vibrio cholerae infection 0.0057 Synaptic vesicle cycle 0.0081
8 Vibrio cholerae infection 0.0121 Shigellosis 0.0057 Prostate cancer 0.0112
9 Endocrine and other factor-
regulated calcium reabsorp-
tion
0.0133 Huntington’s disease 0.0057 Vasopressin-regulated
water reabsorption
0.0112
10 Pancreatic cancer 0.0133 Bacterial invasion of epithe-
lial cells
0.0057 Epithelial cell signaling in
Helicobacter pylori infec-
tion
0.0118
11 Focal adhesion 0.0190 Parkinson’s disease 0.0057 Systemic lupus erythemato-
sus
0.0150
12 Shigellosis 0.0222 Glioma 0.0057 Amyotrophic lateral sclero-
sis (ALS)
0.0174
13 Bacterial invasion of epithe-
lial cells
0.0245 Vasopressin-regulated
water reabsorption
0.0057 Shigellosis 0.0193
14 Alzheimer’s disease 0.0334 Cardiac muscle contraction 0.0057 Endocrine and other factor-
regulated calcium reabsorp-
tion
0.0193
15 Notch signaling pathway 0.0334 Wnt signaling pathway 0.0057 Phagosome 0.0302
16 SNARE interactions in
vesicular transport
0.0465 Synaptic vesicle cycle 0.0057 Lysosome 0.0302
17 Wnt signaling pathway 0.0465 Dorso-ventral axis forma-
tion
0.0119 Ribosome biogenesis in eu-
karyotes
0.0302
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Table 2.2: The 20 top ranked pathways and FDR-corrected p-values obtained by combining the PADOG p-values using 6
meta-analysis methods for Alzheimer’s disease. Only DANUBE identifies the target pathway Alzheimer’s disease as significant
and ranks it in position 6th. The horizontal lines show the 1% significance threshold. The target pathway Alzheimer’s disease
is highlighted in green. Pathways highlighted in red are examples of false positives (see Figure 2.5 panels C1-C3 and Figure 2.8).
These include Adherens junction and several cancer-related pathways, which are not considered to be implicated in Alzheimer’s
disease.
PADOG + Stouffer’s method PADOG + Z-method PADOG + Brown’s method
Pathway pvalue.fdr Pathway pvalue.fdr Pathway pvalue.fdr
1 Adherens junction < 10−4 Adherens junction 0.6725 HIF-1 signaling pathway 0.6495
2 Shigellosis 0.0002 Shigellosis 0.6725 Adherens junction 0.6495
3 Renal cell carcinoma 0.0002 Renal cell carcinoma 0.6725 Gap junction 0.6495
4 Prostate cancer 0.0005 Prostate cancer 0.6725 Long-term potentiation 0.6495
5 Bacterial invasion of epithe-
lial cells
0.0014 Bacterial invasion of epithe-
lial cells
0.6725 Long-term depression 0.6495
6 Long-term depression 0.0036 Long-term depression 0.6725 Endocrine and other factor-
regulated calcium reabsorp-
tion
0.6495
7 Pathogenic Escherichia coli
infection
0.0036 Pathogenic Escherichia coli
infection
0.6725 Bacterial invasion of epithe-
lial cells
0.6495
8 Colorectal cancer 0.0036 Colorectal cancer 0.6725 Vibrio cholerae infection 0.6495
9 Gap junction 0.0036 Gap junction 0.6725 Pathogenic Escherichia coli
infection
0.6495
10 Glioma 0.0036 Glioma 0.6725 Shigellosis 0.6495
11 Pancreatic cancer 0.0036 Pancreatic cancer 0.6725 Colorectal cancer 0.6495
12 Vibrio cholerae infection 0.0036 Vibrio cholerae infection 0.6725 Renal cell carcinoma 0.6495
13 Endocrine and other factor-
regulated calcium reabsorp-
tion
0.0043 Endocrine and other factor-
regulated calcium reabsorp-
tion
0.6725 Pancreatic cancer 0.6495
14 ErbB signaling pathway 0.0053 ErbB signaling pathway 0.6725 Endometrial cancer 0.6495
15 Endometrial cancer 0.0063 Endometrial cancer 0.6725 Glioma 0.6495
16 HIF-1 signaling pathway 0.0063 HIF-1 signaling pathway 0.6725 Prostate cancer 0.6495
17 Neurotrophin signaling
pathway
0.0067 Neurotrophin signaling
pathway
0.6725 ErbB signaling pathway 0.6533
18 Long-term potentiation 0.0076 Long-term potentiation 0.6725 Neurotrophin signaling
pathway
0.6533
19 Synaptic vesicle cycle 0.0160 Synaptic vesicle cycle 0.7324 mRNA surveillance path-
way
0.7157
20 VEGF signaling pathway 0.0317 VEGF signaling pathway 0.7324 MAPK signaling pathway 0.7157
PADOG + Fisher’s method PADOG + Additive method PADOG + DANUBE
Pathway pvalue.fdr Pathway pvalue.fdr Pathway pvalue.fdr
1 Adherens junction 0.0008 Adherens junction < 10−4 Vibrio cholerae infection < 10−4
2 Shigellosis 0.0022 Renal cell carcinoma < 10−4 Shigellosis < 10−4
3 Renal cell carcinoma 0.0022 Shigellosis < 10−4 Parkinson’s disease 0.0007
4 Prostate cancer 0.0049 Prostate cancer 0.0001 Synaptic vesicle cycle 0.0007
5 Bacterial invasion of epithe-
lial cells
0.0065 Long-term depression 0.0006 Gap junction 0.0007
6 Pathogenic Escherichia coli
infection
0.0149 Colorectal cancer 0.0009 Alzheimer’s disease 0.0007
7 Endocrine and other factor-
regulated calcium reabsorp-
tion
0.0199 Gap junction 0.0011 Pathogenic Escherichia coli
infection
0.0007
8 Glioma 0.0199 ErbB signaling pathway 0.0013 Cardiac muscle contraction 0.0007
9 Pancreatic cancer 0.0199 Bacterial invasion of epithe-
lial cells
0.0013 Epithelial cell signaling in
Helicobacter pylori infec-
tion
0.0009
10 Long-term depression 0.0199 Vibrio cholerae infection 0.0013 Huntington’s disease 0.0013
11 Gap junction 0.0199 Pancreatic cancer 0.0021 Renal cell carcinoma 0.0024
12 Colorectal cancer 0.0199 Glioma 0.0022 Vasopressin-regulated
water reabsorption
0.0047
13 Vibrio cholerae infection 0.0199 Neurotrophin signaling
pathway
0.0028 VEGF signaling pathway 0.0052
14 Long-term potentiation 0.0226 HIF-1 signaling pathway 0.0037 Endocrine and other factor-
regulated calcium reabsorp-
tion
0.0072
15 Endometrial cancer 0.0226 Pathogenic Escherichia coli
infection
0.0042 Bacterial invasion of epithe-
lial cells
0.0078
16 HIF-1 signaling pathway 0.0257 Endometrial cancer 0.0052 GABAergic synapse 0.0102
17 ErbB signaling pathway 0.0326 VEGF signaling pathway 0.0052 Adherens junction 0.0103
18 Neurotrophin signaling
pathway
0.0352 Endocrine and other factor-
regulated calcium reabsorp-
tion
0.0052 Long-term depression 0.0103
19 Synaptic vesicle cycle 0.0600 Synaptic vesicle cycle 0.0086 Salmonella infection 0.0134
20 Dopaminergic synapse 0.1305 Long-term potentiation 0.0106 Colorectal cancer 0.0198
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Table 2.3: The 20 top ranked pathways and FDR-corrected p-values obtained by combining the SPIA p-values using 6 meta-
analysis methods for Alzheimer’s disease. The target pathway Alzheimer’s disease is significant for all methods. The horizontal
lines show the 1% significance threshold. The target pathway Alzheimer’s disease is highlighted in green.
SPIA + Stouffer’s method SPIA + Z-method SPIA + Brown’s method
Pathway pvalue.fdr Pathway pvalue.fdr Pathway pvalue.fdr
1 Parkinson’s disease < 10−4 Parkinson’s disease < 10−4 Parkinson’s disease < 10−4
2 Alzheimer’s disease < 10−4 Alzheimer’s disease < 10−4 Synaptic vesicle cycle < 10−4
3 Synaptic vesicle cycle < 10−4 Synaptic vesicle cycle < 10−4 Alzheimer’s disease < 10−4
4 Huntington’s disease < 10−4 Huntington’s disease < 10−4 Huntington’s disease < 10−4
5 Pathogenic Escherichia coli
infection
< 10−4 Pathogenic Escherichia coli
infection
0.0006 Pathogenic Escherichia coli
infection
< 10−4
6 Cardiac muscle contraction < 10−4 Cardiac muscle contraction 0.0015 Phagosome 0.0003
7 Phagosome < 10−4 Phagosome 0.0034 Cardiac muscle contraction 0.0003
8 Mineral absorption < 10−4 Mineral absorption 0.0232 Mineral absorption 0.0003
9 Vibrio cholerae infection < 10−4 Vibrio cholerae infection 0.0247 Vibrio cholerae infection 0.0064
10 Endocrine and other factor-
regulated calcium reabsorp-
tion
0.0003 Endocrine and other factor-
regulated calcium reabsorp-
tion
0.0846 Endocrine and other factor-
regulated calcium reabsorp-
tion
0.0274
11 Epstein-Barr virus infection 0.0006 Epstein-Barr virus infection 0.1054 Long-term potentiation 0.0293
12 GABAergic synapse 0.0011 GABAergic synapse 0.1281 Retrograde endocannabi-
noid signaling
0.0293
13 Long-term potentiation 0.0045 Long-term potentiation 0.2162 GABAergic synapse 0.0293
14 Epithelial cell signaling in
Helicobacter pylori infec-
tion
0.0052 Epithelial cell signaling in
Helicobacter pylori infec-
tion
0.2203 RNA transport 0.0324
15 Gap junction 0.0103 Gap junction 0.2786 Glutamatergic synapse 0.0400
16 RNA transport 0.0138 RNA transport 0.3015 Epstein-Barr virus infection 0.0533
17 Gastric acid secretion 0.0297 Gastric acid secretion 0.3990 Epithelial cell signaling in
Helicobacter pylori infec-
tion
0.0536
18 HIF-1 signaling pathway 0.0378 HIF-1 signaling pathway 0.4242 Gap junction 0.1045
19 Axon guidance 0.0579 Axon guidance 0.4242 Long-term depression 0.1433
20 Long-term depression 0.0579 Long-term depression 0.4242 Axon guidance 0.1630
SPIA + Fisher’s method SPIA + Additive method SPIA + DANUBE
Pathway pvalue.fdr Pathway pvalue.fdr Pathway pvalue.fdr
1 Parkinson’s disease < 10−4 Parkinson’s disease < 10−4 Parkinson’s disease 0.0051
2 Synaptic vesicle cycle < 10−4 Alzheimer’s disease < 10−4 Alzheimer’s disease 0.0081
3 Alzheimer’s disease < 10−4 Synaptic vesicle cycle 0.0002 Synaptic vesicle cycle 0.0081
4 Huntington’s disease < 10−4 Huntington’s disease 0.0002 Cardiac muscle contraction 0.0081
5 Pathogenic Escherichia coli
infection
< 10−4 Pathogenic Escherichia coli
infection
0.0006 Huntington’s disease 0.0081
6 Phagosome < 10−4 Cardiac muscle contraction 0.0006 Pathogenic Escherichia coli
infection
0.0104
7 Cardiac muscle contraction < 10−4 Phagosome 0.0046 Epstein-Barr virus infection 0.0104
8 Mineral absorption < 10−4 Epstein-Barr virus infection 0.0046 Phagosome 0.0140
9 Vibrio cholerae infection < 10−4 Vibrio cholerae infection 0.0065 Vibrio cholerae infection 0.0374
10 Endocrine and other factor-
regulated calcium reabsorp-
tion
< 10−4 Endocrine and other factor-
regulated calcium reabsorp-
tion
0.0328 Endocrine and other factor-
regulated calcium reabsorp-
tion
0.0584
11 Long-term potentiation 0.0001 GABAergic synapse 0.0459 HIF-1 signaling pathway 0.0712
12 Retrograde endocannabi-
noid signaling
0.0001 Lysosome 0.0459 Lysosome 0.0842
13 GABAergic synapse 0.0001 Epithelial cell signaling in
Helicobacter pylori infec-
tion
0.0459 p53 signaling pathway 0.0842
14 RNA transport 0.0002 Amyotrophic lateral sclero-
sis (ALS)
0.0543 Epithelial cell signaling in
Helicobacter pylori infec-
tion
0.1161
15 Glutamatergic synapse 0.0003 Gastric acid secretion 0.0546 Amyotrophic lateral sclero-
sis (ALS)
0.1161
16 Epstein-Barr virus infection 0.0007 Melanogenesis 0.0568 Bacterial invasion of epithe-
lial cells
0.1390
17 Epithelial cell signaling in
Helicobacter pylori infec-
tion
0.0007 HIF-1 signaling pathway 0.0594 GABAergic synapse 0.1551
18 Gap junction 0.0035 Endocytosis 0.0678 Gap junction 0.1744
19 Long-term depression 0.0077 Gap junction 0.0681 Melanogenesis 0.1774
20 Axon guidance 0.0110 Long-term potentiation 0.0731 Mineral absorption 0.1774
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Table 2.4: The 11 top ranked pathways and FDR-corrected p-values obtained by combining the GSEA p-values using 6 meta-
analysis methods for Alzheimer’s disease. The additive method and DANUBE yield similar results because GSEA has no bias.
These two methods rank the target pathway Alzheimer’s disease higher than other methods. The horizontal lines show the
1% significance threshold. The target pathway Alzheimer’s disease is highlighted in green.
GSEA + Stouffer’s method GSEA + Z-method GSEA + Brown’s method
Pathway pvalue.fdr Pathway pvalue.fdr Pathway pvalue.fdr
1 Cardiac muscle contraction < 10−4 Cardiac muscle contraction < 10−4 Cardiac muscle contraction < 10−4
2 Serotonergic synapse < 10−4 Serotonergic synapse < 10−4 Serotonergic synapse < 10−4
3 Dopaminergic synapse < 10−4 Dopaminergic synapse < 10−4 Dopaminergic synapse < 10−4
4 Alzheimer’s disease < 10−4 Alzheimer’s disease < 10−4 Alzheimer’s disease < 10−4
5 Parkinson’s disease < 10−4 Parkinson’s disease < 10−4 Parkinson’s disease < 10−4
6 Amyotrophic lateral sclero-
sis (ALS)
< 10−4 Amyotrophic lateral sclero-
sis (ALS)
< 10−4 Amyotrophic lateral sclero-
sis (ALS)
< 10−4
7 Huntington’s disease < 10−4 Huntington’s disease < 10−4 Huntington’s disease < 10−4
8 Arrhythmogenic right ven-
tricular cardiomyopathy
(ARVC)
< 10−4 Arrhythmogenic right ven-
tricular cardiomyopathy
(ARVC)
< 10−4 Arrhythmogenic right ven-
tricular cardiomyopathy
(ARVC)
< 10−4
9 Ribosome biogenesis in eu-
karyotes
0.0021 Ribosome biogenesis in eu-
karyotes
0.0559 Ribosome biogenesis in eu-
karyotes
0.0516
10 RNA transport 0.0126 RNA transport 0.1491 RNA transport 0.0885
11 Notch signaling pathway 0.0176 Notch signaling pathway 0.1739 Notch signaling pathway 0.1305
GSEA + Fisher’s method GSEA + Additive method GSEA + DANUBE
Pathway pvalue.fdr Pathway pvalue.fdr Pathway pvalue.fdr
1 Cardiac muscle contraction < 10−4 Cardiac muscle contraction 0.0004 Cardiac muscle contraction 0.0005
2 Serotonergic synapse < 10−4 Huntington’s disease 0.0004 Huntington’s disease 0.0005
3 Dopaminergic synapse < 10−4 Alzheimer’s disease 0.0004 Alzheimer’s disease 0.0005
4 Alzheimer’s disease < 10−4 Parkinson’s disease 0.0005 Parkinson’s disease 0.0006
5 Parkinson’s disease < 10−4 Ribosome biogenesis in eu-
karyotes
0.0169 Ribosome biogenesis in eu-
karyotes
0.0179
6 Amyotrophic lateral sclero-
sis (ALS)
< 10−4 Prostate cancer 0.0629 Prostate cancer 0.0614
7 Huntington’s disease < 10−4 Oocyte meiosis 0.0645 Oocyte meiosis 0.0625
8 Arrhythmogenic right ven-
tricular cardiomyopathy
(ARVC)
< 10−4 PI3K-Akt signaling path-
way
0.0892 PI3K-Akt signaling path-
way
0.0930
9 Ribosome biogenesis in eu-
karyotes
0.0039 Notch signaling pathway 0.0892 Notch signaling pathway 0.0930
10 RNA transport 0.0100 Basal cell carcinoma 0.0892 Basal cell carcinoma 0.0937
11 Notch signaling pathway 0.0197 Chemokine signaling path-
way
0.0907 Chemokine signaling path-
way
0.0937
highlighted green is the target pathway Alzheimer’s disease. Pathways highlighted in red are
examples of false positives. These pathways were expected to be reported as false positives
because their null distribution is very skewed towards zero (see Figure 2.5 panels A1–A3 and
Figure 2.6). These include Adherens junction and several cancer-related pathways, none of
which are known to be implicated in Alzheimer’s disease. Stouffer’s method, the additive
method, and DANUBE identify the target pathway as significant. DANUBE yields the best
ranking.
Both Stouffer’s and the additive method identify the target pathway as significant
using GSA, as shown in Table 2.1. However, the inherent bias of the null distribution brings
irrelevant results into the list of significant pathways. For Stouffer’s method, pathways
having p-values biased toward zero, such as Prostate cancer, Adherens junction, Pathways
in cancer, and Pancreatic cancer are still among the significant pathways. For the additive
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method, pathways having p-values biased toward zero, such as Prostate cancer, Adherens
junction and Pathways in cancer are still among the significant pathways.
Table 2.2 displays the results using PADOG combined with the 6 meta-analysis meth-
ods. Only DANUBE identifies the target pathway as significant. Z-method and Brown’s
method return no significant pathways. For Stouffer’s, Fisher’s, and the additive method,
the systematic bias of the pathway analysis method greatly influences the outcome of the
meta-analyses. Pathways having p-values biased toward zero, such as Adherens junction
and cancer related pathways (see Figure 2.5 panels C1–C3 and Figure 2.8) are among the
significant pathways.
Table 2.3 displays the results using SPIA combined with the 6 meta-analysis methods.
The target pathway is significant and is ranked near the top for all methods. DANUBE yields
the shortest list of significant pathways. All the 5 significant pathways, Parkinson’s disease,
Alzheimer’s disease, Synaptic vesicle cycle, Cardiac muscle contraction, and Huntington’s
disease are also significant when we combine DANUBE with GSA and PADOG.
Table 2.4 displays the results using GSEA combined with the 6 meta-analysis methods.
The horizontal line across each list marks the cutoff FDR = 0.01. The pathway highlighted
green is the target pathway Alzheimer’s disease. The target pathway is significant for all the
6 meta-analysis methods. Because GSEA is unbiased, the additive method and DANUBE
have equivalent results. These two methods have a shorter list of significant pathways and
rank the target pathway higher than other methods. In addition, all the 4 significant path-
ways, Cardiac muscle contration, Huntington’s disease, Alzheimer’s disease, and Parkinson’s
disease appear in the lists of significant pathways when we combine DANUBE with GSA,
PADOG, and SPIA.
There is no gold standard for assigning true or false values to each of the results, apart
from the expectation that a disease under study should impact its namesake pathway. In-
deed, the target pathway Alzheimer’s disease is ranked as significant for all of the 4 pathway
analysis methods when combined with DANUBE. The target pathway is also ranked higher
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Table 2.5: MetaPath result for 7 Alzheimer’s datasets. The target pathway Alzheimer’s disease is not significant and is
outranked by 6 other pathways.
MetaPath
Pathway pvalue.fdr
1 Parkinson’s disease 0.0060
2 Vasopressin-regulated water reabsorption 0.0307
3 Synaptic vesicle cycle 0.0360
4 Vibrio cholerae infection 0.0392
5 Huntington’s disease 0.0684
6 Pathogenic Escherichia coli infection 0.0686
7 Alzheimer’s disease 0.0735
when using DANUBE compared to the results of other 5 meta-analysis methods. In addi-
tion, the pathways Parkinson’s disease, Alzheimer’s disease, Cardiac muscle constration, and
Huntington’s disease, consistently appear as significant in the results of all the 4 pathway
analysis methods when combined with DANUBE.
Alzheimer’s, Parkinson’s, and Huntington’s diseases are three neurological disorders
that have many commonalities including abnormal protein folding, endoplasmic reticulum
stress, and ubiquitin mediated breakdown of proteins, leading to programmed cell death.
Given that the pathway Alzheimer’s disease is influenced by the mitochondrial compart-
ment, which is strongly implicated in the disease [79–82], it is not surprising that other
pathways with strong mitochondrial components also garner high rankings. Previous stud-
ies [83] have shown the presence of a cross-talk that makes the neurological disease pathways,
Alzheimer’s disease, Parkinson’s disease and Huntington’s disease, along with Cardiac mus-
cle contraction, appear as significant simultaneously, due to their dominant mitochondrial
module. Cardiac muscle contraction has a strong mitochondrial component and is highly
dependent on calcium signaling, which is also prevalent in Synaptic vesicle cycle, Alzheimer’s
disease, and Huntington’s disease. Ca2+ regulates mitochondrial metabolism, but calcium
overload to mitochondria can result in cell damage from reactive oxygen [84].
We also use MetaPath to combine the 7 studies. MetaPath is a stand-alone meta-
analysis method, which does not need an external pathway analysis tool. This method
performs meta-analysis at both gene (MAPE_G) and pathway levels (MAPE_P), and
then combines the results (MAPE_I) to give the final p-value and ranking of pathways.
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Table 2.5 shows the top 7 pathways using MetaPath for the 7 Alzheimer’s datasets. The
target pathway Alzheimer’s disease is not significant and is outranked by 6 other pathways.
2.4.4.2 Pathway analysis applications: AML
The 9 AML datasets are GSE14924_CD4 (CD4 T cells, 10 cases and 9 controls),
GSE17054 (stem cells, 5 cases and 4 controls), GSE14924_CD8 (CD8 T cells, 10 cases
and 11 controls), GSE12662 (CD34+ cells, promyelocytes, and neutrophils and PR9 cell
line, 75 cases and 24 controls), GSE57194 (CD34+ cells, 6 cases and 6 controls), GSE33223
(peripheral blood, bone marrow, 20 cases and 10 controls), GSE42140 (peripheral blood,
bone marrow, 26 cases and 5 controls), GSE8023 (CD34+ cells, 9 cases and 3 controls), and
GSE15061 (bone marrow, 201 cases and 68 controls).
We combine the 4 pathway analysis methods with the 6 meta-analysis methods. Using
a pathway analysis method M , each pathway has 9 p-values – one per study. These 9 p-
values are combined using each of the 6 meta-analysis methods Therefore, each pathway
analysis method produces 6 lists of pathways. Each list has 150 pathways ranked according
to the combined p-values. We then adjust the combined p-values for multiple comparisons
in each list using FDR.
In order to run DANUBE, we generated the null distributions from control samples as
described in Section 2.4.3. We took the 140 control samples of the 9 AML datasets, and
randomly designated “control” and “disease” subgroups. We generated 10, 000 simulations
of 10 controls and 10 diseases, 10, 000 simulations of 30 controls and 50 diseases, 10, 000 of
50 controls and 30 diseases, and 10, 000 of 70 controls and 70 diseases, for a total of 40, 000
simulations. For each pathway analysis method, we constructed 150 empirical distributions
for 150 KEGG signaling pathways (totally 600 empirical distributions for the 4 pathway
analysis methods). We then used the empirical distributions to calculate the empirical p-
values before applying the add-CLT method to combine the empirical p-values for each
pathway, resulting in 150 combined p-values. Finally, we adjusted the combined p-values
for multiple comparisons using FDR.
42
Table 2.6: The 21 top ranked pathways and FDR-corrected p-values obtained by combining the GSA p-values using 6 meta-
analysis methods for acute myeloid leukemia (AML). The target pathway Acute myeloid leukemia is significant for Stouffer’s,
the additive method, and DANUBE with rankings 13th, 2nd, and 1st, respectively.The horizontal lines show the 1% significance
threshold. The target pathway Acute myeloid leukemia is highlighted in green.
GSA + Stouffer’s method GSA + Z-method GSA + Brown’s method
Pathway pvalue.fdr Pathway pvalue.fdr Pathway pvalue.fdr
1 ErbB signaling pathway < 10−4 ErbB signaling pathway < 10−4 ErbB signaling pathway < 10−4
2 Sulfur relay system < 10−4 Sulfur relay system < 10−4 Sulfur relay system < 10−4
3 Adherens junction < 10−4 Adherens junction < 10−4 Adherens junction < 10−4
4 Tight junction < 10−4 Tight junction < 10−4 Tight junction < 10−4
5 Circadian rhythm < 10−4 Circadian rhythm < 10−4 Circadian rhythm < 10−4
6 Alcoholism < 10−4 Alcoholism < 10−4 Alcoholism < 10−4
7 Shigellosis < 10−4 Shigellosis < 10−4 Shigellosis < 10−4
8 Transcriptional misregula-
tion in cancer
< 10−4 Transcriptional misregula-
tion in cancer
< 10−4 Transcriptional misregula-
tion in cancer
< 10−4
9 Renal cell carcinoma < 10−4 Renal cell carcinoma < 10−4 Renal cell carcinoma < 10−4
10 Glioma < 10−4 Glioma < 10−4 Glioma < 10−4
11 Systemic lupus erythemato-
sus
< 10−4 Systemic lupus erythemato-
sus
< 10−4 Systemic lupus erythemato-
sus
< 10−4
12 Non-small cell lung cancer 0.0003 Non-small cell lung cancer 0.0606 Non-small cell lung cancer 0.1250
13 Acute myeloid leukemia 0.0012 Acute myeloid leukemia 0.1011 mTOR signaling pathway 0.2120
14 VEGF signaling pathway 0.0017 VEGF signaling pathway 0.1139 VEGF signaling pathway 0.2120
15 Endometrial cancer 0.0025 Endometrial cancer 0.1298 Pathways in cancer 0.2120
16 Pathways in cancer 0.0029 Pathways in cancer 0.1352 Acute myeloid leukemia 0.2120
17 mTOR signaling pathway 0.0033 mTOR signaling pathway 0.1386 HIF-1 signaling pathway 0.2252
18 Chronic myeloid leukemia 0.0081 Chronic myeloid leukemia 0.1933 Endometrial cancer 0.2252
19 Prostate cancer 0.0081 Prostate cancer 0.1933 Prostate cancer 0.2252
20 Pancreatic cancer 0.0097 Pancreatic cancer 0.2037 Insulin signaling pathway 0.2379
21 HIF-1 signaling pathway 0.0150 HIF-1 signaling pathway 0.2394 Pancreatic cancer 0.2628
GSA + Fisher’s method GSA + Additive method GSA + DANUBE
Pathway pvalue.fdr Pathway pvalue.fdr Pathway pvalue.fdr
1 ErbB signaling pathway < 10−4 Non-small cell lung cancer 0.0003 Acute myeloid leukemia 0.0065
2 Sulfur relay system < 10−4 Acute myeloid leukemia 0.0003 Transcriptional misregula-
tion in cancer
0.0231
3 Adherens junction < 10−4 VEGF signaling pathway 0.0005 VEGF signaling pathway 0.0489
4 Tight junction < 10−4 ErbB signaling pathway 0.0005 Alcoholism 0.1161
5 Circadian rhythm < 10−4 Endometrial cancer 0.0008 Non-small cell lung cancer 0.5968
6 Alcoholism < 10−4 Transcriptional misregula-
tion in cancer
0.0020 Bladder cancer 0.5968
7 Shigellosis < 10−4 Chronic myeloid leukemia 0.0038 HIF-1 signaling pathway 0.5968
8 Transcriptional misregula-
tion in cancer
< 10−4 mTOR signaling pathway 0.0043 Apoptosis 0.5968
9 Renal cell carcinoma < 10−4 Pathways in cancer 0.0043 mTOR signaling pathway 0.5968
10 Glioma < 10−4 Colorectal cancer 0.0084 Cocaine addiction 0.5968
11 Systemic lupus erythemato-
sus
< 10−4 Glioma 0.0108 Autoimmune thyroid dis-
ease
0.6141
12 Non-small cell lung cancer 0.0048 Pancreatic cancer 0.0108 Amyotrophic lateral sclero-
sis (ALS)
0.6458
13 Pathways in cancer 0.0153 Prostate cancer 0.0108 Notch signaling pathway 0.6458
14 Acute myeloid leukemia 0.0181 Small cell lung cancer 0.0177 ErbB signaling pathway 0.6458
15 mTOR signaling pathway 0.0188 Bacterial invasion of epithe-
lial cells
0.0177 HTLV-I infection 0.6458
16 VEGF signaling pathway 0.0188 Adherens junction 0.0184 Natural killer cell mediated
cytotoxicity
0.6458
17 Endometrial cancer 0.0243 Renal cell carcinoma 0.0239 Chronic myeloid leukemia 0.6458
18 HIF-1 signaling pathway 0.0252 Melanoma 0.0326 Endocytosis 0.6458
19 Prostate cancer 0.0252 Endocytosis 0.0403 Small cell lung cancer 0.6458
20 Insulin signaling pathway 0.0295 HIF-1 signaling pathway 0.0447 Fc gamma R-mediated
phagocytosis
0.6458
21 Pancreatic cancer 0.0378 Circadian rhythm 0.0447 African trypanosomiasis 0.6458
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Table 2.7: The 23 top ranked pathways and FDR-corrected p-values obtained by combining the PADOG p-values using 6 meta-
analysis methods for acute myeloid leukemia (AML). The target pathway Acute myeloid leukemia is significant for Stouffer’s,
Fisher’s, the additive method and DANUBE. DANUBE yields the best ranking. The horizontal lines show the 1% significance
threshold. The target pathway Acute myeloid leukemia is highlighted in green.
PADOG + Stouffer’s method PADOG + Z-method PADOG + Brown’s method
Pathway pvalue.fdr Pathway pvalue.fdr Pathway pvalue.fdr
1 Non-small cell lung cancer < 10−4 Non-small cell lung cancer 0.0705 Chronic myeloid leukemia 0.0412
2 Chronic myeloid leukemia < 10−4 Chronic myeloid leukemia 0.0705 Non-small cell lung cancer 0.0412
3 Glioma < 10−4 Glioma 0.2152 Glioma 0.1240
4 ErbB signaling pathway < 10−4 ErbB signaling pathway 0.2239 ErbB signaling pathway 0.2149
5 Colorectal cancer < 10−4 Colorectal cancer 0.2565 VEGF signaling pathway 0.2806
6 Prostate cancer < 10−4 Prostate cancer 0.2565 Pathways in cancer 0.2806
7 Acute myeloid leukemia < 10−4 Acute myeloid leukemia 0.2565 Colorectal cancer 0.2806
8 VEGF signaling pathway 0.0001 VEGF signaling pathway 0.2565 Pancreatic cancer 0.2806
9 Endometrial cancer 0.0001 Endometrial cancer 0.2565 Prostate cancer 0.2806
10 Pancreatic cancer 0.0001 Pancreatic cancer 0.2565 Acute myeloid leukemia 0.2806
11 Pathways in cancer 0.0001 Pathways in cancer 0.2565 Endometrial cancer 0.3398
12 Transcriptional misregula-
tion in cancer
0.0005 Transcriptional misregula-
tion in cancer
0.3509 mTOR signaling pathway 0.4198
13 T cell receptor signaling
pathway
0.0012 T cell receptor signaling
pathway
0.4055 T cell receptor signaling
pathway
0.4198
14 mTOR signaling pathway 0.0012 mTOR signaling pathway 0.4055 Circadian rhythm 0.4198
15 Circadian rhythm 0.0015 Circadian rhythm 0.4061 Insulin signaling pathway 0.4198
16 Neurotrophin signaling
pathway
0.0021 Neurotrophin signaling
pathway
0.4184 Transcriptional misregula-
tion in cancer
0.4198
17 Small cell lung cancer 0.0024 Small cell lung cancer 0.4184 Small cell lung cancer 0.4491
18 Renal cell carcinoma 0.0054 Renal cell carcinoma 0.4837 Neurotrophin signaling
pathway
0.4568
19 Insulin signaling pathway 0.0063 Insulin signaling pathway 0.4837 mRNA surveillance path-
way
0.4695
20 Endocytosis 0.0070 Endocytosis 0.4837 MAPK signaling pathway 0.4695
21 Adherens junction 0.0070 Adherens junction 0.4837 HIF-1 signaling pathway 0.4695
22 Wnt signaling pathway 0.0168 Wnt signaling pathway 0.5674 Endocytosis 0.4695
23 Melanoma 0.0195 Melanoma 0.5674 Wnt signaling pathway 0.4695
PADOG + Fisher’s method PADOG + Additive method PADOG + DANUBE
Pathway pvalue.fdr Pathway pvalue.fdr Pathway pvalue.fdr
1 Chronic myeloid leukemia < 10−4 Non-small cell lung cancer < 10−4 Acute myeloid leukemia < 10−4
2 Non-small cell lung cancer < 10−4 Chronic myeloid leukemia < 10−4 VEGF signaling pathway 0.0007
3 Glioma < 10−4 ErbB signaling pathway < 10−4 Non-small cell lung cancer 0.0008
4 ErbB signaling pathway < 10−4 Endometrial cancer < 10−4 T cell receptor signaling
pathway
0.0021
5 Colorectal cancer 0.0003 Glioma < 10−4 Colorectal cancer 0.0023
6 Prostate cancer 0.0006 Colorectal cancer < 10−4 Chronic myeloid leukemia 0.0027
7 Acute myeloid leukemia 0.0006 Acute myeloid leukemia < 10−4 Endometrial cancer 0.0057
8 Pancreatic cancer 0.0007 Prostate cancer < 10−4 Transcriptional misregula-
tion in cancer
0.0095
9 VEGF signaling pathway 0.0007 Transcriptional misregula-
tion in cancer
0.0001 Glioma 0.0153
10 Pathways in cancer 0.0009 VEGF signaling pathway 0.0001 mTOR signaling pathway 0.0160
11 Endometrial cancer 0.0021 Pathways in cancer 0.0001 Prostate cancer 0.0203
12 Transcriptional misregula-
tion in cancer
0.0056 Pancreatic cancer 0.0002 Apoptosis 0.0239
13 T cell receptor signaling
pathway
0.0080 mTOR signaling pathway 0.0005 ErbB signaling pathway 0.0390
14 mTOR signaling pathway 0.0098 Neurotrophin signaling
pathway
0.0005 B cell receptor signaling
pathway
0.0464
15 Insulin signaling pathway 0.0098 Renal cell carcinoma 0.0006 Circadian rhythm 0.0521
16 Circadian rhythm 0.0098 T cell receptor signaling
pathway
0.0006 Thyroid cancer 0.0844
17 Small cell lung cancer 0.0138 Circadian rhythm 0.0006 Progesterone-mediated
oocyte maturation
0.1040
18 Neurotrophin signaling
pathway
0.0165 Small cell lung cancer 0.0011 Oocyte meiosis 0.1040
19 Adherens junction 0.0318 Endocytosis 0.0036 Systemic lupus erythemato-
sus
0.1441
20 Endocytosis 0.0356 Adherens junction 0.0052 Neurotrophin signaling
pathway
0.1697
21 Renal cell carcinoma 0.0502 Melanoma 0.0072 Shigellosis 0.1697
22 Axon guidance 0.0564 Bacterial invasion of epithe-
lial cells
0.0081 Fc epsilon RI signaling
pathway
0.1697
23 Wnt signaling pathway 0.0564 Wnt signaling pathway 0.0128 Pancreatic cancer 0.2083
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Table 2.8: The 12 top ranked pathways and FDR-corrected p-values obtained by combining the SPIA p-values using 6 meta-
analysis methods for acute myeloid leukemia (AML). The target pathway Acute myeloid leukemia is significant for Stouffer’s,
Fisher’s, the additive method, and DANUBE. DANUBE and the additive method have the best ranking. The horizontal lines
show the 1% significance threshold. The target pathway Acute myeloid leukemia is highlighted in green.
SPIA + Stouffer’s method SPIA + Z-method SPIA + Brown’s method
Pathway pvalue.fdr Pathway pvalue.fdr Pathway pvalue.fdr
1 Transcriptional misregula-
tion in cancer
< 10−4 Transcriptional misregula-
tion in cancer
< 10−4 Transcriptional misregula-
tion in cancer
< 10−4
2 Cell cycle < 10−4 Cell cycle 0.0121 Cell cycle 0.0002
3 Viral carcinogenesis < 10−4 Viral carcinogenesis 0.0121 RNA transport 0.0035
4 Acute myeloid leukemia < 10−4 Acute myeloid leukemia 0.0317 Viral carcinogenesis 0.0035
5 p53 signaling pathway < 10−4 p53 signaling pathway 0.0364 p53 signaling pathway 0.0104
6 RNA transport 0.0002 RNA transport 0.0677 Acute myeloid leukemia 0.0211
7 Colorectal cancer 0.0072 Colorectal cancer 0.2742 Osteoclast differentiation 0.0289
8 T cell receptor signaling
pathway
0.0084 T cell receptor signaling
pathway
0.2742 Colorectal cancer 0.0487
9 HTLV-I infection 0.0281 HTLV-I infection 0.4142 HTLV-I infection 0.0620
10 Epstein-Barr virus infection 0.0294 Epstein-Barr virus infection 0.4142 Cytokine-cytokine receptor
interaction
0.1123
11 Osteoclast differentiation 0.0432 Osteoclast differentiation 0.4569 Phagosome 0.1311
12 Phagosome 0.0465 Phagosome 0.4569 T cell receptor signaling
pathway
0.1611
SPIA + Fisher’s method SPIA + Additive method SPIA + DANUBE
Pathway pvalue.fdr Pathway pvalue.fdr Pathway pvalue.fdr
1 Transcriptional misregula-
tion in cancer
< 10−4 Transcriptional misregula-
tion in cancer
< 10−4 Transcriptional misregula-
tion in cancer
0.0001
2 Cell cycle < 10−4 Acute myeloid leukemia 0.0004 Acute myeloid leukemia 0.0022
3 Viral carcinogenesis < 10−4 Viral carcinogenesis 0.0004 Viral carcinogenesis 0.0022
4 RNA transport < 10−4 p53 signaling pathway 0.0114 p53 signaling pathway 0.0422
5 p53 signaling pathway < 10−4 T cell receptor signaling
pathway
0.0268 T cell receptor signaling
pathway
0.0809
6 Acute myeloid leukemia < 10−4 Cell cycle 0.0405 Hippo signaling pathway 0.0809
7 Osteoclast differentiation 0.0001 Epstein-Barr virus infection 0.0480 Cell cycle 0.0809
8 Colorectal cancer 0.0005 RNA transport 0.0965 Small cell lung cancer 0.2041
9 HTLV-I infection 0.0010 Hepatitis B 0.1839 Alcoholism 0.2041
10 Cytokine-cytokine receptor
interaction
0.0040 Alcoholism 0.1920 RNA transport 0.2041
11 Phagosome 0.0062 Colorectal cancer 0.2187 Epstein-Barr virus infection 0.2041
12 T cell receptor signaling
pathway
0.0115 HTLV-I infection 0.2187 Pathways in cancer 0.2041
Table 2.9: The 10 top ranked pathways and FDR-corrected p-values obtained by combining the GSEA p-values using 6 meta-
analysis methods for acute myeloid leukemia (AML). Since GSEA has no bias, the additive method and DANUBE yield similar
results. The target pathway Acute myeloid leukemia is not significant for any method. The target pathway Acute myeloid
leukemia is highlighted in green.
GSEA + Stouffer’s method GSEA + Z-method GSEA + Brown’s method
Pathway pvalue.fdr Pathway pvalue.fdr Pathway pvalue.fdr
1 Acute myeloid leukemia 0.0998 Acute myeloid leukemia 0.2417 Cocaine addiction 0.4512
2 Alcoholism 0.0998 Alcoholism 0.2417 Amphetamine addiction 0.4512
3 Cocaine addiction 0.0998 Cocaine addiction 0.2417 Alcoholism 0.4512
4 Amphetamine addiction 0.1966 Amphetamine addiction 0.4017 Acute myeloid leukemia 0.4604
5 Pancreatic secretion 0.3086 Pancreatic secretion 0.5247 Pancreatic secretion 0.5563
6 ErbB signaling pathway 0.3995 ErbB signaling pathway 0.5247 Allograft rejection 0.5563
7 Pathways in cancer 0.4281 Pathways in cancer 0.5247 Ribosome biogenesis in eu-
karyotes
0.5879
8 Gastric acid secretion 0.4281 Gastric acid secretion 0.5247 Fanconi anemia pathway 0.5879
9 Gap junction 0.4408 Gap junction 0.5247 ErbB signaling pathway 0.5879
10 p53 signaling pathway 0.4408 p53 signaling pathway 0.5247 p53 signaling pathway 0.5879
GSEA + Fisher’s method GSEA + Additive method GSEA + DANUBE
Pathway pvalue.fdr Pathway pvalue.fdr Pathway pvalue.fdr
1 Cocaine addiction 0.2454 Acute myeloid leukemia 0.1125 Acute myeloid leukemia 0.1036
2 Amphetamine addiction 0.2454 Alcoholism 0.1216 Alcoholism 0.1221
3 Alcoholism 0.2454 Cocaine addiction 0.1216 Cocaine addiction 0.1221
4 Acute myeloid leukemia 0.2648 Gastric acid secretion 0.3409 Gastric acid secretion 0.3393
5 Allograft rejection 0.3559 Pancreatic secretion 0.3409 Pancreatic secretion 0.3393
6 Pancreatic secretion 0.3559 ErbB signaling pathway 0.3409 ErbB signaling pathway 0.3393
7 Graft-versus-host disease 0.4198 Amphetamine addiction 0.4882 Amphetamine addiction 0.4840
8 Pathways in cancer 0.4575 Pathways in cancer 0.4935 Pathways in cancer 0.4840
9 ErbB signaling pathway 0.4575 Gap junction 0.4935 Gap junction 0.4840
10 Salivary secretion 0.4575 VEGF signaling pathway 0.4935 VEGF signaling pathway 0.4840
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Table 2.6 displays the results of GSA combined with the 6 meta-analysis methods,
ordered by the FDR corrected p-values. We place a horizontal line across each list to mark
our 1% cutoff. Stouffer’s method, the additive method, and DANUBE identify the target
pathway as significant. DANUBE yields the best ranking (ranked 1st), followed by the
additive (2nd) and Stouffer’s method (13th). In addition, the target pathway is the only
significant pathway in DANUBE’s result.
Table 2.7 shows the results of PADOG combined with the 6 meta-analysis methods.
The target pathway is significant for the 4 methods: DANUBE, Stouffer’s, Fisher’s, and
the additive method. For DANUBE, Acute myeloid leukemia is ranked 1st compared to 7th
using the other three meta-analysis methods. There are no significant pathways using the
Z-method and Brown’s method.
Table 2.8 shows the results of SPIA combined with the 6 meta-analysis methods, or-
dered by the FDR corrected p-value. Again, the target pathway is significant using Stouf-
fer’s, Fisher’s, the additive method, and DANUBE. The additive method and DANUBE
have the same list of significant pathways. In addition, both methods place the target
pathway higher than the other two methods.
Table 2.9 displays the results of GSEA combined with the 6 meta-analysis methods.
The target pathway Acute myeloid leukemia is highlighted in green. For all 6 meta-analyses,
the target pathway is not significant despite being ranked among the top pathways. Since
GSEA has no bias, the additive method and DANUBE yield similar results. In essence,
even though it is completely unbiased, GSEA lacks the power to identify the Acute myeloid
leukemia (AML) as significant in the AML data.
We also use MetaPath to combine the 9 acute myeloid leukemia studies. Table 2.10
shows the top 5 pathways using MetaPath. The target pathway is not significant (p=0.4),
and is outranked by 2 other pathways.
Table 2.11 summarizes all the results for the 25 approaches (4 pathway analysis meth-
ods each combined with one of 6 meta-analysis approaches, plus MetaPath). On average,
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Table 2.10: MetaPath results for 9 acute myeloid leukemia datasets. The target pathway Acute myeloid leukemia is not
significant and is outranked by two other pathways.
MetaPath
Pathway pvalue.fdr
1 Thyroid cancer 0.2680
2 Circadian rhythm 0.3320
3 Acute myeloid leukemia 0.4075
4 Gap junction 0.7228
5 Staphylococcus aureus infection 0.9966
Table 2.11: Ranking and significance of the target pathway for Alzheimer’s disease and acute myeloid leukemia (AML). The
first and second columns show the disease and the pathway analysis methods. The next 6 columns show the ranking of the
target pathways for 6 meta-analysis combined with the 4 pathway analysis methods. Each row shows the result of the 6
meta-analysis methods combined with the same pathway analysis method. Each cell shows the ranking of the target pathways.
The Y(es) or N(o) letters next to the ranking denote if the target pathway is significant or not. Cells highlighted in green
are those that are significant and have the best rankings in their row. The last column shows the result of MetaPath. For
both diseases, and for all the 4 pathway analysis methods, the target pathway is significant and is ranked the highest when
using DANUBE. The target pathway is not significant for AML data when the GSEA p-values are combined with any of the
6 meta-analysis methods.
Stouffer’s Z-method Brown’s Fisher’s Additive DANUBE MetaPath
method method method method
Pathway analysis
Alzheimer’s
GSEA 4 (Y) 4 (Y) 4 (Y) 4 (Y) 3 (Y) 3 (Y)
7 (N)
GSA 11 (Y) 11 (N) 15 (N) 14 (N) 6 (Y) 2 (Y)
SPIA 2 (Y) 2 (Y) 3 (Y) 3 (Y) 2 (Y) 2 (Y)
PADOG 21 (N) 21 (N) 31 (N) 23 (N) 21 (N) 6 (Y)
AML
GSEA 1 (N) 1 (N) 4 (N) 4 (N) 1 (N) 1 (N)
4 (N)
GSA 13 (Y) 13 (N) 16 (N) 14 (N) 2 (Y) 1 (Y)
SPIA 4 (Y) 4 (N) 6 (N) 6 (Y) 2 (Y) 2 (Y)
PADOG 7 (Y) 7 (N) 10 (N) 7 (Y) 7 (Y) 1 (Y)
DANUBE performs best in terms of ranking, as well as in terms of identifying the target
pathway as significant at the 1% cutoff.
We note that for both diseases, DANUBE and the additive methods have the same
results when combined with GSEA because GSEA is an unbiased method with uniform
distributions of p-values under the null. In addition, the results of the two methods for
SPIA are almost equivalent because the distributions of the p-values produced by SPIA
under the null are closer to the expected uniform. Notably, DANUBE is more useful in
conjunction with methods that have more skewed empirical null distributions.
2.4.4.3 Time complexity
The data analysis is done on our Linux server X8OBNF, Intel E7-8837 that has 1TB
RAM (64 X 16GB DDR3, 1067MHz) and multi-core CPU (64 cores, 8 chips, 8 cores/chip,
Intel Xeon E7-8837, 2.67GHz). The running time of the pathway analysis methods for
real datasets is reported in Table 2.12. Once we have the individual p-values computed, it
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Table 2.12: Running time of classical meta-analysis methods (Stouffer’s, Z-method, Brown’s, Fisher’s, the additive method
combined with GSA, GSEA, SPIA, and PADOG) and MetaPath for Alzheimer’s and AML data using a single core (processor).
The running time is rounded to minutes (m).
Disease Dataset GSA GSEA SPIA PADOG MetaPath
Alzheimer’s
GSE28146 1m 5m 3m 12m
1h13m
GSE5281_EC 1m 5m 3m 11m
GSE5281_HIP 1m 5m 3m 11m
GSE5281_MTG 1m 6m 3m 12m
GSE5281_PC 1m 6m 3m 11m
GSE5281_SFG 1m 6m 3m 14m
GSE5281_VCX 1m 6m 3m 13m
Meta-analysis 7m 39m 21m 1h24m –
AML
GSE14924_CD4 1m 5m 2m 14m
1h14m
GSE14924_CD8 1m 5m 2m 14m
GSE17054 1m 5m 2m 12m
GSE12662 2m 5m 5m 15m
GSE57194 1m 5m 2m 10m
GSE33223 1m 5m 3m 11m
GSE42140 1m 6m 3m 11m
GSE8023 1m 6m 2m 10m
GSE15061 3m 9m 13m 27m
Meta-analysis 13m 51m 34m 2h04m –
Table 2.13: Running time of each pathway analysis on simulated datasets. The running time is rounded to minutes (m).
Data Groups Number of GSA GSEA SPIA PADOG
simulations Cores Time Cores Time Cores Time Cores Time
Alzheimer’s
10 vs. 10 10,000 60 2h21m 60 20h10m 60 3h36m 20 92h37m
10 vs. 20 10,000 60 2h44m 60 18h33m 60 4h04m 20 94h12m
20 vs. 10 10,000 60 2h32m 60 18h07m 60 3h58m 20 90h35m
37 vs. 37 10,000 60 3h48m 60 19h59m 60 4h11m 20 107h15m
Total 40,000 60 11h25m 60 76h49m 60 15h49m 20 384h39m
AML
10 vs. 10 10,000 60 2h24m 60 17h23m 60 4h11m 40 49h21m
30 vs. 50 10,000 60 3h58m 60 19h36m 60 5h03m 40 63h09m
50 vs. 30 10,000 60 3h53m 60 19h32m 60 4h42m 40 61h50m
70 vs. 70 10,000 60 3h44m 60 19h31m 60 5h23m 40 78h22m
Total 40,000 60 13h59m 60 76h02m 60 19h19m 40 252h42m
takes less than a second to combine them using the 5 classical meta-analysis (Stouffer’s, Z-
method, Brown’s, Fisher’s method, and the additive method). Therefore, the running time
of these 5 meta-analysis methods in conjunction with a pathway analysis method is the
time to compute the individual p-values. For example, the time needed for GSA combined
with Stouffer’s, Z-method, Brown’s, Fisher’s method, or the additive method is 7m for
Alzheimer’s data and is 13m for AML data. We also report the running time for MetaPath.
MetaPath combines multiple studies without an external pathway analysis method and
therefore does not require an additional explicit meta-analysis step.
The time needed for DANUBE consists of three parts. First, we need to generate
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the null distributions (Table 2.13). Second, we need to calculate the p-values for the real
datasets (Table 2.12). Third, we need to calculate and combine the empirical p-values. The
third part takes only some seconds and therefore is negligible. Therefore, the running time
of DANUBE in conjunction with a pathway analysis method is the time needed to generate
the empirical distributions and to calculate the p-values using a pathway analysis method.
For example, the time needed for DANUBE combined with GSA to analyze Alzheimer’s
data is 11h25m + 7m = 11h32m. Note that we need to create the empirical distribution
only once. Once the empirical distribution of the p-values generated by a particular pathway
analysis method is calculated, it is subsequently reused for any other analyses.
2.4.5 Simulation studies
2.4.5.1 General case: t-test and Wilcoxon test
In this section we will demonstrate the generality of the problem, beyond pathway
analysis applications. In order to do so, we have used the one sample t-test [85, 86] and the
one sample Wilcoxon signed-rank test [87–89], as illustrative examples of parametric and
non-parametric tests. Using simulated null distributions, we show that both the t-test and
Wilcoxon tests have systematic bias depending on the shape and the symmetry of the null
distribution. When the p-values are biased towards zero, combining multiple studies results
in an increase of type I error (prevalence of false positives). When the p-values are biased
towards one, the test loses power and more evidence is needed to identify true positives.
In Figure 2.13, panel (a) displays a simulated null distribution H0 which is not sym-
metrical and does not follow any standard distribution. Panel (b) displays an alternative
distribution H1, which has the same shape as H0, but a slightly smaller median. Panel (c)
displays another alternative distribution H2 which has the same shape as H0 but a slightly
larger median. Each population has 100, 000 elements. The goal here is to investigate
the ability of each approach to distinguish between H0 and H1, and between H0 and H2,
respectively. This is attempted using both a t-test and a Wilcoxon test.
Denoting M0 and m0 as the mean and median of the null distribution H0, M0 is used
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as the parameter (mean) for the t-tests where m0 is used as the parameter (median) for
Wilcoxon test. To make the analysis more general, the sample size is randomized between 3
and 10 everytime we pick a sample. Since DANUBE uses the additive method to combine the
p-values, we also use the additive method to combine the p-values of t-test and Wilcoxon
test. When the number of studies is larger or equals to 20, the combined p-values are
calculated using the Central Limit Theorem.
Panels (d–h) show the results using the one sample left-tailed t-test for the mean;
panels (i–m) show the results using the one sample right-tailed t-test for the mean; panels
(n–r) show the results using the one sample left-tailed Wilcoxon test for the median; panels
(s–w) show the results using one sample right-tailed Wilcoxon test for the median.
Panel (d) shows the distribution of p-values for samples drawn from the null distribution
H0. To plot this panel, we randomly select 100, 000 samples from H0 and then calculate the
p-values using the left-tailed t-test. Since the null distributionH0 is not normal, the resulting
p-values are not uniformly distributed. Panel (e) displays the distribution of combined
p-values for samples drawn from the null distribution H0. To calculate a combined p-
value, we randomly pick 10 samples from the null population H0 and then calculate the
10 p-values using the left-tailed t-test. From these 10 p-values, we calculate a combined
p-value using the additive method. This procedure is repeated 100, 000 times to generate
the distribution of the combined p-values under the null hypothesis. Similarly, panel (f)
displays the distribution of the combined p-values for samples drawn from the alternative
distribution H1.
The red dashed lines in panels (e, f) show the 0.05 cutoff. Since the combined p-values
in (e) are calculated under the null hypothesis, values smaller than the cutoff are false
positives. Therefore, the blue area to the left of the red dashed line is type I error of the
classical meta-analysis using the left-tailed t-test. Similarly, combined p-values larger than
the cutoff in panel (f) are false negatives. The blue area to the right of the red line panel
(f) displays type II error.
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(a) An alternative distribution (H1)
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(b) An alternative distribution (H2)
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Figure 2.13: Type I and Type II errors of the classical meta-analysis using one sample t-test and Wilcoxon signed-ranked test.
Panel (a) displays the probability distribution under the null hypothesis H0. Panel (b) displays an alternative distribution
H1 which has the same shape as the null distribution with a slightly smaller median. Panel (c) displays another alternative
distribution H2 which has the same shape as the null distribution with a slightly larger median. Panels (d–h) display the
results using left-tailed t-tests. Panel (d) displays the distribution of p-values using left-tailed t-test for samples drawn from
the null distribution H0. Panel (e) displays the distribution of combined p-values using left-tailed t-test for samples drawn
from the null distribution H0. The red dashed line represents the threshold (0.05). The blue area to the left of the red dashed
line is type I error (false positives). Panel (f) displays the distribution of combined p-values using a left-tailed t-test for samples
drawn from the alternative distribution H1. The blue area to the right of the red dashed line is type II error (false negatives).
Panel (g) displays the type I error. Panel (h) displays the type II error using a left-tailed t-test for samples drawn from the
alternative distribution H1. Similarly, panels (i–m) display the results using right-tailed t-test; panels (n–r) display the results
of left-tailed Wilcoxon signed-rank test; panels (s–w) display the results of right-tailed Wilcoxon signed-rank test. In this
example, the left-tailed t-test and right-tailed Wilcoxon tests are biased towards 0 as shown in (e,f). Therefore, an increase
in the number of studies makes the combined p-values more biased towards 0, causing an increase in type I error as shown in
(g,v). On the contrary, the right-tailed t-test and left-tailed Wilcoxon test are biased towards 1. This kind of bias makes the
test less powerful. For example, with 10 studies, type II errors using right-tailed t-test and left-tailed Wilcoxon test are 0.51
and 0.61, respectively.
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(a) An alternative distribution (H1)
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(b) An alternative distribution (H2)
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(d) p−values using mean (H0, right tailed)
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Figure 2.14: Type I and type II errors of DANUBE using mean and median as discriminative statistics. Panel (a) displays the
probability distribution under the null hypothesis (H0). Panel (b) displays an alternative distribution (H1), which has the same
shape but a slightly smaller median. Panel (c) displays an alternative distribution (H2) which has a slightly larger median.
Panels (d–h) display the results of the left-tailed DANUBE using mean; panels (i–m) display the results of the right-tailed
DANUBE using mean; panels (n–r) display the results of left-tailed DANUBE using median; panels (s–w) display the results
of right-tailed DANUBE using median. Panels (d, i, n, s) show the p-value distributions for samples drawn from the null.
For all four tests, p-values are uniformly distributed under the null hypothesis. Consequently, the combined p-values (using
the additive method) are also uniformly distributed under the null hypothesis as shown in (e, j, o, t). The result is that the
type I error equals the threshold (0.05) regardless of the number of studies combined, as shown in (g, l, q, v). Panels (h, m,
r, w) show that the type II error converges quickly to zero. Combining 10 studies, the type II errors of left and right-tailed
DANUBE for the mean are both less than 0.3 compared to 0.51 for the right-tailed t-test. Similarly, using the median, the
type II error of DANUBE is less than 0.2 compared to 0.61 for the left-tailed Wilcoxon test.
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The results show that combined p-values will be biased towards zero, since p-values
of the left-tailed t-test are biased towards zero. To understand the behavior of the meta-
analysis, we display type I and type II error in panels (g, h) with varying numbers of studies
to be combined. As the number of studies increases, the meta-analysis becomes more biased,
and type I error increases. For example, when the number of studies reaches 50, the analysis
has more than 60% false positives. Paradoxically, increasing the number of studies will make
the meta-analysis less useful due to the increase of type I error.
Panels (i–m) display the results of the right-tailed t-test. Panel (i) displays the dis-
tribution of p-values for samples drawn from the null distribution H0. Panel (j) displays
the combined p-values for samples drawn from the null distribution H0. Panel (k) displays
the combined p-values for samples drawn from the alternative distribution H2. Each com-
bined p-value is calculated from 10 individual p-values. The right-tailed t-test is biased
towards one, therefore more evidence is required to identify true positives. Compared to
the left-tailed t-test, the right-tailed t-test has smaller type I error but larger type II error
(less power). Therefore, many more studies would be required for this test to identify true
positives. Panel (m) shows that for the case of combining 10 studies, the type II error of
the right-tailed t-test is about 0.5 whereas the type II error of the left-tailed t-test is less
than 0.2.
Panels (n–r) display the meta-analysis using the one sample left-tailed Wilcoxon test
for the median. In this example, the left-tailed Wilcoxon test is biased towards one, so
more evidence is required to identify true positives. As shown in panel (r), the expected
type II error of the meta-analysis is about 0.6 when combining 10 studies. Interestingly, the
behavior of the meta-analysis using the left-tailed Wilcoxon test is similar to that of the
the right-tailed t-test. In both cases, the meta-analysis needs a large number of studies to
identify true positives. Panels (m and r) show that type II error converges to zero as the
number of studies increases.
Panels (s–w) display the results of meta-analysis using the one sample right-tailed
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Wilcoxon test for the median. Similar to the t-test, the right-tailed Wilcoxon test is biased
towards zero. As shown in panels (g, v), type I error using either of the two tests increases
as the number of studies increases.
2.4.5.2 General case: DANUBE
In this section, we analyze the performance of DANUBE using the same null and
alternative distributions that were used for the t-test and Wilcoxon tests. Figure 2.14
displays the results using DANUBE. Panels (a, b, c) show the null distribution H0 and
two alternative distributions H1 and H2. Panels (d–h) display the results using left-tailed
DANUBE for the mean; panels (i–m) display the results using right-tailed DANUBE for
the mean; panels (n–r) display the results using left-tailed DANUBE for the median; panels
(s–w) display the results using right-tailed DANUBE for the median.
We randomly select 10, 000 samples from the null distribution and use them to construct
the empirical distribution of sample means (panels d–m) and likewise of sample medians
(panels n–w). For a given empirical distribution, we calculate the probability of observing
the discriminating statistic in a study. Panel (d) displays the distribution of empirical p-
values for samples drawn from the null distribution H0; we see that these are uniformly
distributed under the null hypothesis. Panel (e) displays the distribution of combined p-
values for samples drawn from the null distribution H0. Each combined p-value is calculated
from 10 individual empirical p-values. The blue area to the left of the red dashed line is
type I error. Since the individual p-values are uniformly distributed, the combined p-values
are also uniformly distributed. Consequently, the type I error of this test is equal to the
threshold. Panel (f) displays the distribution of combined p-values for samples drawn from
the alternative distribution H1. The blue area to the right of the red dashed line is the type
II error.
Panels (g, h) display the type I and type II error of DANUBE with varying numbers of
combined studies. The graphs show that the type I error of DANUBE consistently equals
the threshold while type II error decreases when the number of studies increases. When
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combining 10 studies, the type I and type II errors of the left-tailed DANUBE for the mean
are 0.05 and 0.27, respectively, compared to 0.24 and 0.14 for the left-tailed t-test. When
the number of the studies increases over 30, one can expect DANUBE to give a 0.05 type I
error and an almost zero type II error.
Similar to the left-tailed test, right-tailed DANUBE on the mean has the expected
type I error and a reasonable type II error as shown in panels (l, m). With 10 studies
to be combined, the right-tailed DANUBE’s type I and type II errors are 0.05 and 0.25,
respectively, compared to 0.01 and 0.51 for the right-tailed t-test. The results for the mean
show that both left- and right-tailed type I errors are equal to the threshold while the type II
error decreases rapidly. On the contrary, the left and right-tailed t-tests have unpredictable
behavior due to the skewness of the null distribution.
Panels (n–w) show the results of left- and right-tailed DANUBE for the median. As
expected, the type I error for the median is also equal to the threshold, regardless of the
number of studies that are combined. The test is proven to be powerful for both tails with
type II error less than 0.2 for 10 studies. When compared to the left-tailed Wilcoxon test
on 10 studies, the DANUBE left-tailed type II error is 0.17 as opposed to 0.61.
2.4.6 Summary
We have presented DANUBE, a new framework to combine the results of multiple
studies in order to gain more statistical power. Our framework first calculates the empirical
p-values for each study using the empirical distribution of the discriminating statistic. It
then combines the empirical p-value using the add-CLT method. The new framework makes
no statistical assumptions about the data and is therefore usable in many practical cases
when no simple model is appropriate. In addition, use of the additive method makes the
framework more robust to outliers.
The advantage of the new meta-analysis framework is demonstrated using both simu-
lation and real-world data. In our simulation study, we compare the results of DANUBE
to the classical additive method using the one sample t-test and Wilcoxon signed-rank test.
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The skewness and the non-normality of the simulated null distribution produces systematic
bias in classical meta-analysis, either increasing type I error or decreasing the power of the
test. In contrast, the type I error of DANUBE is equal to the threshold cutoff and type II
error declines quickly when the number of studies increases.
To evaluate the proposed framework for pathway analysis applications, we examine 7
Alzheimer’s and 9 acute myeloid leukemia datasets using 25 approaches: 6 meta-analysis
methods, Stouffer’s, Z-method, Brown’s, Fisher’s, the additive method and DANUBE, each
of them combined with 4 representative pathway analysis methods, GSA, SPIA, PADOG,
and GSEA, plus an additional independent meta-analysis method MetaPath. The results
confirm the advantage of DANUBE over classical meta-analysis to identify pathways relevant
to the phenotype.
This work describes an important limitation of current meta-analysis techniques, and
provides a general statistical approach to increase the power of an analysis method using
empirical distributions. With vast databases of biological data being made available, this
framework may be powerful because it lets the data speak for itself. The proposed framework
is flexible enough to be applicable to various types of studies, including gene-level analysis,
pathway analysis, or clinical trials to assess the effect of a therapy in complex diseases.
2.5 A bi-level meta-analysis approach
One practical drawback of most p-value based meta-analysis approaches is that, because
they perform just one statistical test for each individual experiment, they may not fully
exploit the potentially large number of samples within each study. A statistical test which
is not powerful enough to reject the null hypothesis in one individual experiment can only
derive power by amassing a large number of experiments. Low power in the case of a single
experiment can be due in part to a mathematical design which favors a moderate number
of samples, but may fail to fully exploit large sample sizes.
To gain power from the large number of samples within each experiment, we propose a
bi-level meta-analysis that integrates multiple independent studies on two levels: an intra-
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experiment analysis, and an inter-experiment analysis. First, for each individual experiment,
the intra-experiment analysis splits the dataset into smaller datasets, performs a statistical
test on each of the newly created small datasets, then combines the p-values. Next, the
inter-experiment analysis combines those processed p-values, from each of the individual
experiments.
We illustrate our approach using one of the most popular statistical methods for path-
way analysis, Gene Set Enrichment Analysis (GSEA), applying it to KEGG pathways, and
21 public gene expression datasets, conducted in independent laboratories, from three con-
ditions: acute myeloid leukemia (9 datasets), type II diabetes (5 datasets), and Alzheimer’s
disease (7 datasets). We compare the result of the proposed framework with three classical
meta-analysis methods (Fisher’s, Stouffer’s, and the additive method), plus the standalone
meta-analysis method - MetaPath. For all three conditions, our framework outperforms
other approaches and correctly identifies the pathways designed to describe the biological
processes responsible for these diseases. Via extensive simulation studies, we also demon-
strate that framework is sufficiently general to be applied to any type of statistical meta-
analysis.
2.5.1 Bi-level meta-analysis framework
The input of the framework is as follows. First, we have m studies (datasets) of the
same disease. Each dataset consists of a group of healthy samples and a group of disease
samples. Second, we have a list of k pathways from an existing pathway database. Third,
we have a pathway analysis method that can be used to identify the significantly impacted
pathways in a given dataset. This pathway analysis method is used for each dataset, thus
calculating a p-value for each of the k pathways in each of the m datasets.
Figure 2.15 displays the overall procedure of our framework. The framework is di-
vided into two stages: intra-experiment analysis and inter-experiment analysis. The intra-
experiment analysis works with one dataset at a time. Given a dataset DSi (i ∈ [1..m]), we
divide the disease samples into ni smaller groups. Each data subset consists of a small group
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of disease samples and all the control samples in the dataset. We impose that each small
group include at least 5 disease samples, therefore, ni approximately equals the number
of disease samples divided by 5. Using the chosen pathway analysis method, we calculate
the p-values for the k pathways for each of the ni small datasets. The result is ni lists of
p-values, each with k p-values for the k pathways. Therefore, each pathway will have ni
p-values, one from each of the ni lists. The ni p-values are then combined into a single
p-value for each pathway using the add-CLT described above.
After performing intra-level-analysis on all m studies (datasets), we have m lists of p-
values - one per study, and each pathway has m independent p-values. Using add-CLT, the
inter-experiment analysis combines the m p-values of each pathway into one meta p-value
that represents the significance of the pathway. The output of the whole framework is a list
of k pathways ranked according to the meta p-values.
While our bi-level framework is described in the context of pathway analysis, it can
be modified and applied in any context. For example, the pathway analysis method can be
substituted with another statistical test, or applied in totally different field. In addition,
our add-CLT method maybe replaced by another meta-analysis method. However, we favor
add-CLT for several reasons. First, it is robust against small p-values and against bias under
the null. Second, it is more powerful than Fisher’s method in detecting changes in signal as
we demonstrated in Section 2.3.4.
2.5.2 Results and validation
For the experiments based on real expression data, we compare 5 different meta-analysis
approaches in the context of pathway analysis: our bi-level approach with add-CLT, three
classical meta-analysis methods (Fisher’s, Stouffer’s and the additive method), and one
standalone, dedicated, pathway meta-analysis method - MetaPath. We use the KEGG
pathway database (version 65, 150 human pathways). For the 4 methods that need a
pathway analysis algorithm, we select GSEA [39], which is currently one of the most popular
methods.
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Bi-level meta-analysis
Figure 2.15: Bi-level meta-analysis framework to identify significant pathways. The input includes m datasets, k pathways,
and a pathway analysis method. The intra-experiment analysis divides the dataset DSi (i ∈ [1..m]) into smaller datasets
dsi1, . . . , dsini and then performs pathway analysis for each of the small datasets, resulting in ni p-values for each pathway.
The intra-experiment analysis combines the ni p-values into one p-value for each pathway using add-CLT. After this process
is done for all m studies (datasets), each pathway has m independent p-values – one per study. The inter-experiment analysis
then combines the m p-values for each pathway into one meta p-value using the add-CLT method. This meta p-value for
each pathway represents the overall significance of the pathway. The output of the framework is a list of k pathways ranked
according to the meta p-values.
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We chose 21 datasets related to three human diseases: type II diabetes (5 datasets),
acute myeloid leukemia (AML) (9 datasets), and Alzheimer’s disease (7 datasets). These
disease datasets were chosen for several reasons - not only are they well suited for meta-
analysis, but we have a good way to evaluate the results. For each disease, there is a
dedicated pathway in KEGG that was created in order to describe the known mechanisms
involved in these specific diseases. Thus, the five analysis methods can be assessed by their
ability to identify these “target pathways” in their respective conditions.
2.5.2.1 Pathway analysis using type II diabetes data
The diabetes datasets we use in our data analysis were obtained from Gene Expression
Omnibus (GEO) with IDs: GSE25462 (skeletal muscle, 10 cases and 15 controls), GSE19420
(skeletal muscle, 10 cases and 12 controls), GSE18732 (skeletal muscle, 45 cases and 47
controls), GSE23343 (liver biopsy, 10 cases and 7 controls), and GSE22309 (skeletal muscle,
30 cases and 40 controls).
We use Gene Set Enrichment Analysis (GSEA) to analyze the 5 diabetes datasets
individually. For each dataset, GSEA produces a list of 150 KEGG pathways ranked by p-
values. Proceeding to meta-analysis of these 5 datasets, the most straightforward approach is
to combine the 5 p-values produced by GSEA for each pathway, using classical p-value based
meta-analysis methods. Here we use three classical approaches to combine the independent
p-values: Fisher’s [56], Stouffer’s [57], and the additive method [64, 69, 70]. Fisher’s and
Stouffer’s method have been used in [63] to combine p-values of pathways in independent
experiments. Stouffer’s method is similar to Fisher’s method, with the difference that, as
the random variable, it uses the sum of p-values transformed into standard normal variables
instead of the log product. Alongside these three classical meta-analysis techniques, we
juxtapose our bi-level meta-analysis. The result of each is a list of all 150 pathways ranked
according to the combined p-values, which we adjust for multiple comparisons using FDR.
Table 2.14 shows the top 5 ranked pathways and FDR-corrected p-values obtained
by combining the 5 diabetes datasets using the 4 meta-analysis approaches. The pathway
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Table 2.14: Results of combining GSEA p-values using 4meta-analysis approaches for type II diabetes data. The target pathway
Type II diabetes mellitus is the only significant pathway using the bi-level meta-analysis. The three classical approaches,
Fisher’s, Stouffer’s, and the additive method, fail to identify the target pathway as significant and rank it in positions 7th,
10th, and 12th, respectively. The pathways are sorted by the combined p-values, from low to high. The horizontal lines show
the 5% significance threshold. The target pathway Type II diabetes mellitus is highlighted in green.
GSEA + Fisher’s method GSEA + Stouffer’s method
Pathway pvalue.fdr Pathway pvalue.fdr
1 Oocyte meiosis 0 Oocyte meiosis 0
2 Prostate cancer 0.3881 Prostate cancer 0.1796
3 Endocytosis 0.4591 Endocytosis 0.1987
4 Hippo signaling pathway 0.4591 TGF-beta signaling pathway 0.1987
5 Long-term depression 0.4591 Hippo signaling pathway 0.2621
GSEA + Additive method GSEA + bi-level meta-analysis
Pathway pvalue.fdr Pathway pvalue.fdr
1 Endocytosis 0.0951 Type II diabetes mellitus 0.0151
2 TGF-beta signaling pathway 0.0951 Endocytosis 0.1888
3 Prostate cancer 0.1483 MAPK signaling pathway 0.5271
4 Hepatitis B 0.1824 Amyotrophic lateral sclerosis (ALS) 0.5271
5 Chagas disease (American trypanosomia-
sis)
0.2108 TGF-beta signaling pathway 0.5271
highlighted green is the target pathway Type II diabetes mellitus, which was created in
order to describe the phenomena involved in this disease. The horizontal line marks the
cutoff of 0.05 of the FDR-corrected p-values. All three classical meta-analysis approaches,
Fisher’s, Stouffer’s, and the additive method, fail to identify the target pathway as significant
(p > 0.4) with rankings 7, 10, and 12, respectively. The Oocyte meiosis pathway has a
combined p-value equal to zero for Fisher’s and Stouffer’s methods because the p-value was
zero for one of the datasets (GSE22309). As discussed above, these approaches are sensitive
to such occurrences. The bi-level meta-analysis approach identifies the target pathway Type
II diabetes mellitus as the most significant pathway (p = 0.0151). Also, this is the only
significant pathway at the 5% significance threshold.
As a fifth method, we employ MetaPath [62], to combine the 5 studies. MetaPath [62]
is a dedicated pathway meta-analysis which is open source and does not require an external
pathway analysis method. In our work, we use the R package provided in [74]. MetaPath
performs meta-analysis at both gene and pathway levels with a GSEA-like approach, and
then combines the results to give the final p-value and ranking of pathways. Table 2.15
shows the top 5 pathways using MetaPath. The target pathway Type II diabetes mellitus is
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Table 2.15: MetaPath results for 5 diabetes datasets. The target pathway Type II diabetes mellitus is ranked 80th.
MetaPath
Pathway pvalue.fdr
1 Maturity onset diabetes of the young 0.9975
2 Lysosome 0.9988
3 Ribosome biogenesis in eukaryotes 1.0000
4 RNA transport 1.0000
5 mRNA surveillance pathway 1.0000
ranked 80th out of 150 with an FDR-corrected p-value of 1.
2.5.2.2 Pathway analysis using AML data
The following AML datasets from GEO were used for our analysis: GSE14924 (CD4
T-cells, 10 cases and 9 controls, and CD8 T-cells, 10 cases and 11 controls), GSE17054
(hematopoietic stem cells, 5 cases and 4 controls), GSE12662 (fractionated bone marrow:
CD34+ cells, promyelocytes, neutrophils and the PR9 cell line, 75 cases and 24 controls),
GSE57194 (primary CD34+ cells, 6 cases and 6 controls), GSE33223 (peripheral blood
mononuclear cells, 20 cases and 10 controls), GSE42140 (peripheral blood mononuclear cells,
26 cases and 5 controls), GSE8023 (CD34+ cells from cord blood, 9 cases and 3 controls),
and GSE15061 (bone marrow, 201 cases and 68 controls).
We use Gene Set Enrichment Analysis (GSEA) [39] to analyze the 9 AML datasets
individually. The AML pathway is assigned an FDR-corrected p-value ranging from 0.23
(GSE57194) to 1 (GSE33223) and a ranking between 12 (GSE42140) and 114 (GSE14924)
across the 9 datasets analyzed. In essence, the AML pathway, which was created precisely
to describe the most important biological mechanisms involved in AML, is neither found to
be significant, nor ranked anywhere close to the top in any of the individual datasets.
We again use the 4 meta-analysis approaches to combine GSEA results: Fisher’s, Stouf-
fer’s, the additive method, and the bi-level meta-analysis. The output for each of these 4
approaches is a list of 150 pathways ranked according to the combined p-values. Table 2.16
shows the top 5 ranked pathways and FDR-corrected global p-values yielded by the 4 meta-
analysis approaches. The green highlight shows the target pathway Acute myeloid leukemia.
The horizontal line is the selected significance cutoff of 0.05.
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Table 2.16: Results of combining GSEA p-values using 4 meta-analysis approaches for acute myeloid leukemia (AML). The
target pathway Acute myeloid leukemia is significant only when using bi-level meta-analysis. The pathways are sorted by the
combined p-values, from low to high. The horizontal lines show the 5% significance threshold. The target pathway Acute
myeloid leukemia is highlighted in green.
GSEA + Fisher’s method GSEA + Stouffer’s method
Pathway pvalue.fdr Pathway pvalue.fdr
1 Cocaine addiction 0.2454 Acute myeloid leukemia 0.0998
2 Amphetamine addiction 0.2454 Alcoholism 0.0998
3 Alcoholism 0.2454 Cocaine addiction 0.0998
4 Acute myeloid leukemia 0.2648 Amphetamine addiction 0.1966
5 Allograft rejection 0.3559 Pancreatic secretion 0.3086
GSEA + Additive method GSEA + bi-level meta-analysis
Pathway pvalue.fdr Pathway pvalue.fdr
1 Acute myeloid leukemia 0.1125 Acute myeloid leukemia 0.0005
2 Alcoholism 0.1216 Arrhythmogenic right ventricular car-
diomyopathy (ARVC)
0.0110
3 Cocaine addiction 0.1216 Alcoholism 0.0731
4 Gastric acid secretion 0.3409 Cocaine addiction 0.0731
5 Pancreatic secretion 0.3409 Pathways in cancer 0.0731
Table 2.17: MetaPath results for 5 acute myeloid leukemia datasets. The target pathway Acute myeloid leukemia is not
significant and is ranked 3rd.
MetaPath
Pathway pvalue.fdr
1 Thyroid cancer 0.2680
2 Circadian rhythm 0.3320
3 Acute myeloid leukemia 0.4075
4 Gap junction 0.7228
5 Staphylococcus aureus infection 0.9966
None of the three classical meta-analysis approaches identify the target pathway Acute
myeloid leukemia as significant. Fisher’s yields a global p-value of 0.264, Stouffer’s yield a
global p-value of 0.099, and the additive method yields a p-value of 0.112. Fisher’s method
ranked the target pathway as 4th out of 150. The bi-level meta-analysis with add-CLT
identifies the target pathway as significant with a p-value of 0.0005, and also ranks it 1st.
Again, we also provide the results of MetaPath [62] when analyzing the 9 studies
together. Table 2.17 shows the top 5 pathways using MetaPath for the 9 acute myeloid
leukemia datasets. The target pathway Acute myeloid leukemia is highlighted green. This
pathway is not significant (p=0.4), and is ranked 3rd.
2.5.2.3 Pathway analysis using Alzheimer’s data
As a final case, we selected Alzheimer’s disease because we want to give an example
of a situation with more than one expected pathway. Alzheimer’s disease, Parkinson’s
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disease and Huntington’s disease are three neurological disorders that share many signaling
mechanisms and affect the same tissue (brain). The common elements include abnormal
protein folding, endoplasmic reticulum stress, and ubiquitin mediated breakdown of proteins,
leading to programmed cell death [79–82]. Furthermore, previous studies have shown the
presence of a strong cross-talk that makes these three neurological disease pathways appear
as significant simultaneously, due to their dominant mitochondrial module [83]. Therefore,
we expect a good analysis method to find all three of these pathways as significant in this
meta-analysis of Alzheimer’s data.
The Alzheimer’s datasets we use in our data analysis were obtained from Gene Ex-
pression Omnibus (GEO) with IDs: GSE1297 (hippocampus, 22 cases and 9 controls),
GSE28146 (hippocampus, 22 cases and 8 controls) and GSE5281 (a mixture of entorhinal
cortex, hippocampus, medial temporal gyrus, posterior cingulate, superior frontal gyrus,
and primary visual cortex, 87 cases and 74 controls), GSE16759 (parietal lobe cortex, 4
cases and 4 controls), GSE48350 (a mixture of post central gyrus, superior frontal gyrus,
hippocampus, and entorhinal cortex, 80 cases and 173 controls), GSE39420 (brain tissues,
14 cases and 7 controls), and GSE4757 (entorhinal cortex, 10 cases and 10 controls).
Again, we use the 5 meta-analysis approaches, Fisher’s, Stouffer’s, the additive method,
the bi-level meta-analysis, and MetaPath, to combine the 7 Alzheimer’s studies. Table 2.18
shows the top 5 ranked pathways and FDR-corrected p-values obtained by combining the
7 Alzheimer’s datasets using the 4 existing meta-analysis approaches. Table 2.19 shows the
top 5 ranked pathways using MetaPath. The horizontal line marks the 5% cutoff for the
FDR-corrected p-values.
All 4 meta-analysis approaches, Fisher’s, Stouffer’s, the additive method, and MetaP-
ath, fail to identify the primary target pathway Alzheimer’s disease as significant, and rank
it on positions 5, 11, 28, and 40, respectively. They also fail to identify Parkinson’s disease
as significant. Among 4 existing meta-analysis approaches, only Fisher’s method identifies
Huntington’s disease as significant.
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Table 2.18: Results of combining GSEA p-values using 4 meta-analysis approaches for Alzheimer’s data. Only the bi-level
meta-analysis identifies all three neurological disease pathways, Alzheimer’s disease, Parkinson’s disease and Huntington’s
disease, as significant. The pathways are sorted by the combined p-values, from low to high. The horizontal lines show the 5%
significance threshold. The target pathway Alzheimer’s disease and two neurological disease pathways, Parkinson’s disease
and Huntington’s disease, are highlighted in green.
GSEA + Fisher’s method GSEA + Stouffer’s method
Pathway pvalue.fdr Pathway pvalue.fdr
1 Amyotrophic lateral sclerosis (ALS) 0 Amyotrophic lateral sclerosis (ALS) 0
2 Cardiac muscle contraction 0 Cardiac muscle contraction 0
3 Chemokine signaling pathway 0 Chemokine signaling pathway 0
4 Huntington’s disease 0.0330 Melanogenesis 0.1744
5 Alzheimer’s disease 0.0736 Huntington’s disease 0.1744
GSEA + Additive method GSEA + Multiple-level meta-analysis
Pathway pvalue.fdr Pathway pvalue.fdr
1 Melanogenesis 0.5205 Huntington’s disease 0.0149
2 Vascular smooth muscle contraction 0.6916 Alzheimer’s disease 0.0149
3 Non-small cell lung cancer 0.6916 Parkinson’s disease 0.0467
4 Prostate cancer 0.6916 Adipocytokine signaling pathway 0.1818
5 Measles 0.6916 Vascular smooth muscle contraction 0.1818
Table 2.19: MetaPath results for Alzheimer’s data. None of the three neurological disease pathways, Huntington’s disease,
Alzheimer’s disease, and Parkinson’s disease, appears as significant. They are ranked on positions 4th, 40th, and 16th,
respectively.
MetaPath
Pathway pvalue.fdr
1 Epithelial cell signaling in Helicobacter pylori in-
fection
0.1634
2 Thyroid cancer 0.1860
3 Endocrine and other factor-regulated calcium re-
absorption
0.2018
4 Huntington’s disease 0.2198
5 Renal cell carcinoma 0.2335
In contrast, the bi-level meta-analysis identifies the target pathway Alzheimer’s disease
as significant (p = 0.0149) with ranking 2. In addition, the pathways Huntington’s disease
and Parkinson’s disease also appear as significant in the results of the bi-level meta-analysis.
Furthermore, the proposed approach does not produce any false positives.
For all three disease conditions, diabetes, AML, and Alzheimer’s disease, the classi-
cal meta-analysis approaches and MetaPath were unable to identify the target pathway as
significant. Only the proposed bi-level meta-analysis identifies the target pathway as signif-
icant. This is likely due to two reasons. First, the combination of the additive method and
the Central Limit Theorem is reliable in terms of both false positive rate and true positive
rate. Second, the intra-experiment analysis performed within each of the individual studies
increases the power of the pathway analysis.
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2.5.3 Simulation studies
In order to provide a deeper understanding of why intra-experiment analysis improves
results on a mathematical level, we applied it to a two-sample t-test and compared the
results to a standard t-test [85, 86]. We show that splitting datasets and combining p-values
using add-CLT results in a gain of power. We also investigated the false positive rate of the
bi-level meta-analysis and the robustness with respect to various split sizes.
2.5.3.1 Comparison between t-test and intra-experiment analysis
Our bi-level meta-analysis framework is comprised of intra- and inter-experiment anal-
ysis. In intra-experiment analysis, we split each experiment into smaller studies and then
combine the small studies using add-CLT. In inter-experiment analysis, we combine multiple
experiments using add-CLT again. Our reasoning for the first stage is that performing a
statistical test on a large experiment is not as powerful as splitting it into smaller studies and
then combining them using add-CLT. We demonstrate this using the classical two-sample
t-test [85, 86].
In the first simulation, we use normal null (control) and alternative (disease) distribu-
tions that have the same variance but different means. Analogous to case-control analyses
done in biological experiments, we randomly pick a set of samples from the null distribution
and a set of samples from the alternative distribution and then compare the two sets. We
compare true positive rates (TPR) using two approaches, the two-sample t-test, and a com-
bination of the t-test and our intra-experiment analysis method. For the intra-experiment
analysis, we split the disease set into smaller sets of size 5 to form multiple small studies. We
then perform a right-tailed t-test to compare each newly created small disease set against
the full control set. The resulting p-values are then combined using add-CLT. We will show
that a combination of the t-test and the intra-experiment analysis method is more powerful
than t-test alone (right-tailed as well).
Figure 2.16 shows comparisons between the t-test and the intra-experiment analysis
method for three different alternative distributions. In the left panel of Figure 2.16A, the
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Figure 2.16: Comparison between the t-test and the intra-experiment analysis method. In each row, the left row panel displays
a hypothetical null (control) distribution H0 (black) and an alternative (disease) distribution HA (red). The middle and right
panels show the true positive rate (TPR) of the t-test and the intra-experiment analysis method as they vary with increasing
the number of samples. The horizontal axes of the middle and right panels represent the number of samples while the vertical
axes represent the TPR. Given n as the number of samples, we randomly pick n control samples from H0 and n disease samples
from HA. The first approach is to use a right-tailed t-test to compare the two groups of samples. The second approach is to
split the disease group into smaller groups of size 5 and then perform a right-tailed t-test to compare each newly created small
disease group against the control group. The resulting p-values are then combined using add-CLT. We repeat the procedure
1, 000 times to get 1, 000 p-values for the t-test and 1, 000 p-values for the intra-experiment analysis method. We then calculate
the TPR for each approach as the number of p-values smaller than the threshold 0.01 divided by 1, 000. In (A), when the null
and alternative distributions are very different, the intra-experiment analysis method is only slightly better than the t-test in
terms of TPR (85% TPR compared to 75% TPR with 20 samples). In (B), when the alternative distribution is closer to the
null distribution, the difference in TPR of the two approaches increases (35% TPR compared to 75% TPR with 20 samples). In
(C), when the alternative distribution is very close to the null distribution, the difference in TPR between the two approaches
is much larger. The TPR of the intra-experiment analysis method is almost three times higher than the TPR of the t-test. In
summary, when the two distributions are closer, the intra-experiment analysis method is much more powerful than the t-test
and its power increases more rapidly than that of the t-test.
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null distributionH0 (black) is a standard normal distribution with mean µ0 = 0 and variance
σ20 = 1 while the alternative distribution HA (red) has the same variance but different mean,
µA = 1. The horizontal axis represents the expression values and the vertical axis represents
the density of the expression values. Given n as the number of samples, we pick n control
samples from H0 and n disease samples from HA. We then use the t-test and the intra-
experiment analysis method (combined with t-test) to compare the two sets of samples.
Each of the two approaches produces a p-value. We repeat the procedure 1, 000 times to get
1, 000 p-values for the t-test and 1, 000 p-values for the intra-experiment analysis method.
We then calculate the true positive rate (TPR) of each method as the number of p-values
smaller than the threshold 0.01 divided by 1, 000.
The middle and right panels of Figure 2.16A display the true positive rate (TPR) of
t-test and of the intra-experiment analysis method. The horizontal axes show the number of
samples while the vertical axes show the TPR. These panels show that the intra-experiment
analysis method has a slightly better TPR than the t-test alone. With 20 samples, the TPR
of the intra-experiment analysis method is around 85% whereas the TPR of t-test is close
to 75%.
Figure 2.16B shows the comparison between the two approaches for another alternative
distribution with mean µA = 0.5. The alternative distribution is closer to the null distribu-
tion and thus it is harder for both approaches to identify the true positives. In this case, the
intra-experiment analysis method (combined with t-test) has notably higher TPR than the
t-test. With 20 samples, the TPR of the intra-experiment analysis method is 35% compared
to 20% for the t-test.
Similarly, Figure 2.16C shows the comparison between the two approaches for another
alternative distribution with mean µA = 0.1. In this case, the alternative distribution is
very close to the null distribution and thus both approaches have much lower TPR than
cases (B) and (C). Interestingly, the TPR of the t-test barely increases when the number
of samples increases - only from 2% to 5% when the number of samples increases from
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20 to 100. Similarly, the TPR of the intra-experiment analysis method is also low but it
increases rapidly when the number of samples increases. For example, the TPR increases
from 6% with 20 samples to 15% with 100 samples. The figure shows that the TPR of the
intra-experiment analysis is approximately three times higher that that of t-test.
In summary, the intra-experiment analysis method (combined with the t-test) is more
powerful than the t-test alone for comparative analysis. According to the comparison shown
in Figure 2.16, the difference in performance between the two approaches increases when
the difference between the null and alternative distributions decreases. Therefore, the intra-
experiment analysis approach is especially powerful when there is only a small change in
gene expression profile between the two phenotypes compared.
2.5.3.2 False positive rate of the bi-level meta-analysis
Since the control samples are used in every test in the intra-experiment meta-analysis,
the individual p-values of the split datasets in the intra-experiment analysis are not com-
pletely independent. As a result, the combined p-values of the intra-experiment analysis
may not be uniformly distributed in certain situations, in particular when the number of
control samples is small. However, we will show that this does not have significant impact
on the final results of the bi-level meta-analysis.
Given a sound statistical test, the empirical p-values of independent datasets should
be uniformly distributed under the null. Let us consider one dataset DSi, which has an
associated empirical p-value pi (produced by something like a t-test). The intra-experiment
analysis produces a set of p-values (one for each split dataset) and then combines these p-
values to produce one p-value pˆi. We can consider that pˆi is a transformation of pi using the
add-CLT function. Under the null hypothesis, the empirical p-values {pi} are symmetrical
around 0.5 (because they are uniformly distributed). Since, the add-CLT function is sym-
metrical around 0.5, one can expect that the transformed p-values pˆi are also symmetrical
around 0.5. This is also demonstrated by the simulations in Figure 2.17. These p-values
are combined again in the inter-experiment analysis using add-CLT. Since add-CLT relies
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on the mean of these intra-experiment p-values, the distribution of the inter-experiment
p-values will become closer to the uniform distribution. As a result, the false positive rate
(FPR) of the bi-level meta-analysis will be close to the significance threshold even if the
FPR yielded at the intra-experiment level were to be higher than the threshold.
Please note that the intra-experiment p-values that are potentially biased, are only
intermediate values that are not used to draw any conclusions. This phenomenon is illus-
trated in Figure 2.17. Panel (a) shows the distribution of the intermediate intra-experiment
p-values obtained with the same setting of 20 control and 20 disease samples. Due to the
small number of control samples and the lack of independence, this distribution is not per-
fectly uniform. However, even in this case, the distribution is symmetrical. When these
intermediate p-values are combined in the inter-experiment analysis, the distribution of the
p-values yielded by the add-CLT method is close to the uniform. Note that this effect of
the lack on independence caused by the use of the same control samples is greatly allevi-
ated when the number of control samples increases. Panels (c) and (d) in Figure 2.17 show
that the distributions of the intermediate intra-experiment p-values become uniform as the
number of control samples increases.
Figure 2.18A shows the false positive rate (FPR) of the intra-experiment and inter-
experiment analyses using t-test. The left panel displays the hypothetical null distribution
H0 while the middle and right panels displays the FPR of the intra- and inter-experiment
analyses, respectively. The middle panel shows that the intermediate FPR of the intra-
experiment analysis is notably higher than then threshold 0.01, due to the dependency of
the split datasets from a study. However, when multiple studies are combined using add-
CLT in the inter-experiment analysis, the final FPR is reduced to the threshold again. The
right panel shows that the FPR of the bi-level meta-analysis is consistently at 1− 2% when
the number of studies increases.
In the same figure, we illustrate the true positive rate (TPR) of the bi-level meta-
analysis when the null (control) and alternative (disease) distributions are not identical.
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Figure 2.17: Distributions of p-values under the null for the intra-experiment and inter-experiment analyses. The horizontal
axes display the p-values and the vertical axes display the density of the p-values. Panels (a) and (b) display the distributions
of the intra-experiment and inter-experiment p-values when the number of control samples is 20. In each study, we randomly
pick 20 disease samples and 20 control samples, both from the null distribution, and then calculate intra-experiment p-values.
We repeat the procedure 10, 000 times to get the distribution of the intra-experiment p-values. To calculate a meta p-value
for the inter-experiment analysis, we combine 10 independent studies using add-CLT. We repeat this procedure 10, 000 times
to get the distribution of the inter-experiment p-values. The red dashed line in each panel represents the cutoff 0.01. The
p-values to the left of this line are false positives. Panels (c) and (d) are constructed in a similar way, but the number of
control samples is set to 500. Panel (a) shows that the distribution of the intra-experiment analysis is not uniform under
the null when the number of control samples is small. However, when these intermediate p-values are combined again in the
inter-experiment analysis, the distribution of p-values yielded by the add-CLT method is closer to the uniform (panel b). In
addition, this non-uniformity is also alleviated when the number of control samples increases as shown in panels (c) and (d).
In summary, the two levels of add-CLT keeps the false positive rate close to the threshold 0.01.
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Figure 2.18: False positive rate (FPR) and true positive rate (TPR) of the bi-level meta-analysis using t-test. In the first
row (A), the left panel displays a hypothetical null distribution H0 while the middle and right panels display the FPR of
the intra-experiment and inter-experiment analyses, respectively. Given n as the number of samples for the intra-experiment
analysis, we randomly pick n control samples and n disease samples, all from the null distribution H0. We split the disease
group into smaller groups of size 5 and then perform a t-test to compare each newly created small disease group against the
control group. The resulting p-values are then combined using add-CLT. We repeat the procedure 1, 000 times to get 1, 000
p-values for the intra-experiment analysis. We then calculate the FPR for the intra-experiment analysis as the number of
p-values smaller than the threshold 0.01 divided by 1, 000. Given m as the number of studies in the inter-experiment analysis,
we generate m independent datasets, perform intra-experiment analysis for each dataset, and then combine the m resulted
p-values using add-CLT. In each generated study, the disease and control groups have the same size, but the number of samples
in each group is randomized. We repeat the procedure 1, 000 times to get 1, 000 p-values for the inter-experiment analysis.
We then calculate the FPR as the number of p-values smaller than the threshold 0.01 divided by 1, 000. The panels show that
the FPR of the inter-experiment analysis is smaller than that of the intra-experiment analysis and is consistently at 1 − 2%.
In the second row (B), the left panel displays the null distribution (black) H0 and the alternative distribution (red) HA. The
sampling procedure in (B) is similar to (A) with the exception is that the disease samples are picked from the alternative
distribution HA. In this case, the TPR is calculated as the number of p-values smaller than the threshold 0.01 divided by
1, 000. The middle and right panels display the TPR of the intra- and inter-experiment analyses, respectively. The TPR of
the bi-level meta-analysis increases linearly with the number of studies. The TPR increases from 10% with 2 studies to almost
50% with 20 studies. On the contrary, the FPR stays at 1− 2% regardless of the number of studies and the number of samples
in each study.
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In Figure 2.18B, the left panel displays the null distribution (black) H0 and the alternative
distribution (red)HA. The middle and right panels displays the TPR of the intra-experiment
and inter-experiment analyses, respectively. In this case, the TPR is calculated as the
number of p-values smaller than the threshold 0.01 divided by 1, 000. The TPR of the
bi-level meta-analysis increases linearly with the number of studies. The TPR increases
from 10% with 2 studies to almost 50% with 20 studies. On the contrary, the FPR stays at
1− 2% regardless of the number of studies and the number of samples in each study.
2.5.3.3 The effect of group size setting
We would like to have as many split datasets as possible to increase the power of the
add-CLT. Many splits would suggest small group sizes. However, we also need the sample
size of disease groups to be large enough so each split group has enough biological replicates
needed for a meaningful analysis. This would require large group sizes. The default group
size of 5 allows each split dataset to have a reasonable sample size, while still allowing for a
sufficient number of splits.
However, the choice of the group size does not influence dramatically the results of
the approach. Figure 2.19 shows the true positive rate (TPR) of the intra-experiment
analysis using a t-test with different settings of group size. In each row, the left panel
displays a hypothetical null distribution H0 (black) and an alternative distribution HA
(red). The middle panels show the true positive rate (TPR) of the intra-experiment analysis
method as they vary with increasing the number of samples. The right panels show the
confidence interval of the intra-experiment p-values. Each segment represents the mean and
95% confidence interval of the p-values for a given g (group size) and n (number of samples).
The figure shows that the curves of size 6, 7, and 8 are notably lower than the curves of size
3, 4, and 5. This suggests the TPR of the test is likely to decrease if we were to increase
the number of group size above 5. However, changing the settings of group size from 3 to 8
makes the TPR and p-value distributions change only slightly. Most importantly, the TPR
curves tend to converge when the number of samples increases, showing that the proposed
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Figure 2.19: True positive rate (TPR) of the intra-experiment analysis with varying group size. In each row, the left panel
displays a hypothetical null distribution H0 (black) and an alternative distribution HA (red). The middle panels show the
true positive rate (TPR) of the intra-experiment analysis method as they vary with increasing the number of samples. The
horizontal axes represent the number of samples while the vertical axes represent the TPR. The right panels show the confidence
interval of the intra-experiment p-values. Given n as the number of samples and g as the minimum group size, we randomly
pick n control samples from H0 and n disease samples from HA. We split the disease group into smaller groups of size g and
then perform a right-tailed t-test to compare each newly created small disease group against the control group. The resulting
p-values are then combined using add-CLT. We repeat the procedure 1, 000 times to get 1, 000 p-values for the intra-experiment
analysis method. We then calculate the TPR as the number of p-values smaller than the threshold 0.01 divided by 1, 000.
Each curve in the middle panels shows the TPR for each setting of group size g. In the right panels, each segment represents
the mean and 95% confidence interval of the p-values for a given group size g and number of samples n. The middle panels
show that the curves for group size 6, 7, and 8 are notably lower than the curves for group size 3, 4, and 5. This suggests
the TPR of the test can only decrease when we increase the number of group size over 5. In addition, the TPR and p-values
distribution are very similar when g equals to 3, 4, and 5.
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approach is very stable as the number of data points increases. In summary, the TPR of
the intra-experiment analysis is stable against the settings of group size in our analysis.
2.5.4 Summary
We have presented a novel meta-analysis approach that combines multiple studies to
gain more statistical power. The new framework exploits not only the vast number of studies
performed in independent laboratories, but also makes better use of the available number
of samples within individual studies. In addition, the use of the additive method and the
Central Limit Theorem makes the framework robust to outliers and keeps the false positive
rate under the desired threshold.
To evaluate the proposed framework for pathway analysis applications, we analyze 5
diabetes datasets, 9 acute myeloid leukemia datasets, and 7 Alzheimer’s datasets using 5
different approaches: Fisher’s, Stouffer’s, the additive method, MetaPath, and the bi-level
meta-analysis. For each of these three diseases, there is a KEGG pathway, referred to as
the target pathway, that describes the phenomena associated with these conditions. All
4 existing meta-analysis methods fail to identify the target pathways as significant after
combining all available datasets for each condition. In contrast, the proposed bi-level meta-
analysis identifies the target pathways as significant in all three conditions. These results
confirm the increased power of the bi-level meta-analysis with respect to the other meta-
analysis approaches.
Although the bi-level meta-analysis framework is illustrated in the context of pathway
analysis, it is in fact a general meta-analysis method that can easily replace existing meta-
analysis procedures in a wide range of research areas, such as biomarker/oncogene detection,
genome-wide association studies (GWAS), enrichment analysis (Gene Ontology, gene set
analysis), or even clinical trials to assess the effect of a therapy in complex diseases.
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CHAPTER 3: VERTICAL INTEGRATIVE
ANALYSIS – OMICS DATA INTEGRATION AND
DISEASE SUBTYPING
3.1 Introduction to disease subtyping
The advent of high-throughput genomics technologies has resulted in massive amounts
of diverse genome-scale data. Gene expression data, measured by microarrays or next gen-
eration sequencing platforms, is the most prevalent data type available. Gene Expression
Omnibus [27, 90] stores thousands of datasets with independent experimental series of sim-
ilar patient cohorts and experiment design. As technologies advance, other data types
become available and together they offer complementary information on the same disease
or biological phenomenon. The Cancer Genome Atlas (TCGA) [91] has already gathered
genome, transcriptome, and epigenome information for over 20 cancers for thousands of
patients. The challenge is to interpret high-dimensional and heterogeneous data types to
gain insights into biological processes.
Disease subtyping is often the first step to better understand a disease or biological
phenomenon. The goal is to detect unknown groups of patients based on intrinsic features
without external information. The disease subtyping problem includes the following fun-
damental issues: 1) how to determine the number of clusters and assign patients to each
group, 2) how to combine complementary information to determine the final partitioning.
The former problem often involves clustering, usually of one data type where the data has
small sample size but very high dimension. The latter problem includes integration of multi-
omics data, such as mRNA expression, DNA methylation, and miRNA, for class discovery.
With the rapidly advancing technologies, more and more data types are available for the
same set of patients, creating an urgency for methods of combining multi-omics data.
In functional genomics, agglomerative hierarchical clustering (HC) is a frequently used
approach for clustering genes or samples that show similar patterns [92–94]. HC provides
for a structural view of the data that makes it an appealing exploratory data analysis
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method. However, classical HC imposes a tree structure on the data that might not reflect
the underlying structure, and is highly sensitive to the metric used to assess similarity
among elements. Other approaches, such as neural network based methods [95–99]), matrix
factorization [100, 101], large-margin methods [102–104] that are based on the support vector
machine (SVM) [105, 106], model-based approaches [107–109] that are based on expectation
maximization [110], and graph-theoretical or kernel-based approaches [111–113], have also
been used. However, most of them do not scale well to problems that involve hundreds
of instances and tens of thousands of dimensions, as we consider here. To reduce the
computational complexity and noise, these methods rely on the gene selection step and this
leads to a biased analysis. In addition, all these methods need a pre-specified number of
clusters.
Resampling-based methods have been proposed to determine the number of clusters
for high-dimensional data [114, 115]. They assess the stability of the clustering results
with respect to resampling variability. Arguably the state-of-the-art approach in this area is
Consensus Clustering (CC) [116, 117]. It develops a general, model independent resampling-
based methodology of class discovery, cluster validation, and visualization. CC calculates
the pair-wise similarities (frequency of how often the elements are grouped together) and
their empirical cumulative distribution function (CDF) using sub-sampling. The pair-wise
similarities are then used for visualization and for estimating the cluster number. This
approach has been widely used and has gained applaudable results [1–10]. The main as-
sumption of CC is that if the samples were drawn from K distinct sub-populations that
truly exist, different sub-samples would show the greatest level of stability at the true K.
Unfortunately, this makes CC produce apparent structure even when there is none, or de-
clare cluster stability when the stability is subtle [118, 119]. In addition, CC is unable to
integrate multiple types of data.
The goal of an integrative analysis is to identify subgroups of samples that are similar
not only at one level (e.g. mRNA), but from a holistic perspective, that can take into
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consideration phenomena at various other levels (DNA methylation, miRNA, etc.). One
strategy is to analyze each data type independently before combining them with the help of
experts in the field [3–5, 8]. However, this might lead to discordant results that are hard to
interpret. Another approach, iPF [120], integrates multiple data types by concatenates all
measurements to a single matrix and then clusters the patients using correlation distance and
partitioning around medoids [121]. This concatenation-based integration, however, further
aggravates the “curse of dimensionality” [122]. In turn, this leads to the use of gene filtering,
which can introduce bias. Another challenge of this approach is identifying the best way to
concatenate multiple data types that come from different platforms (microarray, sequencing,
etc.) and different scales [123].
Machine learning approaches, such as Bayesian consensus clustering [124], MDI [125],
iClusterPlus [126], and iCluster [127, 128], address the challenge of integration by using a
joint statistical modeling. They model the distribution of each data type and then maximize
the likelihood of the observed data. The recent iClusterPlus makes an extra effort to reduce
the parameter space by imposing sparse models, such as lasso [129]. Though powerful, these
approaches are limited by their strong assumptions about the data and by the gene selection
step used to reduce the computational complexity. Similarity Network Fusion (SNF) [130]
was the first approach that allows for discovery of disease subtypes through integration of
several types of high-throughput data on a genomic scale. SNF creates a fused network of
patients using a metric fusion technique [131], and then partitions the data using spectral
clustering [132]. SNF appears to be the state-of-the-art in this area and has proven to
be very powerful [130]. However, the unstable nature of kernel-based clustering makes the
algorithm sensitive to small changes in molecular measurements or in its parameter settings.
Here we propose a radically different integrative approach, Perturbation clustering
for data INtegration and disease Subtyping (PINS), that addresses both challenges above:
subtype discovery, as well as integration of multiple data types. The algorithm is built upon
the resilience of patient connectivity and cluster ensembles [133] to ensure robustness against
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noise and bias. In an extensive analysis, we compare PINS with three subtyping algorithms
that are selected to represent each of the main existing subtyping strategies: Consensus
Clustering (CC) [116], Similarity Network Fusion (SNF) [130], and iClusterPlus [126]. CC
is a resampling-based approach that has been used in many recent articles in top journals
such as Nature [1–5, 134], Cancer Cell [6–8], and Cell [9, 10]. SNF is a graph-theoretical
approach purported to allow discovery of disease subtypes based on either a single data type
or through integration of several data types. The third method, iClusterPlus is a model-
based approach and is the enhanced version of two popular methods, iCluster [127] and
iCluster2 [128].
We compare the proposed approach with these state-of-the-art methods on 8 gene
expression data sets involving a total of 12 tissues types and over 1,000 samples. In each of
these data sets, we show that PINS is able to better retrieve known subtypes. In order to
compare the data integration abilities of these four approaches, we also applied them to 6
types of cancer, each involving mRNA, methylation, and miRNA data. These results also
show that PINS is better able to discover subtypes that have significant survival differences,
compared to the other three existing approaches.
3.2 PINS: Perturbation clustering for data INtegration and dis-
ease Subtyping
3.2.1 Discovering subtypes based on a single data type
The approach is based on the observation that differences are naturally present between
individuals, even in the most homogeneous population. Therefore, we hypothesize that if
true subtypes of a disease do exist, they should be stable with respect to small changes in
the features that we measure.
We will describe this approach using an illustrative example shown in Figure 3.1a. In
this example, we have three distinct classes of patients in which each class has a different
set of differentially expressed genes (DEGs). Without any loss of generality, the genes are
ordered such that the DEGs in the first class are plotted first (1-100), the DEGs in the
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second class are plotted second (101-200), etc. In order to find subtypes, we repeatedly
perturb the data (by adding Gaussian noise) and partition the samples/patients using any
classical clustering algorithm (by default k-means, repeated 200 times). We test a range
of potential cluster numbers k (by default k ∈ [2..10]) and identify the partitioning that is
least affected by such perturbations. We then assess the cluster stability by comparing the
partitionings obtained from the original data to those found with perturbed data, for any
given k. To quantify these differences, we first construct a binary connectivity matrix, in
which the element (i, j) represents the connectivity between patients i and j, and is equal
to 1 (blue) if they belong to the same cluster, and 0 (white) otherwise. The upper parts
in Figure 3.1b–e show the original connectivity. The middle parts of the same panels show
the average connectivity for k ∈ [2..5] over the 200 trials. Next, we calculate the absolute
difference between the original and the perturbed connectivity matrices and compute the
empirical cumulative distribution functions of the entries of the difference matrix (CDF-DM)
(Figure 3.1f). The area under this CDF-DM curve (AUC) is used to assess the stability of
the clustering. Figure 3.1g shows the behavior of the AUC (red curve), as the number of
clusters varies from 2 to 10. In the ideal case of perfectly stable clusters, the original and
perturbed connectivity matrices are identical, yielding a difference matrix of 0’s, a CDF-DM
that jumps from 0 to 1 at the origin, and an AUC of 1. Based on this criterion, we chose
the partitioning with the highest AUC. As shown in Figure 3.1g, the correct number of
subtypes is 3, as this corresponds to the largest AUC. The connectivity corresponding to
this partitioning is considered the optimal connectivity, which will serve as input for data
integration.
Interestingly, the perturbed connectivity matrices (middle parts of Figure 3.1b–e)
clearly suggest that there are three distinct classes of patients. This demonstrates that
for truly distinct subtypes the true connectivity between patients within each class is re-
covered when the data is perturbed, no matter how we set the value of k. This resilience
of patient connectivity occurs consistently regardless of the clustering algorithm being used
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Figure 3.1: The PINS algorithm applied on a single data type. (a) The dataset consists of the three subtypes of patients,
each having a different set of 100 differentially expressed genes. (b–e) Original connectivity matrix (upper panel), perturbed
connectivity matrix (middle panel), and CDF of the difference matrix (lower panel) for k=2, 3, 4, and 5, respectively. (f) CDF
of the difference matrix (CDF-DM) for k ∈ [2..10]. (g) AUC values for Dataset3 (red curve), random data (black curve) and
the difference (blue) between the two curves.
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(e.g. k-means, hierarchical clustering, or partitioning around medoids), or the distribu-
tion of the data. When there are no truly distinct subtypes, the connectivity is randomly
distributed. When the number of true classes changes, the perturbed connectivity always
reflects the true structure of the data.
One of the disadvantages of existing clustering approaches, such as k-means, is that
they will produce k clusters even for completely random data. The question is whether
this artificially forced partitioning will also translate to the proposed approach. In order
to demonstrate that this is not the case, we show the CDF-DM curves for completely
random data as the black curves in the lower panels of Figure 3.1b–e. For each case of
k ∈ {2, 4, 5}, the red curve (Dataset3) and the black curve (random data) are close to each
others, reflecting that the perturbed connectivity for Dataset3 is almost as unstable as that
of data without any structure. In contrast, for the correct number of clusters (k=3) the red
curve is far from the black curve indicating that the clustering obtained for this number of
clusters is very different from random. Figure 3.1g contrasts the behavior of the AUC for
Dataset3 against that of random data for all values of k from 2 to 10. The red and black
curves show the AUC values for Dataset3 and random data whereas the blue curve displays
the difference (∆AUC) between the two sets of AUC for k ∈ [2..10].
In summary, the number of subtypes present in the data can be identified based on any
of the following three equivalent criteria: (i) the best (closest to upper left corner) CDF-MD
(see Figure 3.1f), (ii) the highest AUC value (the peak of the red curve in Figure 3.1g), or
(iii) the maximum difference between the AUC constructed from the data and the AUCs of
random data (the peak of the blue curve in Figure 3.1g).
3.2.2 Integrating multiple types of data
The challenge of integrating multiple types of data is addressed in two stages. In the
first stage, we identify subgroups of patients that are strongly connected across heteroge-
neous data types. In the second stage, we analyze each subgroup to decide whether or not
it may warrant further splitting.
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Let us consider T data types from N patients. In the first stage, PINS works with each
data type to build T connectivity matrices, one for each data type. A connectivity matrix
can be represented as a graph, with patients as nodes, and connectivity between patients as
edges. Our goal is to identify subgraphs that are strongly connected across all data types.
We merge the T connectivity matrices into a combined similarity matrix that represents
the overall connectivity between patients. This matrix is used as input for similarity-based
clustering algorithms, such as hierarchical clustering, partitioning around medoids [121], and
dynamic tree cut [135]. By default, we use all three algorithms to partition the patients and
then choose the partitioning that agrees the most with the partitionings of individual data
types [133]. This completes Stage I. Since a very strong signal may dominate the clustering
in Stage I, we next consider each group one at a time, and decide whether to split it further.
A group may be split again if the data types are separable according to gap statistics [136]
and the Stage I clustering is extremely unbalanced with low normalized entropy [137] (see
Methods Section for details).
We illustrate the two stages of the procedure on the kidney renal clear cell carcinoma
(KIRC) dataset from TCGA (Figure 3.2). The input consists of sample-matched mRNA,
methylation, and microRNA measurements (Figure 3.2a–c). We first build the optimal
connectivity between patients for each data type (Figure 3.2d–f). We then construct the
similarity between patients that is consistent across all data types (Figure 3.2g). Partitioning
this similarity matrix results in three groups of patients. Group 1 corresponds to the second
largest blue square while group 2 corresponds to the largest blue square. Group 3 includes
all other patients.
In Stage II, we check each discovered group independently to decide if it can be further
divided. As a result, only group 1 is further split into two subgroups (Figure 3.2h). The first
PCA plot shows the connectivity between patients in group 1 using mRNA data while the
second and third PCA plots show that for methylation and miRNA data, respectively. The
connectivities reflects that this group 1 consists of two subgroups of patients: subgroup 1-1
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Figure 3.2: Data integration and disease subtyping illustrated on the kidney renal clear cell carcinoma (KIRC) dataset. (a–c)
The input consists of three matrices that have the same set of patients but different sets of measurements. (d–f) The optimal
connectivity between the samples for each data type. (g) The similarity between patients that are consistent across all data
types. Partitioning this matrix results in three groups of patients. (h) Group 1 is further split into two subgroups in stage II.
(i) Kaplan-Meier survival curves of 4 subtypes after Stage II splitting of group 1. The survival analysis indicates that the 4
groups discovered after Stage II have significantly different survival profiles (Cox p-value 0.00013).
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in which patients are strongly connected to each others across all the three data types, and
subgroup 1-2 in which patients are loosely connected to each others. Figure 3.2i displays
the four groups discovered by PINS. These groups have very different survival profiles.
3.3 Mathematical description of PINS
3.3.1 Perturbation clustering
The pipeline of the algorithm is shown in Figure 3.3. The input is a dataset (matrix)
I ∈ RN×M , where N is the number of patients and M is the number of measurements for
each patient. In the example of gene expression, N is the number of samples and M is the
number of genes (or probes) measured in each sample. In short, the rows of the matrix I
represent the patients and the columns represent the components (features). The algorithm
parameters are the maximum number of clustersK (default 10) and the number of iterations
H (default 200).
Construction of original connectivity (steps 1-2). In step 1, we partition the patients
using all possible number of clusters k ∈ [2..K]. Formally, the input I can be presented as
a set of N patients I = {e1, e2, . . . , eN} where each element vector ei ∈ RM represents
the molecular profile of the ith patient (i ∈ [1..N ]). A partitioning Pk (k clusters) of I
can be written in the form Pk = {P1,P2, . . . ,Pk} where Pi is a set of patients, such that
∪ki=1Pi = I and Pi∩Pj = ∅, ∀i, j ∈ [1..k], i 6= j. After step (1), we have (K−1) partitionings:
{P2, . . . ,PK}, one for each value of k ∈ [2..K].
In step 2, we build the pair-wise connectivity for each partitioning obtained from step
1. For a partitioning Pk, two patients are connected if they are clustered together. We
build the connectivity matrix Ck ∈ {0, 1}N×N from the partitioning Pk = {P1,P2, . . . ,Pk}
as follows:
Ck(i, j) =
 1 if ∃t ∈ [1..k] : ei, ej ∈ Pt0 otherwise (3.1)
In other words, the connectivity between two patients is 1 if and only if they belong
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Figure 3.3: Perturbation clustering algorithm for high dimensional data. The data are first partitioned with different values of
k (number of clusters). For each value of k, we construct the pair-wise connectivity matrix. To identify the number of clusters
we add noise to the data and then build the pair-wise connectivity for the perturbed data. We calculate the discrepancy in
pair-wise connectivity between before and after data perturbation. We choose kˆ as the optimal number of clusters for which
the pair-wise connectivity is the most stable.
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to the same cluster. For example, we cluster a set of 5 elements into two clusters with the
resulted partitioning P2 = {P1,P2} where P1 = {e1, e2} and P1 = {e3, e4, e5}. In this case,
e1 is connected to e2 and is not connected to other elements (e3, e4, e5). Similarly, elements
{e3, e4, e5} are all connected to each other, but not to elements {e1, e2}. The constructed
connectivity matrix for P2 is as follows:
C2 =

1 1 0 0 0
1 1 0 0 0
0 0 1 1 1
0 0 1 1 1
0 0 1 1 1

Intuitively, a partitioning can be presented as a graph in which each patient is a node
and the connectivity between two patients is an edge, such that the edge exists if and only
if the two patients have similar molecular profile and thus are clustered together. Any two
patients of a cluster are connected by an edge, and any two patients of different clusters are
not connected. The connectivity matrix of the clustering is exactly the adjacency matrix of
the graph.
We construct one connectivity matrix for each value of k ∈ [2..K]. After step 2, we
have (K − 1) connectivity matrices C2, . . . ,CK . We refer to these matrices as original
connectivity matrices because they were constructed from the original data without data
perturbation.
Generating perturbed datasets (step 3). In order to assess the stability of the par-
titionings obtained in steps 1 and 2, we generate H new datasets by perturbing the data.
One way to do so is to add Gaussian noise to the original data I. The noise variance can be
adjusted according to the preference of users. If each component is normalized to follow the
standard normal distribution, then by default the noise will be the variance of the standard
normal distribution. Otherwise, the noise will be automatically set to the median of the
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variances. By default, the noise variance is calculated as follows:
σ2 = median{σ21, . . . , σ2M} (3.2)
where σ2j = var{I(i, j), i ∈ [1..N ]},∀j ∈ [1..M ].
We then generate H new datasets J(h) ∈ RN×M , h ∈ [1..H] by adding Gaussian noise
N (0, σ2) to the original data:
J(h) = I+N (0, σ2) (3.3)
where σ2 is calculated as in Equation (3.2). After this step, we have H perturbed datasets
J(1),J(2), . . . ,J(H) that will be used to compute the perturbed connectivity matrices.
Construction of perturbed connectivity (steps 4-6). To construct the connectivity
between patients for the perturbed data (step 4), we cluster each of theH perturbed datasets
using k-means with varying values of k ∈ [2..K]. For example, for k = 2, we partition the
dataset J(1) into two clusters and get the Q
(1)
2 partitioning. We perform k-means with k = 2
for each of the H perturbed datasets and get H different partitionings Q
(1)
2 ,Q
(2)
2 , . . . ,Q
(H)
2
for k = 2. Note that all of these perturbed datasets were generated by adding a small
amount of noise to the same input I. In the ideal case, adding noise to the data would
not influence the clustering results, i.e. all of the partitionings Q
(1)
2 ,Q
(2)
2 , . . . ,Q
(H)
2 would
be identical to P2. The more differences there are between the perturbed partitionings, the
less reliable the original P2 partitioning is.
Now we have H different partitionings Q
(1)
k , Q
(2)
k , . . . , Q
(H)
k for each value of k ∈
[2..K]. In step 5, we construct a connectivity matrix for each partitioning created in step 4.
Specifically, for the partitioning Q
(h)
k (h ∈ [1..H], k ∈ [2..K]), we construct the connectivity
matrix G
(h)
k ∈ {0, 1}N×N as follows:
G
(h)
k (i, j) =
 1 if i, j belong to the same cluster0 otherwise (3.4)
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After this step, we have H connectivity matrices G
(1)
k , G
(2)
k , . . . , G
(H)
k for each value of
k. In step 6, we calculate the perturbed connectivity matrix by averaging the connectivity
from G
(1)
k , G
(2)
k , . . . , G
(H)
k as follows:
Ak =
1
H
H∑
h=1
G
(h)
k where Ak ∈ [0, 1]N×N , k ∈ [2..K] (3.5)
We refer to these matrices as perturbed connectivity matrices. For each value of k ∈ [2..K],
we have one original connectivity matrix and one perturbed connectivity matrix.
Stability assessment (steps 7-9). Given the number of clusters k, we would like to
quantify the discrepancy between Ck and Ak. In step 7, we calculate the difference matrix
Dk ∈ [0, 1]N×N as follows:
Dk = |Ck −Ak| (3.6)
Dk(i, j) represents the absolute change in connectivity between ei and ej when the data
are perturbed. The smaller Dk(i, j), the more robust the connectivity between ei and ej.
Ideally, when the clustering is the most stable, there would be no differences between Ck
and Ak, i.e. all entries of Dk are equal to zero. The distribution of the entries of Dk reflect
the stability of the clustering. The more this distribution shifts towards 1, the less robust
the clustering. In step 8, we compute the empirical cumulative distribution function (CDF)
Fk of the elements of Dk. For a value c on the interval [0, 1], we calculate Fk(c) as follows:
Fk(c) =
card{Dk(i, j) ≤ c ∧ i, j ∈ [1..N ]}
N2
(3.7)
where the card{·} operator in the numerator represents the cardinality of a set. In essence,
the numerator is the number of elements in Dk that are smaller than or equal to c while
the denominator represents the total number of elements in the matrix Dk.
In step 9, we calculate the area under the curve AUCk, for each of the Fk CDFs. If
Ck and Ak are identical, then the data perturbations do not change the clustering results,
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the difference matrix Dk will consist of only 0’s, Fk(0) = 1, and AUCk = 1. However, if Ck
and Ak differ, then the entries of Dk shift towards 1, and AUCk < 1. In step 10, we choose
the optimal kˆ for which the area under the curve (AUC) is maximized as follows:
kˆ = argmax
k
(AUCk, k ∈ [2..K]) (3.8)
This kˆ is the optimal number of clusters found by the algorithm. This is the number of
clusters that produces the clustering exhibiting the least disruption when the original data
is perturbed by the added noise. Upon finishing, the algorithm returns the optimal value of
kˆ, the partitioning Pkˆ, the original connectivity matrix Ckˆ, and the perturbed connectivity
matrix Akˆ.
3.3.2 Subtyping multi-omics data
Here we describe the workflow of PINS for integrating multi-omics data. The input
of PINS is now a set of T matrices I = {I1, I2, . . . , IT} where T is the number of data
types, Ii ∈ RN×Mi represents the measurements of the ith data type, N is the number of
patients, and Mi is the number of measurements per patient for the i
th data type. The
T matrices have the same number of rows (patients) but might have different number of
columns. For example, for kidney renal clear cell carcinoma (KIRC), we have three date
types: mRNA, DNA methylation, and microRNA. The three data types have the same
the number of patients N = 124, but different numbers of measurements. The numbers of
measurements for mRNA, methylation, and microRNA are M1 =17,974, M2 =23,165, and
M3 = 590, respectively.
The workflow consists of two stages. In stage I, we construct the combined similarity
matrix between patients using the connectivity information from individual data types. We
then partition the patients using the integrated similarity matrix. In stage II, we further
split each discovered group of patients into subgroups if possible.
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Stage I - data integration and subtyping. The algorithm starts by clustering each
data type using the perturbation clustering described above. Consider the ith data type with
the data matrix Ii. The perturbation clustering estimates kˆi as the number of subtypes for
this data type and then partitions the data into kˆi clusters. The algorithm then constructs
the original connectivity matrix Ci for this data type, in which the connectivity between
elements of the same cluster is 1 and the connectivity between elements of different clusters
is 0. Note that the index i here denotes the index of the data type. For T data types, we
have T original connectivity matrices C1,C2, . . . ,CT . If we consider each patient as a node,
and the connectivity between two patients as an edge, then each connectivity matrix for
each data type represents a graph. Each graph represents the connection between patients
from the perspective of one specific data type. Our goal is to identify groups of patients
that are strongly connected across all data types.
In the ideal case, different data types give consistent connectivity between patients
and thus we can easily identify the subtypes. Otherwise, we need to rely on the average
connectivity between data types to partition the samples. To start with, we measure the
agreement between the T data types using a concept similar to the pair-wise agreement of
the Rand index (RI). Given two partitionings of the same set of items, the RI is calculated
as the number of pairs that “agree”, divided by the total number of possible pairs. A pair
“agrees” if the two samples are either grouped together in both partitionings or they are
separated in both partitionings. We extend this concept to T partitionings of T data types.
First we define that the connectivity between two patients is consistent if it does not change
across data types, i.e. the two patients are either connected in all the data types or are not
connected at all in any data type. We then define the agreement of T data types as the
number of pairs having consistent connectivity, divided by the number of possible pairs.
We first calculate the average pair-wise connectivity between patients as follows:
SC =
∑T
i=1Ci
T
(3.9)
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We refer to SC as the original similarity matrix because it is constructed from the
original connectivity matrices. An entry SC(i, j) will be 0 if the elements i and j are never
clustered together; it will be 1 if the elements i and j are always clustered together, and it
will be between 0 and 1 if the two elements are clustered together only in some data types.
We then calculate the agreement between the data types as follows:
agree(SC) =
card{SC(i, j) = 0 ∨ SC(i, j) = 1}
N2
(3.10)
In this equation, the numerator counts only the situations in which the connectivity of
the pair is consistent across all data types (either the two samples are always together or
always separated). If the majority of pairs are consistent (agree(SC) > 50%), we say that
the T data types have a strong agreement. In this case, we also define a strong similarity
matrix SˆC as follows:
SˆC(i, j) =
 1 if SC(i, j) = 10 otherwise (3.11)
where SˆC(i, j) = 1 if and only if i and j are clustered together in all data types. A
hierarchical clustering is then applied directly on this matrix and the resulting tree is cut
at the height that provides maximum cluster separation.
When the data types do not have a strong agreement, we need to partition the patients
using the average connectivity between them. The matrix {SC} represents the overall sim-
ilarity between patients, and therefore {1 − SC} represents the distance between patients.
The matrix of pair-wise distance can be directly used by similarity-based clustering algo-
rithms, such as hierarchical clustering, partitioning around medoids [121], or dynamic tree
cut [135]. Here we use all the three algorithms to partition the patients and then choose the
partition that agrees the most with the partitionings of individual data types.
The dynamic tree cut algorithm can automatically determine the number of clusters,
but the other two algorithms, hierarchical clustering (HC) and partitioning around medoids
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(PAM), require that the number of clusters is provided. To determine the number of clusters
for HC and PAM, we introduce the perturbed similarity matrix, which is the average of the
perturbed connectivity between patients across T data types:
SA =
∑T
i=1Ai
T
(3.12)
where Ai is the perturbed connectivity matrix of the i
th data type. Note that SC is con-
structed by averaging the original connectivity of T data types while SA is constructed by
averaging the perturbed connectivity of T data types. Analogous to the case of using a
single data type, we use both matrices to determine the number of subtypes for HC and
PAM.
For HC, we first build the H1 tree using the original similarity matrix SC , and then we
build the H2 tree using the perturbed similarity matrix SA. For each value of k ∈ [2..10],
we cut H1 to get k clusters and then build the connectivity matrix. We cut the tree H2 for
the same value of k and then construct another connectivity matrix. We then calculate the
instability dk as the sum of absolute difference between the two connectivity matrices. We
choose kˆ for which the dk is the smallest, i.e. kˆ = argmink(dk, k ∈ [2..K]).
For PAM, we partition the patients using both original and perturbed similarity ma-
trices. For each value of k, we have one partitioning using the original similarity matrix SC
and one partitioning using the perturbed similarity matrix SA. We build the connectivity
matrices for the two partitionings and then calculate the instability dk as the absolute dif-
ference between the two connectivity matrices. We choose kˆ for which the dk is the smallest,
i.e. kˆ = argmink(dk, k ∈ [2..K]).
After finding the three partitionings using the three similarity-based clustering algo-
rithms, we calculate the agreement between each partitioning and the T data types. Again,
we use the agreement concept introduced in Equation (3.10). For each algorithm, we cal-
culate the agreement between its partitioning and the T partitionings for the T data types.
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We then choose the result of the algorithm that has the highest agreement with the T data
types.
Stage II - further splitting discovered groups. In stage II, the goal is to discover
true partitions whose presence may have been obscured by the dominant signal in the first
stage. Therefore, we attempt to sub-split each discovered group individually, based on
several reasonable conditions set to avoid over-splitting. First, we check if the connectivity
of the data types found in stage I strongly agrees. In the first case, when the connectivity
between patients are consistent in stage I, we continue to check the consistency between
patients within each group. If each data type of a group can be further partitioned and the
optimal partitionings of all data types strongly agree, we further split the group using the
strong similarity matrix generated for the patients only in that group.
In the second case, when the data types do not have strong agreement in stage I,
the connectivity is likely to have even weaker agreement in stage II. To avoids extremely
unbalanced subtyping, which might be caused by extreme outliers, we also proceed to stage
II but only with the the support of entropy [137] and the gap statistic [136]. Briefly, the
entropy of a partitioning can be calculated as follows. Consider a set of N samples that
are divided into k bins. Each bin consists of ni samples, i ∈ [1..k]. The multiplicity W ,
which is the total number of ways of arranging the samples into the bins, can be calculated
as W = N !∏
i(ni!)
. The entropy is then defined as the logarithm of the multiplicity scaled
by a constant: H = 1
N
lnW = 1
N
ln(N !) − 1
N
∑k
i ln(ni!). For large values of N , and using
Stirling’s approximation, ln(N !) ' N lnN −N , the entropy can be calculated as:
H ' lnN − 1− 1
N
k∑
i
(ni lnni − ni)
= −
k∑
i
(
ni
N
) ln(
ni
N
) = −
k∑
i
pi ln pi
(3.13)
In Equation (3.13), pi =
ni
N
is the fraction of elements that belongs to the ith bin.
The entropy value is maximized when the elements are equally distributed in k bins, i.e.
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p1 = p2 = . . . = pk =
1
k
. In this case Hmax = −
∑k
i (
1
k
) ln( 1
k
) = ln k. To scale the metric, we
use the normalized entropy which is the ratio between H and Hmax:
Hˆ = −
∑k
i pi ln pi
ln k
(3.14)
where Hˆ ∈ [0, 1]
We note that Hˆ = 1 represents an ideally balanced clustering, and Hˆ = 0 represents an
unrealistically unbalanced clustering, e.g. all the N elements fall into one bin. We proceed to
stage II only when the entropy is smaller than 50% of the maximum entropy, i.e. normalized
entropy Hˆ < 0.5. In addition to entropy, we also use the gap statistic to check if the data
can be further clustered before we proceed to stage II. Briefly, the gap statistic compares the
total within cluster variation Wk (residual sum of square for k-means) for different values
of k, with their expected values under the null reference distribution, i.e. the distribution
with no obvious clustering:
GapN(k) = E
∗
N{ln(Wk)} − ln(Wk) (3.15)
where E∗n denotes the expectation under a sample of size N from the reference distribution.
E∗n is calculated via bootstrapping by generating B copies of the reference datasets and by
computing the average ln(W ∗k ). The gap statistic measures the deviation of the observedWk
value from its expected value under the null hypothesis. The algorithm returns the first k
such that gapN(k) ≥ gapN(k+ 1)− sk+1 where sk+1 is the standard deviation of W ∗k+1. The
null hypothesis is that the data is from the reference distribution (no obvious clustering).
If the algorithm returns 1, we say that we do not find enough evidence to reject the null
hypothesis [136]. We only proceed to stage II if the majority of data types can be clearly
separated using the gap statistic.
In summary, when the data types are not consistent, we avoid unbalanced clustering
by attempting to further split each group based on two conditions. First, the normalized
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entropy of the clustering in stage I must be very low (< 0.5). Second, the gap statistic must
clearly support a separation of the patients.
3.4 Results and validation
3.4.1 Simulation studies
In this section, we will demonstrate that the proposed approach: i) does not produce
spurious clusters when the data does not contain any true classes, and ii) is able to find the
correct subtypes when the data consists of distinct classes. In the first case, when the data
has no structure, we show that any partitioning is unstable. In the second case, when the
data consists of distinct classes, we show that the connectivity between samples is stable if
and only if the partitioning is identical to the true classes.
In order to do this, we constructed 10 datasets: Gaussian1, Dataset2, . . . , Dataset10,
where the number in each name represents the number of classes of the dataset. Each
dataset has 100 samples and 1, 000 genes. The samples are equally divided among the
classes. For example, Dataset2 has two classes of size 50 and Dataset3 has three classes of
size 33, 33, and 34. The dataset Gaussian1 has no distinct classes and thus will be used
to demonstrate that PINS does not report false clusters. We will show that the pair-wise
connectivity between samples are very unstable when the data is perturbed, regardless of
the number of k. In consequences, the perturbed connectivity matrices are very different
from the original connectivity matrices. This results in low AUC values for all values of k.
Each of the other 9 datasets, Dataset2, . . . , Dataset10, has distinct classes and thus will be
used to demonstrate PINS’ ability to retrieve the correct number of clusters in a mixture of
data. We will show that for each of these datasets, the pair-wise connectivity is stable only
when the number of clusters equals to the true number of classes.
The distribution of gene expression for the dataset Gaussian1 is shown in Figure 3.4A.
The expression values of all genes follow a Gaussian distribution N (0, 1) with mean 0 and
variance 1. We note that the variance of the normal distribution for each gene has no impact
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on the result of PINS because the noise variance is set to be the median variance of the genes.
For each value of k, the algorithm partitions the original data and then builds an original
connectivity matrix. It then calculates the variance of each gene and the median variance
σ2. Since σ2i ≈ 1, ∀i ∈ [1..1000], we have the median variance σ2 is approximately 1. This
median variance is used as the noise variance to construct 200 perturbed datasets. From the
perturbed dataset, the algorithm constructs 200 connectivity matrices G
(h)
k (h ∈ [1..200])
for each value of k. The perturbed connectivity matrix is then calculated as the average of
these 200 matrices, Ak =
∑200
h=1G
(h)
k
200
. For each value of k ∈ [2..10], we have one original and
one perturbed connectivity matrix.
Figure 3.4B shows several of the original connectivity matrices (upper row) with their
corresponding perturbed connectivity matrices just below. Using the original data, when
k = 2, the algorithm forms two clusters of approximately equal size. Perturbation of the
data moves each data point around its original location, allowing it to be grouped together
with any other point with the same probability. Visually, the perturbed connectivity matrix
A2 in panel (B) shows that data points are randomly connected. This is also true for other
values of k ∈ [2..10]. Thus, the perturbed connectivity greatly diverges from the original
connectivity, for any value of k ∈ [2..10], using dataset Gaussian1.
Figure 3.4C shows the CDF curves obtained from the difference matrices Dk for all
values of k ∈ [2..10]. The horizontal axis represents the entries of the difference matrix while
the vertical axis represents Fk values. Figure 3.4D shows the area under the curve (AUC)
of the CDFs. The horizontal axis shows different values of k as the numbers of clusters and
the vertical axis shows the AUC values. These AUC values monotonically increase with k,
and they range from 0.5 to 0.85.
To understand the variability of the AUC values, we repeat the whole process 20 times.
Each time we regenerate the gene expression of the dataset Gaussian1 and recalculate the
AUC values for k ∈ [2..10]. The vertical lines of Figure 3.4D show the 95% confidence
interval of the AUC values at each value of k. We also plot the AUC values for another
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simulated dataset, in which the expression values of all genes are uniformly distributed on
the interval [0..1]. The figure shows that both uniform data and Gaussian data have very
similar AUC values.
Having demonstrated the behavior of PINS using data without structure, we next show
that PINS determines the correct clusters using simulated datasets with separable classes.
Dataset2 is created to have two classes, each with 50 samples. As shown in Figure 3.5A, the
first class has the genes 1− 100 up-regulated while the second class has the genes 101− 200
up-regulated. Figure 3.5B shows several original connectivity matrices (upper row) and
their corresponding perturbed connectivity matrices (lower row). When k = 2, the algo-
rithm correctly separates the two classes using the original data. We see that the perturbed
connectivity matrix is identical to the original connectivity matrix when k = 2, but when
k > 2, the algorithm further splits each group into smaller groups of patients. For example,
when k = 3, the upper-left cluster from the k = 2 result is split into two smaller groups.
When the data are perturbed, however, the connectivity between data points of the same
class tend to recover. Regardless of the value of k being used, the perturbed connectivity
matrices clearly show that there are only two groups of strongly connected patients, reflect-
ing the true structure of the dataset. Panel (C) shows the CDF curves obtained from the
difference matrices while panel (D) shows the AUC values. Since the original and perturbed
connectivity matrices are identical for k = 2, we have F2(0) = 1 and AUC2 = 1. In other
words, P2 is the only partitioning that is stable against data perturbation, and therefore
kˆ = 2 is the optimal number of subtypes for the dataset Dataset2. PINS correctly and
deterministically recovers the true classes of the dataset Dataset2.
Similarly, Dataset3 is created to have three classes, with 33, 33, and 34 samples, totaling
100, as before. Each class has 100 up-regulated genes, as shown in Figure 3.6A: gene numbers
1 − 100 for the first class, 101 − 200 for the second, and 201 − 300 for the third. Original
and perturbed connectivity matrices are shown for k = 2, k = 3, and k = 10 in Figure 3.6B.
When k = 3, the algorithm correctly separates the data into three classes using the original
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Figure 3.4: PINS workflow for the simulated dataset Gaussian1. The dataset consists of 100 samples and 1, 000 genes. Panel
(A) shows the expression profile of the dataset, in which all patients belong to one class. All gene expression values follow a
normal distribution N (0, 1) with mean 0 and variance 1. Panel (B) shows the original connectivity matrices (upper row) and
perturbed connectivity matrices (lower row), for different numbers of clusters. The two left-most matrices show the original
and the perturbed connectivity matrices for k = 2. For k = 2, the algorithm divides the original data into two clusters. When
the data are perturbed, each data point is randomly moved around its original location and can be grouped together with any
other point with the same probability. The perturbed connectivity matrix shows that the connectivity between any two data
points is random, without any structure. Similarly, the perturbed connectivity matrices for k = 4 and k = 10 have no structure
either. Panel (C) displays the empirical cumulative distribution functions (CDF) Fk of the difference matrix Dk, k ∈ [2..10].
The horizontal axis represents the entries of the difference matrix while the horizontal axis displays the values of the function
(the number of elements in Dk smaller than or equal to each entry). Panel (D) shows the area under the curve (AUC) for each
value of k. To assess the variability of the AUC values, we repeat the whole process 20 times with different simulated datasets
having normally distributed gene expression. The vertical lines show the 95% confidence interval of the AUCs at each value of
k. We also plot the AUC for a simulated dataset with uniformly distributed expression values. The figure shows that when the
data are random, regardless of the distribution, the AUC values vary only slightly. In addition, the AUC values monotonically
increase with k, and range from 0.5 to 0.85.
99
Simulated dataset Dataset2 (2 classes)
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Figure 3.5: PINS workflow for the simulated dataset Dataset2. The dataset consists of 100 samples and 1, 000 genes. Panel
(A) shows the expression of the two classes. Each class has 50 samples. The first class has the genes 1 − 100 up-regulated
while the second class has the genes 101− 200 up-regulated. The expression of the up-regulated genes follow the distribution
N (2, 1) with mean two while the expression of other genes follow the distribution N (0, 1) with mean 0. Panel (B) shows the
original connectivity matrices (upper row) and perturbed connectivity matrices (lower row). For k = 2, the algorithm correctly
separates the two classes using the original data. As we perturb the data, each data point moves around its original position
but still stays close to its own cluster. Therefore, samples of the same class are still grouped together, making the perturbed
connectivity matrix identical to the original connectivity matrix. For k > 2, the algorithm further splits each group into
smaller groups. However, when the data are perturbed, samples of the same class tend to connect to each other. Regardless
of k value being used, the perturbed connectivity matrices clearly suggest that the data consists two groups of samples, which
is the true structure of Dataset2. Panel (C) displays the empirical cumulative distribution functions (cdf) Fk of the difference
matrix Dk, k ∈ [2..10]. The horizontal axis represents the entries of the difference matrix while the vertical axis displays the
values of the function (the number of elements in Dk smaller than or equal to each entry). Panel (D) shows the AUC values
for Dataset2 (red curve), Gaussian1 (black curve) and the difference (blue) between the two curves. Since the original and
perturbed connectivity matrices are identical for k = 2, F2(0) = 1 and AUC2 = 1. The AUC curve shows that only the
partitioning P2 is stable against data perturbation, i.e. kˆ = 2. PINS correctly and deterministically discovers the true classes
of the dataset Dataset2.
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Simulated dataset Dataset3 (3 classes)
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Figure 3.6: PINS workflow for the simulated dataset Dataset3. The dataset consists of 100 samples and 1, 000 genes. Panel
(A) shows the expression of the three classes. Each of the first and second classes have 33 samples while the third class has
34 samples (totally 100 samples). The first class has the genes 1− 100 up-regulated; the second class has the genes 101− 200
up-regulated; the third class has the genes 201− 300. The up-regulated genes’ expression follow the distribution N (2, 1) with
mean two while other genes’ expression follow the distribution N (0, 1) with mean 0. Panel (B) shows the original connectivity
matrices (upper row) and perturbed connectivity matrices (lower row). For k = 3, the algorithm correctly separates the three
classes using the original data. As we perturb the data, samples of the same class are still grouped together, making the
perturbed connectivity matrix identical to the original connectivity matrix. For k > 3, the algorithm further splits each class
into smaller groups. However, when the data are perturbed, samples of the same class tend to connect to each other. For k = 2,
the original connectivity matrix C2 shows that two of the three classes are merged but the connectivity between them is not
stable when the data are perturbed. The perturbed connectivity matrices clearly suggest that the data consists three groups of
samples, which is the true structure of Dataset3. Panel (C) displays the empirical cumulative distribution functions (CDF) Fk
of the difference matrix Dk, k ∈ [2..10]. The horizontal axis represents the entries of the difference matrix while the vertical
axis displays the values of the function (the number of elements in Dk smaller than or equal to each entry). Panel (D) shows
the AUC values for Dataset3 (red curve), Gaussian1 (black curve) and the difference (blue) between the two curves. The AUC
curve shows that only the partitioning P3 is stable against data perturbation, i.e. kˆ = 3. PINS correctly and deterministically
discovers the true classes of the dataset Dataset3.
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Simulated dataset Dataset5 (5 classes)
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Figure 3.7: PINS workflow for the simulated dataset Dataset5. The dataset consists of 100 samples and 1, 000 genes. Panel (A)
shows the expression of the 5 classes. Each class consists of 20 samples. The ith class has genes the ith 100 genes up-regulated,
e.g. genes 1− 100 are up-regulated in the first class and genes 401− 500 are up-regulated in the fifth class. These up-regulated
genes follow the distribution N (2, 1) with mean 2. Other genes follow the distribution N (0, 1) with mean 0. Panel (B) shows
the original connectivity matrices (upper row) and perturbed connectivity matrices (lower row). For k = 5, the algorithm
correctly separates the 5 classes using the original data. As we perturb the data, samples of the same class are still grouped
together, making the perturbed connectivity matrix identical to the original connectivity matrix. For k > 5, the algorithm
further splits each class into smaller groups but samples of the same class tend to connect to each other when the data are
perturbed. For k < 5, some classes are merged together, but the connectivity between samples of different classes is not stable
against data perturbation. The perturbed connectivity matrices clearly suggest that the data consists 5 groups of samples,
which is the true structure of Dataset5. Panel (C) displays the empirical cumulative distribution functions (CDF) Fk of the
difference matrix Dk, k ∈ [2..10]. The horizontal axis represents the entries of the difference matrix while the vertical axis
displays the values of the function (the number of elements in Dk smaller than or equal to each entry). Panel (D) shows the
AUC values for Dataset5 (red curve), Gaussian1 (black curve) and the difference (blue) between the two curves. The AUC
curve shows that only the partitioning P5 is stable against data perturbation, i.e. kˆ = 5. PINS correctly and deterministically
discovers the true classes of the dataset Dataset5.
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Simulated dataset Dataset9 (9 classes)
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Figure 3.8: PINS workflow for the simulated dataset Dataset9. The dataset consists of 100 samples and 1, 000 genes. Panel
(A) shows the expression of the 9 classes. Each of the 8 first classes consists of 11 samples and ninth class consists of 12
samples (totally 100). The ith class has genes the ith 100 genes up-regulated, e.g. genes 1 − 100 are up-regulated in the
first class and genes 801 − 900 are up-regulated in the 9th class. These up-regulated genes are normally distributed with
mean 2 and variance 1. Other genes are normally distributed with mean 0 and variance 1 (N (0, 1)). Panel (B) shows the
original connectivity matrices (upper row) and perturbed connectivity matrices (lower row). For k = 9, the algorithm correctly
separates the 9 classes using the original data. As we perturb the data, samples of the same class are still grouped together,
making the perturbed connectivity matrix identical to the original connectivity matrix. For k = 10, the algorithm further
splits a class into two smaller groups but samples of the same class tend to connect to each other when the data are perturbed.
For k < 9, some classes are merged together, but the connectivity between samples of different classes is not stable against
data perturbation. The perturbed connectivity matrices clearly suggest that the data consists 9 groups of samples, which is
the true structure of Dataset9. Panel (C) displays the empirical cumulative distribution functions (cdf) Fk of the difference
matrix Dk, k ∈ [2..10]. The horizontal axis represents the entries of the difference matrix while the vertical axis displays the
values of the function (the number of elements in Dk smaller than or equal to each entry). Panel (D) shows the AUC values
for Dataset9 (red curve), Gaussian1 (black curve) and the difference (blue) between the two curves. The AUC curve shows
that only the partitioning P9 is stable against data perturbation, i.e. kˆ = 9. PINS correctly and deterministically discovers
the true classes of the dataset Dataset9.
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Figure 3.9: Area under the curve (AUC) of the 10 simulated datasets. The horizontal axis shows the number of clusters while
the vertical axis shows the AUC values. The AUC values of Gaussian1 (random data) are the lowest for all values of k, and
range from 0.5 to 0.85. For all other datasets, PINS correctly identifies the true number of clusters kˆ (AUCkˆ = 1). These
optimal AUC values are much higher than the AUC values of the purely random dataset (Gaussian1).
data or the perturbed data. As k increases beyond k = 3, the non-perturbed data is split into
smaller groups by the algorithm. However, when k 6= 3, data perturbation allows samples of
the same class to connect to each other with higher probability, producing a shadow image of
the correct number of classes in Figure 3.6B. When k = 2, the original connectivity matrix
C2 shows that the second and third classes are merged, but the connectivity between them
is not stable against data perturbation. All perturbed connectivity matrices clearly suggest
that the data consists of three groups of samples, which is the true structure. Panels (C,
D) display the CDF curves and the AUC values for different values of k. P3 is the only
partitioning that is stable against data perturbation with AUC3 = 1. PINS deterministically
discovers the true classes of the dataset Dataset3.
Finally, Figures 3.7 and 3.8 display the PINS results for the simulated datasets Dataset5
(5 classes) and Dataset9 (9 classes). In both cases, the perturbed connectivity matrices
clearly show the true structure of the data and PINS correctly discovers the true classes of
each dataset. A plot of the AUC values for all of the 10 datasets are shown in Figure 3.9.
When the data have no structure as in Gaussian1, the AUC values monotonically increase
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Table 3.1: Description of the 8 gene expression datasets used in the experimental studies. The top 5 datasets were downloaded
from Gene Expression Omnibus. The bottom 3 datasets were downloaded from the Broad Institute website.
Datasets Class Sample Component Platform Description
GSE10245 [138] 2 58 19851 hgu133plus2 40 adenocarcinomas and 18 squamous cell carcino-
mas
GSE19188 [139] 3 91 19851 hgu133plus2 45 adenocarcinomas, 19 large cell carcinomas, and
27 squamous cell carcinomas
GSE43580 [140] 2 150 19851 hgu133plus2 77 adenocarcinomas and 73 squamous cell carcino-
mas
GSE14924 [141] 2 20 19851 hgu133plus2 10 acute myeloid leukemia CD4 T cell and 10 CD8
T cell
GSE15061 [142] 2 366 19851 hgu133plus2 202 acute myeloid leukemia samples and 164
myelodyplastic syndrome samples
Lung2001 [143] 4 237 8641 hgu95a 190 adenocarcinomas, 21 squamous cell carcino-
mas, 20 carcinoid, and 6 small-cell lung carcinomas
AML2004 [97, 100] 3 38 5000 hgu6800 11 acute myeloid leukemia, 19 acute lymphoblastic
leukemia B cell, and 8 T cell
Brain2002 [144] 5 42 5299 hgu6800 10 meduloblastomas, 10 malignant gliolas, 10 atyp-
ical teratoid/rhaboid tumors, 4 normal cerebel-
lums, and 8 primitive neuroectodermal tumors
with k, and range between 0.5 and 0.85. When the data consist of at least two classes, the
AUC values greatly increase. For any value of k, the AUC value of Gaussian1 is always
smaller than the AUC value of any other dataset. PINS correctly identifies the optimal
number of clusters kˆ with AUCkˆ = 1 for all 9 datasets.
3.4.2 Subtyping gene expression data (single data type)
To validate PINS, we test it first using real data with known subtypes. Also, we first
start by using a single data type. In order to do this, we use eight gene expression datasets,
selected to include many samples (> 1, 000), a large variety of conditions and tissues, and a
varied number of known subtypes. To address the particular challenge posed by situations
in which a subtype is poorly represented in the data, we include both balanced datasets with
a ratio of almost 1:1 between the number of samples in the smallest and the largest subtype,
as well as unbalanced sets with ratios between 1:3 and 1:33 (see Table 3.1). We also note
that some of these datasets were used in the publication of classical subtyping procedures,
such as Consensus Clustering [116] and Non-Negative Matrix Factorization [100].
Five of the datasets, GSE10245, GSE19188, GSE43580, GSE14924, and GSE15061,
were downloaded from Gene Expression Omnibus while the other three datasets were down-
loaded from the Broad Institute: AML2004 (www.broadinstitute.org/cancer/pub/nmf),
Lung2001 (www.broadinstitute.org/mpr/lung/), and Brain2002 (www.broadinstitute.
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Table 3.2: The performance of PINS, Consensus Clustering (CC), Similarity Network Fusion (SNF), and iClusterPlus in
discovering subtypes from gene expression data. For each dataset (row), cells highlighted in green have the highest Rand Index
(RI), and Adjusted Rand Index (ARI). For all 8 datasets, PINS outperforms its competitors by having the highest RI and
ARI. SNF produced an error for GSE14924, shown as an NA value.
Dataset PINS CC SNF iClusterPlus
Name Sample Class k RI ARI k RI ARI k RI ARI k RI ARI
GSE10245 58 2 2 0.90 0.80 6 0.64 0.32 2 0.69 0.38 3 0.7 0.43
GSE19188 91 3 3 0.84 0.66 4 0.82 0.6 4 0.61 0.12 6 0.72 0.33
GSE43580 150 2 2 0.72 0.44 3 0.68 0.37 2 0.58 0.15 7 0.6 0.19
GSE15061 366 2 2 0.83 0.65 6 0.72 0.43 2 0.53 0.05 10 0.58 0.17
GSE14924 20 2 2 1.00 1.00 7 0.64 0.25 NA NA NA 3 0.87 0.73
Lung2001 237 4 2 0.82 0.54 8 0.46 0.11 3 0.62 0.28 8 0.47 0.11
AML2004 38 3 4 0.85 0.65 5 0.81 0.56 2 0.59 0.17 4 0.66 0.21
Brain2002 42 5 8 0.89 0.61 5 0.8 0.46 2 0.57 0.13 3 0.71 0.35
org/MPR/CNS/). The dataset AML2004 was already processed and normalized [100]. For
the other seven, Affymetrix CEL files containing raw expression data were processed and
normalized using the threestep function from the package affyPLM version 1.38.0 [76]. For
PINS, CC, and SNF, the gene expression data were analyzed without gene pre-selection.
For iClusterPlus, we select the top 2000 variable genes (using median absolute deviation)
because the software returns NA for unfiltered data.
Since the true disease subtypes are known in these datasets, we use the Rand Index
(RI) [145] and Adjusted Rand Index (ARI) [146] to assess the performance of the resulted
subtypings. RI measures the agreement between a given clustering and the ground truth. In
short, RI = (a+b)/
(
N
2
)
where a is the number of pairs that belong to the same true subtype
and are clustered together, b is the number of pairs that belong to different true subtypes
and are not clustered together, and
(
N
2
)
is the number of possible pairs that can be formed
from the N samples. Intuitively, RI is the fraction of pairs that are grouped in the same
way (either together or not) in the two partitions compared (e.g. 0.9 means 90% of pairs
are grouped in the same way). The Adjusted Rand Index (ARI) is the corrected-for-chance
version of the Rand Index. The ARI takes values from -1 to 1, with the ARI expected to
be 0 for a random subtyping.
Table 3.2 shows the clustering results of PINS, CC, SNF, and iClusterPlus for the 8
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gene expression datasets. Cells highlighted in green have the highest RI and ARI in their
respective rows. For all 8 datasets, PINS considerably outperforms existing approaches in
identifying the known subtypes of each disease. More specifically, PINS yields the highest
RI and ARI values for every single dataset tested.
3.4.3 Subtyping patients using multi-omics data
We analyzed 6 different cancers which have curated level three data, available at
the TCGA website (cancergenome.nih.gov/): kidney renal clear cell carcinoma (KIRC),
glioblastoma multiforme (GBM), acute myeloid leukemia (LAML), lung squamous cell car-
cinoma (LUSC), breast invasive carcinoma (BRCA), and colon adenocarcinoma (COAD).
We used mRNA expression, DNA methylation, and miRNA expression data for each of
the 6 cancers. TCGA contains multiple platform for each data type. We chose the plat-
forms giving the largest set of common tumor samples across the three data types while still
using a single platform for each data type (see Table 3.3). For gene expression, we used
the HT-HG-U133A platform in GBM and LUSC, the Illumina-HiSeq-RNASeq platform in
KIRK and BRCA, and the Illumina-GA-RNASeq platform in LAML and COAD. For mi-
croRNA, we used the Illumina-HiSeq-microRNASeq platform in GBM and the Illumina-GA-
microRNASeq platform in KIRC, LAML, LUSC, BRCA and COAD. For DNA methylation,
we used the JHU-USC-Human-Methylation-27 platform for all 6 cancers.
For each cancer, we first analyze each data type independently and report the resulted
subtypes. We then analyze the three data types together. PINS and SNF take the three
matrices as input without any further processing. Since CC is not designed to integrate
multiple data types, we concatenate the three data types for the integrative analysis. For
iClusterPlus, we used the 2000 features with largest median absolute deviation for each data
type because the software returns NA for unfiltered data. For some cancers, iClusterPlus is
unable to analyze the microRNA data.
The subtypes identified by the four approaches are analyzed using the Kaplan-Meier
survival analysis [147] (Figures 3.10–3.15), and their statistical significance is assessed using
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Table 3.3: Description of the 6 datasets downloaded from The Cancer Genome Atlas (TCGA): kidney renal clear cell carcinoma
(KIRC), glioblastoma multiforme (GBM), lung squamous cell carcinoma (LUSC), breast invasive carcinoma (BRCA), acute
myeloid leukemia (LAML), and colon adenocarcinoma (COAD). For all datasets, we use TCGA-curated level three data of
mRNA expression, DNA methylation, and mRNA expression.
Dataset Sample Data type Component Platform Data level
KIRC 124
mRNA 17974 Illumina HiSeq RNASeq 3
Methylation 23165 HumanMethylation27 3
miRNA 590 Illumina GASeq miRNASeq 3
GBM 273
mRNA 12042 HT HG-U133A 3
Methylation 22833 HumanMethylation27 3
miRNA 534 Illumina HiSeq miRNASeq 3
LAML 164
mRNA 16818 Illumina GASeq RNASeq 3
Methylation 22833 HumanMethylation27 3
miRNA 552 Illumina GASeq miRNASeq 3
LUSC 110
mRNA 12042 HT HG-U133A 3
Methylation 23348 HumanMethylation27 3
miRNA 706 Illumina GASeq miRNASeq 3
BRCA 172
mRNA 20100 Illumina HiSeq RNASeqV2 3
Methylation 22533 HumanMethylation27 3
miRNA 718 Illumina GASeq miRNASeq 3
COAD 146
mRNA 17062 Illumina GASeq RNASeq 3
Methylation 24454 HumanMethylation27 3
miRNA 710 Illumina GASeq miRNASeq 3
Cox regression [148] (Table 3.4). After data integration, CC finds groups with significant
survival differences in 2 out of the 6 cancers: GBM (p = 0.039) and LAML (p = 0.035).
SNF and iClusterPlus find subgroups with significantly different survival only for LAML
(p = 0.037 and p = 0.017, repectively). In contrast, PINS identifies groups that have
statistically significant survival differences in 5 out of the 6 cancers: KIRC (p = 10−4),
GBM (p = 8.7 × 10−5), LAML (p = 0.0024), LUSC (p = 0.0097), and BRCA (p = 0.034),
showing a clear advantage of PINS over this state-of-the-art method.
Notably, the 6 datasets illustrated here include several interesting cases. In the KIRC
data, no single data type appears to carry sufficient information for any of the four methods
to be able to identify groups with significant survival differences. However, when the three
data types are integrated and analyzed together, PINS is able to extract 4 groups with very
significant survival differences (p = 10−4). Note that none of the other algorithms is able to
identify groups with significantly different survival profiles for this disease.
Another interesting situation is that in which a single data type is sufficient for the
discovery of significantly different subtypes. For instance, the methylation appears to be a
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key phenomenon in glioblastoma (GBM) since all four methods are able to identify subgroups
with significant survival differences based on this data type alone (p = 10−4 for PINS, 10−3
for CC, p = 0.017 for SNF, and 3× 10−3 for iClusterPlus). However, when the methylation
data is integrated with mRNA and miRNA data, SNF and iClusterPlus lose their ability
to accurately separate the patients into different survival groups (p = 0.062 for SNF and
p = 0.076 for iClusterPlus). In contrast, PINS is able to combine the complementary signals
available in the three data types to obtain subtypes with even more significant survival
differences (p = 8.7× 10−5).
For LAML, LUSC and BRCA, PINS is able to find subtypes with significantly different
survivals based on a single data type alone, but the integrative analysis of all three data
types greatly enhances the significance of the survival differences. Finally, we include the
COAD as a negative control, i.e. an example of a condition in which no subtypes are known
and for which neither approach identifies subgroups with significant survival differences after
data integration.
In summary, for every single integrative analysis, PINS outperforms the three other
approaches in identifying subtypes with significantly different survival profiles. Furthermore,
the results show a clear advantage of data integration over analysis of individual data types.
3.5 Summary
The novel approach described here is able to address two very important challenges:
data integration and disease subtype discovery. We show that PINS is able to: i) effectively
integrate mRNA, microRNA and methylation data and ii) in an unbiased and unsupervised
manner, discover disease subtypes characterized by significant survival differences. PINS
not only outperforms current state-of-the-art approaches as a method for subtype discovery
based on a single data type, but also for identifying novel subtypes with significantly different
survival profiles by integrating multiple types of data. In addition, the visualization of
pair-wise connectivity between patients can provide additional insight into the discovered
subtypes.
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Figure 3.10: Kaplan-Meier survival analysis for kidney renal clear cell carcinoma (KIRC). The horizontal axis represents the
time passed after entry into the study while the vertical axis represents estimated survival percentage. SNF finds two groups
while CC and iCluster find 6 groups. The survival profiles of the groups discovered by each of the three methods are not
significantly different. In contrast, PINS discovers 4 groups with very different survival profiles (p = 1.3× 10−4).
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Figure 3.11: Kaplan-Meier survival analysis for glioblastoma multiforme (GBM). The horizontal axis represents the time passed
after entry into the study while the vertical axis represents estimated survival percentage. SNF and iClusterPlus discover 4
and 5 groups, respectively, with no significantly different survival profiles. CC finds 7 groups with significant different survival
profiles (p = 0.039). PINS discovers three different groups with very different survival profiles (p = 8.7× 10−5).
110
0 500 1000 1500 2000 2500
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Days
Su
rv
iva
l p
ro
ba
bi
lity
PINS result, LAML, p = 0.0024
Group 1: 19
Group 2: 73
Group 3: 39
Group 4: 33
0 500 1000 1500 2000 2500
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Days
Su
rv
iva
l p
ro
ba
bi
lity
CC result, LAML, p = 0.035
Group 1: 22
Group 2: 11
Group 3: 17
Group 4: 24
Group 5: 16
Group 6: 38
Group 7: 12
Group 8: 24
0 500 1000 1500 2000 2500
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Days
Su
rv
iva
l p
ro
ba
bi
lity
iClusterPlus result, LAML, p = 0.017
Group 1: 22
Group 2: 25
Group 3: 40
Group 4: 49
Group 5: 28
0 500 1000 1500 2000 2500
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Days
Su
rv
iva
l p
ro
ba
bi
lity
SNF result, LAML, p = 0.037
Group 1: 15
Group 2: 72
Group 3: 77
Figure 3.12: Kaplan-Meier survival analysis of acute myeloid leukemia (LAML). The horizontal axis represents the time passed
after entry into the study while the vertical axis represents estimated survival percentage. All the four methods discover groups
of patients that have different survival profiles.
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Figure 3.13: Kaplan-Meier survival analysis for lung squamous cell carcinoma (LUSC). The horizontal axis represents the time
passed after entry into the study while the vertical axis represents estimated survival percentage. CC, iClusterPlus, and SNF
finds 6, 4, and 3 groups, respectively, with no significantly different survival. In contrast, PINS discovers 5 different groups
with different survival profiles (p = 9.7× 10−3).
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Figure 3.14: Kaplan-Meier survival analysis for breast invasive carcinoma (BRCA). The horizontal axis represents the time
passed after entry into the study while the vertical axis represents estimated survival percentage. Only PINS discovers subtypes
with different survival profiles (p = 0.034).
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Figure 3.15: Kaplan-Meier survival analysis for colon adenocarcinoma (COAD). The horizontal axis represents the time passed
after entry into the study while the vertical axis represents estimated survival percentage. For all four methods, the discovered
groups do not exhibit significant differences in survival.
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Table 3.4: Subtypes identified by PINS, CC, SNF, and iClusterPlus for 6 TCGA cancer datasets: kidney renal clear cell
carcinoma (KIRC), glioblastoma multiforme (GBM), acute myeloid leukemia (LAML), lung squamous cell carcinoma (LUSC),
breast invasive carcinoma (BRCA), and colon adenocarcinoma (COAD). The first three columns describe the data while the
next 8 columns show the number of subtypes and Cox p-values. The results for the integrated data are displayed in bold.
The cells highlighted in green have Cox p-values smaller than 0.01. Cells highlighted in yellow have Cox p-values between
0.01 and 0.05. After data integration, PINS finds subtypes with significantly different survival for five out of the six cancers
(KIRC, GBM, LUSC, BRCA, and LAML) whereas SNF and iClusterPlus succeed for only one (LAML) and CC succeeds for
two (GBM and LAML).
TCGA dataset PINS CC SNF iClusterPlus
Name Patients Data type k Cox p-val. k Cox p-val. k Cox p-val. k Cox p-val.
KIRC 124
mRNA 2 0.176 7 0.073 2 0.219 9 0.072
Methylation 3 0.111 6 0.128 3 0.577 10 0.14
miRNA 2 0.138 5 0.509 2 0.138 NA NA
Integration 4 1.3× 10−4 6 0.104 2 0.138 6 0.077
GBM 273
mRNA 2 0.408 5 0.281 2 0.992 10 0.056
Methylation 2 10−4 6 0.001 2 0.017 10 0.003
miRNA 4 0.086 6 0.526 2 0.401 10 0.09
Integration 3 8.7× 10−5 7 0.039 4 0.062 5 0.076
LAML 164
mRNA 5 0.003 6 8× 10−4 2 0.327 6 0.01
Methylation 6 0.239 7 0.049 2 0.993 10 0.002
miRNA 2 0.072 6 0.017 3 0.183 NA NA
Integration 4 2.4× 10−3 8 0.035 2 0.037 5 0.017
LUSC 110
mRNA 3 0.125 5 0.782 3 0.095 7 0.588
Methylation 8 0.019 9 0.129 2 0.376 10 0.606
miRNA 2 0.117 6 0.938 2 0.001 NA NA
Integration 5 9.7× 10−3 6 0.794 3 0.428 4 0.36
BRCA 172
mRNA 2 0.902 8 0.114 2 0.969 9 0.101
Methylation 4 0.048 8 0.578 5 0.878 10 0.083
miRNA 3 0.218 5 0.142 2 0.105 NA NA
Integration 7 3.4× 10−2 7 0.667 2 0.398 10 0.416
COAD 146
mRNA 2 0.113 8 0.048 2 0.148 6 0.29
Methylation 2 0.741 8 0.034 2 0.389 10 0.194
miRNA 4 0.452 7 0.318 3 0.131 NA NA
Integration 5 0.201 5 0.225 2 0.296 10 0.445
PINS can be used to integrate many other high-throughput data types for the purpose
of disease characterization, understanding of disease mechanisms, or biomarker detection. It
can also be used to integrate pharmacokinetic data and drug response data for drug devel-
opment and repurposing. Finally, this method provides a powerful alternative to Consensus
Clustering, a prominent technique in machine learning, with the additional ability to inte-
grate multiple types of data. Unlike many existing machine learning approaches, PINS can
effectively analyze datasets with tens of thousands of variables and hundreds of samples,
without requiring a preliminary step involving data filtering or feature selection. These ca-
pabilities make PINS highly relevant for immediate practical applications rather than just
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a theoretical advance. Since PINS is completely independent of the data types being used,
it can be applied in many areas to tackle unsupervised machine learning problems involving
either single or multiple types of high-dimensional data.
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CHAPTER 4: ORTHOGONAL META-ANALYSIS –
APPLIED TO PATHWAY ANALYSIS
4.1 MicroRNA and pathway analysis
MicroRNAs (miRNAs) are small non-coding RNA molecules whose primary function is
to regulate the expression of gene products via hybridization to mRNA transcripts, resulting
in suppression of translation or mRNA degradation. Data describing observed and predicted
interactions between miRNA and mRNA is accumulating rapidly in several databases, such
as miRTarBase [149], miRWalk [150], starBase [151], and TargetScan [152]. In addition,
miRNA expression platforms, datasets and analysis tools [153, 154] have become more and
more prevalent. Although miRNAs have been implicated in complex diseases, including
cancer, their impact on distinct biological pathways and phenotypes is largely unknown.
Two of the most widely used approaches to include miRNA expression data for the pur-
pose of pathway analysis are Micrographite [155] and PARADIGM [156]. Micrographite [155]
is a topology-aware pathway analysis approach that is able to integrate sample-matched
miRNA and mRNA expression. PARADIGM [156] uses a probabilistic graphical model
(PGM) to integrate information of different data types, which may include mRNA and
miRNA.
The first drawback of these tools for integrating miRNA and mRNA is that they need
sample-matched data. In other words, these tools require both data types to be available for
each individual patient. This reduces their practical availability since sample-matched data
is relatively rare and difficult or expensive to obtain. Therefore, the vast amount of available
expression data, both mRNA and miRNA, is not fully utilized. The second drawback is that
these methods are unable to exploit heterogenous information available across independent
studies. Therefore, they are not able to address the inevitable bias inherent in individual
studies.
It would be tremendously beneficial if all datasets associated with a given condi-
tion could be analyzed together because of the increased power expected to be associ-
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ated with the much larger number of measurements in the combined dataset. Large pub-
lic repositories such as Gene Expression Omnibus [27, 90], The Cancer Genome Atlas
(cancergenome.nih.gov), ArrayExpress [28], and Therapeutically Applicable Research to
Generate Effective Treatments (ocg.cancer.gov/programs/target) store thousands of
datasets, within which there are independent experimental series with similar patient co-
horts and experiment design. Expression data, mRNA as well as miRNA, are particularly
prevalent in public databases, such that some disease conditions are represented by a dozen
studies or more.
The process of combining sample-matched data of different types is referred to as verti-
cal integrative analysis, while that of combining multiple unmatched studies using the same
data type is referred as horizontal meta-analysis [50]. Thus, they are considered orthogonal
classes of data integration. For microarray data, the method proposed by Rhodes et. al. [55]
was one of the earliest horizontal approaches to combine multiple microarray datasets, us-
ing Fisher’s method. Since then, other sophisticated approaches have been proposed for
the integration of multiple gene expression datasets, on both the gene and pathway lev-
els [13, 62, 74]. The majority of these meta-analysis approaches work by combining the
p-values obtained from individual gene expression datasets. However, they typically do not
try to account for the data heterogeneity, attributed to batch effects, patient heterogeneity,
and disease complexity, responsible for expression changes across different sources.
Here we propose a framework that is able to integrate unmatched miRNA and mRNA
data obtained from many independent laboratories. This framework utilizes meta-analysis
techniques based on both p-values and effect-sizes to identify differentially expressed mR-
NAs/miRNAs and their expression change on a genome-scale. The computed statistics
allow for topology-aware analysis of pathways that were augmented to include the interac-
tions between miRNA and mRNA molecules. While introduced in the context of pathway
analysis, the framework can be modified to adapt to other domains or applications. Each
building block or technique of our pipeline can be easily substituted for by any other similar
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technique to suit the purpose of future analysis.
We illustrate the new framework using 15 mRNA and 14 miRNA datasets related
to two human diseases, colorectal cancer and pancreatic cancer. They were generated by
independent labs, for different sets of patients. For both conditions, the new framework is
able to identify pathways relevant to the phenotypes. We demonstrate that the accuracy
is obtained only by integrating the data in both directions (horizontal and vertical). Our
results suggest that orthogonal classes of integrative techniques can be further combined
to unravel the underlying mechanisms of complex diseases. With vast databases of various
data types being made available, this framework is expected to be widely applicable because
of its relaxed restrictions on the data being integrated.
4.2 The orthogonal meta-analysis framework
The classical pathway analysis begins by considering a comparison between two condi-
tions, e.g. disease versus healthy. Evidence for differential gene expression can be provided
by any technique such as fold change, t-statistic, Kolmogorov-Smirnov statistic, or pertur-
bation factor. These statistics are then compared against the null distribution to determine
how unlikely it is for the observed differences between the two conditions to occur by chance,
thereby producing a ranked list of DE genes. After this hypothesis testing is done at the
gene level, the next step is hypothesis testing at the pathway level producing a ranked list of
impacted pathways. In summary, the input of a classical pathway analysis method includes:
i) a pathway database, and ii) a gene expression dataset. The output is a list of pathways
ranked according to their p-values.
Similarly, the input of the new approach includes: i) a pathway database, ii) a database
of miRNA-mRNA interactions, iii) multiple gene expression datasets, and iv) multiple
miRNA expression datasets. Each dataset is obtained from an independent study of the
same disease. Here we describe a framework that transforms the new problem into the
classical pathway analysis problem.
Figure 4.1 illustrates the pipeline of our framework, for the case of colorectal cancer.
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Figure 4.1: Overall pipeline of the proposed framework. The input consists of i) a pathway database and a miRNA database
including known targets (panel a), ii) multiple mRNA expression datasets (panel b), and iii) multiple miRNA expression
datasets (panel c). Each expression dataset consists of two groups of samples, e.g. disease versus control. The framework
first augments the signaling pathways with miRNA molecules and their interactions with coding mRNA genes (panel d). It
then calculates the standardized mean difference and its standard error in each expression dataset. The summary size effect
across multiple datasets for each data type are then estimated using the REstricted Maximum Likelihood (REML) algorithm
(panels e,f). Similarly, the p-value for differential expression is calculated for each dataset and then combined using the additive
method (add-CLT). The augmented pathways, the combined p-values, and the estimated size effects then serve as input for
ImpactAnalysis, which is a topology-aware pathway analysis method (panel g).
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Panel (a) represents the biological knowledge obtained from public databases: pathway
information and miRNA targets. Panel (b) shows a set of gene expression datasets ob-
tained from independent studies, coming from different laboratories. For this example, we
have 7 datasets (GSE4107, GSE9348, GSE15781, GSE21510, GSE23878, GSE41657, and
GSE62322), all related to the same disease, colorectal cancer. Each dataset consists of
two groups of samples: disease (group D) and control/healthy (group C). Panel (c) repre-
sents a set of miRNA expression datasets (GSE33125, GSE35834, GSE39814, GSE39833,
GSE41655, GSE49246, GSE54632, and GSE73487), also from colorectal cancer. Similar to
gene expression datasets, each miRNA dataset consists of disease and control samples. The
data provided in panels (a,b,c) serve as the input for our framework.
Pathways in public databases are typically described as graphs, where nodes are genes
and edges are interactions between genes. In the first step, we extend the existing pathways
with additional interactions between miRNAs and mRNAs. Panel (d) shows a part of
the pathway Colorectal cancer, where blue nodes are genes and red nodes are miRNAs.
The black arrow-headed lines represent activation while the red bar-headed lines represent
inhibition. For example, hsa-miR-483-5p is known to suppress the expression of MAPK3
and therefore an inhibition relationship is added between the two nodes in the pathway. All
pathways are extended to include the known miRNA-mRNA interactions. The next step
is to estimate the expression changes of each node (gene, miRNA) under the effects of the
disease.
Panel (e) shows the expression changes and the p-values for one gene in the mRNA
data, across several datasets. In this case, the MAPK3 gene is used as an example. In the
forest plot shown in this panel, each horizontal line represents the expression change in each
study. The small black box in each line shows the standardized mean difference (SMD) and
the segment shows the confidence interval of SMD. We use the standardized mean difference
instead of the raw difference because the independent studies measure the expression in a
variety of ways (different platforms, sample preparation, etc.). The number on the right
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side of each line is the p-value of the test for differential expression, using the modified t-test
provided in the limma package [157].
As shown in the figure, the SMD and p-value of a gene vary from study to study.
We use the REstricted Maximum Likelihood (REML) algorithm [158–161] to estimate the
central tendency of SMD. We also use the add-CLT method [13] to combine the independent
p-values. Likewise, we compute the estimated SMDs and p-values for miRNA datasets
(panel f). The augmented pathways, the combined p-value, together with the estimated
size effect then serve as input for classical pathway analysis. In this work, we use Impact
Analysis, which is a topology-aware pathway analysis method, to calculate the p-value for
each augmented pathway (panel g).
4.2.1 Standardized mean difference for each gene
Consider a study composed of two independent groups, and suppose we wish to compare
their means for a given gene. Let X¯1 and X¯2 represent the sample means for that gene in
the two groups, n1 and n2 the number of samples in each group, and Spooled the pooled
standard deviation of the two groups. The pooled standard deviation and the standardized
mean difference (SMD) can be estimated as:
Spooled =
√
(n1 − 1)S21 + (n2 − 1)S22
n1 + n2 − 2 (4.1)
d =
X¯1 − X¯2
Spooled
(4.2)
The estimation of the standardized mean difference described in Equation (4.2) is often
called Cohen’s d [162, 163]. The variance of Cohen’s d is given as follows:
Vd =
n1 + n2
n1n2
+
d2
2(n1 + n2)
(4.3)
In the above equation, the first term reflects uncertainty in the estimate of the mean
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difference, and the second term reflects uncertainty in the estimate of Spooled. The standard
error of d is the square root of Vd. We note that Cohen’s d, which is based on sample
averages, tends to overestimate the population effect size for small samples. Let n be the
degrees of freedom used to estimate Spooled, i.e. n = n1 + n2 − 2. The corrected effect size,
or Hedges’ g [164], can be computed as follows:
J =
Γ(n
2
)√
n
2
Γ(n−1
2
)
(4.4)
g = J · d (4.5)
where Γ is the gamma function. In this work, we use Hedge’ g as the standardized mean
difference (SMD) between disease and control groups for each gene/miRNA.
4.2.2 Random-effects model and REML
Consider a collection of m studies where the effect size estimates, y1, . . . , ym have been
derived from a set of studies, each of them modeled as in Equation (4.5). A fixed-effects
model would assume that there is one true effect size which underlies all of the studies in the
analysis, such that all differences in observed effects are due to sampling error. However, this
assumption is implausible since it cannot account for heterogeneity between studies [158–
161].
In contrast, the random-effects model allows for variability of the true effect. For
example, the effect size might be higher (or lower) in studies where the participants are
older, or have a healthier lifestyle compared to others. The random-effects model assumes
that each effect size estimate can be decomposed into two variance components by a two
stage hierarchical process [159, 165, 166]. The first variance represents the variability of the
effect size across studies, and the second variance represents the sampling error within each
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study. We can write the random-effects model as:
yi = µ+N(0, σ
2) +N(0, σ2i) (4.6)
where µ is the central tendency of the effect size, N(0, σ2) represents the error term by which
the effect size in the ith study differs from the central tendency µ, and N(0, σ2i) represents
the sampling error.
The derivation and formulation of the REstricted Maximum Likelihood (REML) algo-
rithm has been described in the literature [159, 167–169]. The log-likelihood function for
Equation (4.6) is given by:
l(µ, σ2; y) = −1
2
m∑
i=1
ln(σ2 + σ2i)−
1
2
ln
m∑
i=1
1
σ2 + σ2i
− 1
2
m∑
i=1
(yi − µ)2
σ2 + σ2i
(4.7)
The REML estimators of µˆ and σˆ2 are then computed by iteratively maximizing the
log-likelihood. In our framework, we calculate µˆ for each node (mRNA and miRNA) of
the extended pathways. The estimated overall effect size µˆ and the combined p-value of
individual genes and miRNAs serve as the input for Impact Analysis. See Appendix for
more details.
4.2.3 Combining independent p-values
In this work, we use the add-CLT [13, 14] to combine the p-values calculated from the
modified t-test (limma package). The additive method [13, 14] uses the sum of the p-values
as the test statistic, instead of the log product. Consider the p-values resulting from m
independent significance tests, P1, P2, . . . , Pm. Let the sum of these p-values, X =
∑m
i=1 Pi
(X ∈ [0,m]), be the new random variable. X is known to follow the Irwin-Hall distribution
[69, 70] with the following probability density function (pdf):
f(x) =
1
(m− 1)!
bxc∑
i=0
(−1)i
(
m
i
)
(x− i)m−1 (4.8)
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When m is large, some addends will be too small or too large to be stored in the
memory. This leads to a totally inaccurate calculation when m passes a certain threshold,
depending on the number of bits used to store numbers on the computer. For this reason,
a modified version of the additive method, named add-CLT, was proposed [13].
Let Y represent the average of p-values: Y =
∑m
i=1 Pi
m
(Y ∈ [0, 1]). Since Y = X
m
, the
probability density function (pdf) and the corresponding cumulative distribution function
(cdf) of Y can be derived using a linear transformation of X as follows:
g(y) =
m
(m− 1)!
bm·yc∑
i=0
(−1)i
(
m
i
)
(m · y − i)m−1
G(y) =
1
m!
bm·yc∑
i=0
(−1)i
(
m
i
)
(m · y − i)m
(4.9)
The variable Y is the mean ofm independent and identically distributed (i.i.d.) random
variables (the p-values from each individual experiment), that follow a uniform distribution
with a mean of 1
2
and a variance of 1
12
. From the Central Limit Theorem [65], the average
of such m i.i.d. variables follows a normal distribution with mean µ = 1
2
and variance
σ2 = 1
12m
, i.e. Y ∼ N (1
2
, 1
12m
) for sufficiently large values of m. The transition from the
additive method to the Central Limit Theorem takes place at the m ≥ 20 threshold.
4.2.4 Graphical presentation of augmented pathways
Here we give the formal description of the pathway augmentation process. Let P =
(V,E) be the graphical presentation of the pathway we want to extend with miRNA-mRNA
interactions. V is the set of vertices (genes) while the directed edges in E represent the
interactions between genes in the pathway. Each interaction consists of an ordered pair of
vertices and the type of interaction between the pair, i.e. E = {(xi, yi, ri} where xi, yi ∈ G
(gene set) and ri is the type of relation between xi and yi, such as activation, repression,
phosphorelation, etc. Topology-based pathway analysis methods, such as Impact Analysis,
use interaction types to weigh the edges or to set the strength of signal propagation along
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the paths in a pathway.
From the miRNA database, we get a set of miRNAs and their targets. Let us denote
Z as the set of known miRNAs, ζ ∈ Z is one miRNA, and t(ζ) is the set of known targets
for the miRNA ζ. The augmented pathway of P = (V,E) is denoted as P ∗ = (V ∗, E∗) and
is constructed as follows:
V ∗ = V ∪ {ζ ∈ Z : t(ζ) ∩ V 6= ∅}
E∗ = E ∪ {(ζ, g, repression) : ζ ∈ Z, g ∈ t(ζ) ∩ V }
(4.10)
In other words, if a miRNA ζ targets a gene g that belongs to the pathway, we add
ζ to the pathway and then connect ζ with its targets in the pathway. By default, the
interaction type of new edges is repression, which represents the translation blockage of
miRNAs to mRNA. The interaction type can be changed to suit the interaction between
the miRNA molecule and its targets. We extend all pathways in the pathway database using
the formulation described in Equation (4.10).
4.2.5 Impact analysis of augmented pathways
The Impact Analysis method [42, 47] takes into account two types of evidence: (i) the
over-representation of differentially expressed genes in a given pathway [37, 38], and (ii) the
perturbation of that pathway, caused by disease, as measured by propagating expression
changes through the pathway topology. These two aspects are captured, respectively, by
the independent probability values, PNDE and PPERT . Here we review the Impact Analysis
formulation.
The first p-value, PNDE, is obtained using the hypergeometric model [37, 38], which is
the probability of obtaining at least the observed number of differentially expressed genes.
The second p-value, PPERT , depends on the identity of the specific genes that are differ-
entially expressed as well as on the interactions described by the pathway. It is calculated
based on the perturbation factor in each pathway. The perturbation factor of a gene, PF (g),
124
is calculated as follows:
PF (g) = ∆E(g) +
∑
u∈USg
βug · PF (u)
Nds(u)
(4.11)
The first term represents the signed normalized expression change of the gene g, i.e. log
standardized mean difference as shown in panels (e, f) of Figure 4.1. The second term is the
sum of perturbation factors of upstream genes, normalized by the number of downstream
genes of each such upstream gene. The value of βug quantifies the strength of interaction
between u and g. Here, βug = 1 for activation and βug = −1 for repression.
The above equation describes the perturbation factor PF for a gene as a linear function
of the perturbation factors. We can compute these impact factors by solving the set of all
equations defining the impact factors of all genes. The net perturbation accumulation then
can be calculated by subtracting the observed expression change from the perturbation
factor.
Acc(g) = PF (g)−∆E(g) (4.12)
The total accumulated perturbation in the pathway is then computed as:
Acc(Pi) =
∑
g∈Pi
Acc(g) (4.13)
The null distribution of Acc(Pi) is built by permutation of expression change. The p-value,
PPERT , is then calculated by the probability of having values more extreme than the actually
observed Acc(Pi).
To compute PNDE and PPERT , the following input is required: the graphical presen-
tation of the pathway, the combined p-value of each node of the graph, and the estimated
overall standardized mean difference. In short, the graphical presentation of the augmented
pathways is provided in Equation (4.10), the p-value for each node of the augmented path-
ways is computed using Equation (2.3), and the expression change, ∆E(g), is estimated by
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Table 4.1: Description of miRNA and mRNA expression datasets used in the experimental studies. All of the data were
downloaded from Gene Expression Omnibus.
Cancer Data Accession ID Control Disease Tissue Platform
Colorectal
mRNA
GSE4107 10 12 Colonic mucosa Affymetrix HG U133 Plus 2.0
GSE9348 12 70 Colonic mucosa Affymetrix HG U133 Plus 2.0
GSE15781 10 13 Colon ABI HG Survey 2
GSE21510 25 123 Colon Affymetrix HG U133 Plus 2.0
GSE23878 24 35 Colon Affymetrix HG U133 Plus 2.0
GSE41657 12 25 Colonic mucosa, epithelial neoplasm Agilent-014850 HG 4x44K G4112F
GSE62322 18 20 Colon Affymetrix HG U133A
miRNA
GSE33125 9 9 Colon Illumina Human v2 MicroRNA
GSE35834 23 55 Colon & rectum Affymetrix miRNA 1.0
GSE39814 9 10 FHC, HCT116, & SW480 cells Agilent-021827 Human miRNA
GSE39833 11 88 Peripheral blood serum Agilent-021827 Human miRNA
GSE41655 15 33 Colonic mucosa, & epithelial neoplasm Agilent-021827 Human miRNA
GSE49246 40 40 Colon Sun Yat-Sen Human microRNA
GSE54632 5 5 Colonic and rectal mucosa Affymetrix miRNA 1.0
GSE73487 23 90 Colon Affymetrix miRNA 1.0
Pancreatic
mRNA
GSE15471 39 39 Pancreas Affymetrix HG U133 Plus 2.0
GSE19279 3 4 Pancreas, pancreatic duct Affymetrix HG U133A
GSE27890 4 4 Pancreas, ductal epithelia Affymetrix HG U133 Plus 2.0
GSE32676 7 25 Pancreas Affymetrix HG U133 Plus 2.0
GSE36076 10 3 Peripheral blood mononuclear cells Affymetrix HG U133 Plus 2.0
GSE43288 3 4 Pancreas Affymetrix HG U133A
GSE45757 9 132 Pancreatic epithelial & cancer cells Affymetrix HG U133A
GSE60601 3 9 CD14++ & CD16- cells Affymetrix HG U133 Plus 2.0
miRNA
GSE24279 22 136 Pancreas Febit human miRBase v11
GSE25820 4 5 Pancreatic duct Agilent-019118 Human miRNA
GSE32678 7 25 Pancreas miRCURY LNA microRNA, v.11.0
GSE34052 6 6 Pancreas Agilent-029297 Human miRNA
GSE43796 5 26 Pancreas Agilent-031181 Human miRNA V16
GSE60978 6 51 Pancreatic duct Agilent-031181 Human miRNA V16
iteratively maximizing the log-likelihood function in Equation (4.7). These two p-values,
PNDE and PPERT , are then combined to get a single p-value that represents how likely the
pathway is impacted under the effect of the disease.
4.3 Experimental results
We analyzed a total of 1,471 samples from 29 public datasets for two human diseases,
colorectal and pancreatic cancer. The datasets were generated in independent laboratories,
from different individual tissue samples, and were run on different high-throughput plat-
forms. The diseases were selected based on two criteria: i) there are many publicly available
miRNA and mRNA datasets, and ii) there is a pathway specific to the disease (target path-
way). The colorectal data consists of 7 mRNA and 8 miRNA datasets while the pancreatic
data consists of 8 mRNA and 6 miRNA datasets. The processed data sets were downloaded
directly from the Gene Expression Omnibus using the GEOquery package [170]. The data
were rescaled using a log transformation if they were not already in log scale (base 2). The
details of each dataset, such as the number of samples, tissues, and platforms, are reported
in Table 4.1.
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The databases used in our data analysis are KEGG for pathways, and miRTarBase for
miRNAs. We downloaded 182 signaling pathways from KEGG version 76 (Dec-04-2015) by
means of the R package ROntoTools [48]. We augmented these pathways with known miR-
NAs and their target interactions, downloaded from miRTarBase. For each mRNA/miRNA,
we use the modified t-test, available in the limma package [157], to test for differential ex-
pression of mRNA/miRNAs. We use add-CLT [13] as the method to combine independent
p-values. We then adjust the combined p-values for multiple comparison using False Dis-
covery Rate (FDR) [171]. For expression change, we use Hedges’ g [164] as effect size, and
the REML method [172] to estimate the central tendency of effect sizes. Following con-
vention, we only take into consideration mRNA/miRNAs having FDR-corrected combined
p-values less than 5%. Among these significant genes, we choose mRNA/miRNAs that
have the highest estimated SMD as differentially expressed, up to 10% of total measured
mRNA/miRNAs. All the R scripts used for data processing, pathway augmentation, and
analysis are available on demand from the authors.
For both diseases, we compare the orthogonal approach (ImpactAnalysis_I) with 5
other approaches: pathway-level meta-analysis (ImpactAnalysis_P), gene-level meta-analysis
(ImpactAnalysis_G), plus the 3 meta-analysis approaches available in MetaPath pack-
age [62, 74]. Since the input data sets consist of multiple studies, none of which are
sample-matched, we are unable to perform pathway analysis using approaches that inte-
grate matched mRNA and miRNA expression.
For pathway-level meta-analysis (ImpactAnalysis_P), we perform Impact Analysis on
each mRNA expression dataset and then combine the independent p-values for each pathway.
For example, if we have 7 mRNA datasets, we have 7 nominal p-values per pathway – one
for each study. These 7 p-values are independent and thus can be combined using the add-
CLT method to get one combined p-value. The final result is a list of 182 p-values for 182
signaling pathways. We then adjust the combined p-values for multiple comparisons using
FDR.
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For gene-level meta-analysis (ImpactAnalysis_G), we perform the modified t-test [157]
for each mRNA dataset and then combine the p-values. With 7 mRNA datasets, for example,
each gene will have 7 independent p-values, which will be combined into one p-value. We
also calculate the SMD and standard error of each gene in each study, then use the REML
algorithm to calculate the overall effect size across the 7 studies. Finally, pathway analysis
is performed on 182 KEGG pathways using the combined p-values and the estimated effect
sizes, resulting in a list of pathways ranked according to their p-values. We then adjust the
p-values of pathways for multiple comparisons using FDR.
The integrative approach (ImpactAnalysis_I) is similar to ImpactAnalysis_G, with the
exception that ImpactAnalysis_I uses both mRNA and miRNA data. The meta-analysis
is done on the mRNA/miRNA level and then the combined p-values and estimated effect
sizes of mRNA/miRNAs serve as the input to the ImpactAnalysis.
MetaPath [62, 74] is a dedicated approach that performs meta-analysis at both gene
(MetaPath_G) and pathway levels (MetaPath_P) with a GSEA-like approach, and then
combines the results (MetaPath_I) to give the final p-value and ranking of pathways. Meta-
Path first calculates the t-statistic for each gene in each study. In MetaPath_G, these statis-
tics are combined for each gene using maxP [59]. The combined statistics are then used to
calculate enrichment scores for each pathway using a Kolmogorov-Smirnov test. In MetaP-
ath_P, the pathway enrichment analysis is done first before meta-analysis. In MetaPath_I,
the p-values of MetaPath_G and MetaPath_P are combined using minP [58].
For each of the two diseases, we have a target KEGG pathway, which is the pathway
created to describe the main phenomena involved in the respective disease. We expect that
a good pathway analysis approach would be able to identify the very pathway that describes
the disease phenomena as the most significant in that particular disease. Hence, we will
compare the various methods based on this criterion.
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4.3.1 Colorectal cancer
We obtained 8 miRNA (GSE33125, GSE35834, GSE39814, GSE39833, GSE41655,
GSE49246, GSE54632, and GSE73487) and 7 mRNA (GSE4107, GSE9348, GSE15781,
GSE21510, GSE23878, GSE41657, and GSE62322) datasets from the Gene Expression Om-
nibus (GEO), as shown in Table 4.1.
Table 4.2 shows the results of the 6 approaches. The horizontal line across each list
marks the cutoff FDR = 0.01. The pathway highlighted in green is the target pathway Col-
orectal cancer. MetaPath_P (pathway-level meta-analysis) identifies no significant pathway
at the 1% cutoff, and ranks the target pathway at position 16th. Similarly, MetaPath_G
(gene-level meta-analysis) and MetaPath_I (combination of gene- and pathway-level) iden-
tify no significant pathways. They rank the target pathway at positions 9th and 15th,
respectively.
The ImpactAnalysis_P approach identifies 12 pathways, among which there are many
pathways that are related to cancer. However, the target pathway Colorectal cancer is
not significant and is ranked 61st with adjusted p = 0.99. The gene-level meta-analysis
(ImpactAnalysis_G) offers some improvement over ImpactAnalysis_P by improving the
ranking (10th) and adjusted p-value (p = 0.1) of the target pathway Colorectal cancer.
However, the target pathway is still not significant with the given threshold. The orthogonal
meta-analysis, ImpactAnalysis_I, is able to further boost the power of the gene-level meta-
analysis. It identifies 5 significant pathways, with the target pathway Colorectal cancer
ranked at the very top. This is very likely due to the additional information provided by
miRNA expression and prior knowledge accumulated in miRTarBase.
Three of the other 4 pathways that are identified by ImpactAnalysis_I appear to
be true positives. The Cell Cycle and Ribosome Biogenesis pathways are implicated in
the proliferation aspect of cancer tissue. PPAR signaling has a role in colorectal cancer,
although it is not fully understood. Progesterone-mediated oocyte maturation is clearly a
false positive which may have appeared due to the presence of several cell cycle genes in
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that pathway.
4.3.2 Pancreatic cancer
We obtained 8 gene expression datasets (GSE15471, GSE19279, GSE27890, GSE32676,
GSE36076, GSE43288, GSE45757, and GSE60601) and 6 miRNA datasets (GSE24279,
GSE25820, GSE32678, GSE34052, GSE43796, and GSE60978) from Gene Expression Om-
nibus (GEO), as shown in Table 4.1. Again, we compare our approach (ImpactAnalysis_I)
with 5 other approaches: pathway-level meta-analysis, gene-level meta-analysis using only
mRNA data, plus 3 meta-analysis approaches available in the MetaPath package [62, 74] as
shown in Table 4.3.
MetaPath_P identifies no significant pathway and Graft-versus-host disease is ranked
on top with adjusted p-value 0.4782. The target pathway Pancreatic cancer is ranked 17th
with adjusted p = 0.89. MetaPath_G identifies 7 significant pathways. The target pathway
is not significant (adjusted p = 0.22) and is ranked 91st. In consequence, the combination
of these two methods, MetaPath_I, also fails to identify the target pathway as significant
(adjusted p = 0.34 with ranking 91st).
The pathway-level meta-analysis (ImpactAnalysis_P) identifies the PI3K-Akt signal-
ing pathway and MicroRNAs in cancer as significant. The significance of MicroRNAs in
cancer may indicate the importance of miRNA in pancreatic cancer, and PI3K-Akt signal-
ing alteration is known to be involved in many cancers. However, the target pathway is
not significant (adjusted p = 0.95 with ranking 32nd). The gene-level meta-analysis (Im-
pactAnalysis_G) improves the ranking of the target pathway (8th) but the p-value of the
target pathway is still not significant. The orthogonal approach, ImpactAnalysis_I, identi-
fies 7 pathways as significant. The target pathway Pancreatic cancer is ranked on top with
FDR-corrected p-value 0.0017.
Of the 6 significant non-target pathways found by ImpactAnalysis_I, three are cancer-
related by name (Small cell lung cancer, Pathways in cancer, Proteoglycans in cancer). The
break down of cell matrix adhesions, such as Focal Adhesion is an important property of
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Table 4.2: The 16 top ranked pathways and FDR-corrected p-values obtained by combining colorectal data using 6 approaches:
MetaPath_P, MetaPath_G, MetaPath_I, ImpactAnalysis_P, ImpactAnalysis_G, and ImpactAnalysis_I. The horizontal lines
show the 1% significance threshold. The target pathway Colorectal cancer is highlighted in green. All other approaches, Meta-
Path_P, MetaPath_G, MetaPath_I, ImpactAnalysis_P, ImpactAnalysis_G fail to identify the target pathway as significant,
and rank it at the positions 16th, 9th, 15th, 61st, and 10th, respectively. On the contrary, the integrative approach, Impact-
Analysis_I, identifies the target pathway as significant and ranks it on top.
MetaPath_P (mRNA, pathway-level) MetaPath_G (mRNA, gene-level) MetaPath_I (mRNA, both-level)
Pathway p.fdr Pathway p.fdr Pathway p.fdr
1 Aldosterone-regulated sodium
reabsorption
0.0940 Thyroid cancer 0.1460 Thyroid cancer 0.1460
2 Peroxisome 0.2319 Dorso-ventral axis formation 0.1533 Aldosterone-regulated sodium
reabsorption
0.1880
3 Pancreatic cancer 0.2402 Mineral absorption 0.1550 Endocrine and other factor-
regulated calcium reabsorp-
tion
0.2006
4 Small cell lung cancer 0.2500 PPAR signaling pathway 0.1575 Mineral absorption 0.2047
5 Endocrine and other factor-
regulated calcium reabsorp-
tion
0.2540 Ribosome biogenesis in eu-
karyotes
0.2376 PPAR signaling pathway 0.2065
6 Epithelial cell signaling in He-
licobacter pylori infection
0.2630 Renin-angiotensin system 0.2609 Dorso-ventral axis formation 0.2270
7 Mineral absorption 0.2727 Vibrio cholerae infection 0.3002 Small cell lung cancer 0.2713
8 Glioma 0.3234 Aldosterone-regulated sodium
reabsorption
0.3478 Renin-angiotensin system 0.2731
9 Dorso-ventral axis formation 0.4665 Colorectal cancer 0.3514 Pancreatic cancer 0.2811
10 Epstein-Barr virus infection 0.4683 Bile secretion 0.4286 Peroxisome 0.2870
11 NOD-like receptor signaling
pathway
0.4772 Pancreatic secretion 0.4361 Ribosome biogenesis in eu-
karyotes
0.2906
12 Legionellosis 0.4772 Epithelial cell signaling in He-
licobacter pylori infection
0.4427 Vibrio cholerae infection 0.2918
13 GnRH signaling pathway 0.4778 Intestinal immune network for
IgA production
0.4519 Epithelial cell signaling in He-
licobacter pylori infection
0.2951
14 Progesterone-mediated
oocyte maturation
0.4946 Type I diabetes mellitus 0.4576 Glioma 0.3561
15 TNF signaling pathway 0.5135 Cardiac muscle contraction 0.4607 Colorectal cancer 0.4047
16 Colorectal cancer 0.5178 Allograft rejection 0.4616 NOD-like receptor signaling
pathway
0.4693
ImpactAnalysis_P (mRNA, pathway) ImpactAnalysis_G (mRNA, gene) ImpactAnalysis_I (mRNA +miRNA)
Pathway p.fdr Pathway p.fdr Pathway p.fdr
1 PPAR signaling pathway <10−4 Ribosome biogenesis in eu-
karyotes
0.0008 Colorectal cancer 0.0002
2 Rheumatoid arthritis <10−4 Cell cycle 0.0008 Ribosome biogenesis in eu-
karyotes
0.0002
3 Cytokine-cytokine receptor
interaction
<10−4 Mineral absorption 0.0185 PPAR signaling pathway 0.0002
4 Chemokine signaling pathway <10−4 p53 signaling pathway 0.0292 Cell cycle 0.0006
5 Bile secretion <10−4 Progesterone-mediated
oocyte maturation
0.0347 Progesterone-mediated
oocyte maturation
0.0077
6 MicroRNAs in cancer 0.0005 Oocyte meiosis 0.0348 Oocyte meiosis 0.0130
7 Malaria 0.0007 Bile secretion 0.0364 TGF-beta signaling pathway 0.0130
8 Mineral absorption 0.0012 PPAR signaling pathway 0.0915 Parkinson’s disease 0.0130
9 Pancreatic secretion 0.0046 Small cell lung cancer 0.1014 Peroxisome 0.0139
10 ECM-receptor interaction 0.0047 Colorectal cancer 0.1036 MicroRNAs in cancer 0.0140
11 Insulin secretion 0.0047 RNA transport 0.1059 Thyroid cancer 0.0214
12 Amoebiasis 0.0056 RNA degradation 0.1720 RNA transport 0.0214
13 Complement and coagulation
cascades
0.0111 MicroRNAs in cancer 0.2051 AGE-RAGE signaling path-
way in diabetic complications
0.0214
14 PI3K-Akt signaling pathway 0.0131 Peroxisome 0.2051 NOD-like receptor signaling
pathway
0.0304
15 TNF signaling pathway 0.0194 Pathways in cancer 0.2080 Endometrial cancer 0.0309
16 Transcriptional misregulation
in cancer
0.0267 Parkinson’s disease 0.3194 Pancreatic cancer 0.0309
131
Table 4.3: The 10 top ranked pathways and FDR-corrected p-values obtained by combining colorectal data using 6 approaches:
MetaPath_P, MetaPath_G, MetaPath_I, ImpactAnalysis_P, ImpactAnalysis_G, and ImpactAnalysis_I. The horizontal lines
show the 1% significance threshold. The target pathway Pancreatic cancer is highlighted in green. All other approaches, Meta-
Path_P, MetaPath_G, MetaPath_I, ImpactAnalysis_P, ImpactAnalysis_G fail to identify the target pathway as significant,
and rank it at the positions 17th, 91st, 91st, 32nd, and 8th, respectively. On the contrary, the integrative approach, Impact-
Analysis_I, identifies the target pathway as significant and ranks it on top.
MetaPath_P (mRNA, pathway-level) MetaPath_G (mRNA, gene-level) MetaPath_I (mRNA, both-level)
Pathway p.fdr Pathway p.fdr Pathway p.fdr
1 Graft-versus-host disease 0.4782 Autoimmune thyroid disease 0.0020 Type I diabetes mellitus 0.0040
2 Small cell lung cancer 0.5440 Allograft rejection 0.0020 Autoimmune thyroid disease 0.0040
3 SNARE interactions in vesic-
ular transport
0.5530 Type I diabetes mellitus 0.0030 Allograft rejection 0.0040
4 Leishmaniasis 0.6404 Graft-versus-host disease 0.0040 Graft-versus-host disease 0.0080
5 Bladder cancer 0.7010 GABAergic synapse 0.0050 GABAergic synapse 0.0100
6 MicroRNAs in cancer 0.7244 Asthma 0.0073 Asthma 0.0147
7 Phagosome 0.7330 Morphine addiction 0.0074 Morphine addiction 0.0149
8 Type I diabetes mellitus 0.7515 ECM-receptor interaction 0.0104 ECM-receptor interaction 0.0208
9 Pertussis 0.7682 Maturity onset diabetes of the
young
0.0139 Maturity onset diabetes of the
young
0.0278
10 Dorso-ventral axis formation 0.7941 Renin-angiotensin system 0.0153 Renin-angiotensin system 0.0307
ImpactAnalysis_P (mRNA, pathway) ImpactAnalysis_G (mRNA, gene) ImpactAnalysis_I (mRNA +miRNA)
Pathway p.fdr Pathway p.fdr Pathway p.fdr
1 PI3K-Akt signaling pathway 0.0019 Small cell lung cancer 0.0217 Pancreatic cancer 0.0017
2 MicroRNAs in cancer 0.0076 Pathways in cancer 0.0217 Small cell lung cancer 0.0017
3 Small cell lung cancer 0.0276 Viral carcinogenesis 0.0217 Pathways in cancer 0.0017
4 Pathways in cancer 0.0962 ECM-receptor interaction 0.0480 Proteoglycans in cancer 0.0017
5 TNF signaling pathway 0.1106 Hepatitis B 0.0480 Amoebiasis 0.0031
6 PPAR signaling pathway 0.1216 HTLV-I infection 0.0623 AGE-RAGE signaling path-
way in diabetic complications
0.0040
7 NF-kappa B signaling path-
way
0.1502 Chronic myeloid leukemia 0.0623 Focal adhesion 0.0040
8 Shigellosis 0.2491 Pancreatic cancer 0.0623 HTLV-I infection 0.0119
9 Chemokine signaling pathway 0.2742 Amoebiasis 0.0639 Chronic myeloid leukemia 0.0125
10 T cell receptor signaling path-
way
0.3200 Pathogenic Escherichia coli
infection
0.0639 ECM-receptor interaction 0.0142
metastasis - most pancreatic cancers are discovered when they are already high grade.
In contrast to the 3 variations of the existing method, MetaPath, the proposed method
ImpactAnalysis_I was able to effectively combine both independent datasets, as well as the
two different types of data (mRNA and miRNA), and correctly report the target pathway
as the most significantly impacted pathway in both meta-analysis studies. The results
demonstrate that the correct pathways are identified only when the data are integrated
both horizontally (combining multiple studies using the same data type) and vertically
(combining miRNA with mRNA expression). This orthogonal meta-analysis uses three
different kinds of data integration: integration of mRNA and miRNA, combining p-values
and combining SMDs for genes and miRNA molecules.
4.3.3 Time complexity
The data analysis was done on a personal MacBook Pro that has 8 GB 1600 MHz
DDR3 RAM, 2.9 GHz Intel Core i7. Since MetaPath cannot exploit multiple processors, we
run all the analysis using a single core. The time needed to run MetaPath was 39 minutes
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Table 4.4: Running time of each pathway analysis in minutes (m).
Method Input Colorectal Pancreatic
ImpactAnalysis_I mRNA & miRNA 4m 4m
MetaPath mRNA 39m 47m
for Colorectal cancer and 47 minutes for Pancreatic cancer.
For ImpactAnalysis_I, we first calculate the p-value for each gene/miRNA in each
dataset using the limma package [157]. We then combine the p-values to get one combined
p-value per gene/miRNA. Next, we calculate the standardized mean difference (SMD) for
each dataset and then apply the REML algorithm to estimate to overall SMD, using the
metafor package [172]. The estimated SMDs and the combined p-values are processed by
ROntoTools to produce the p-value for each pathway. ImpactAnalysis_I performes the
analysis using the pathways augmented with the relevant miRNAs. The running time for
ImpactAnalysis_I is 4 minutes for each of Colorectal and Pancreatic. The running time of
each approach is reported in Table 4.4.
4.4 Discussion
One straightforward horizontal integration is to combine individual p-values provided
by each study. In this way, one can apply any pathway analysis approach (such as GSEA [39]
or GSA [40]) to the collected mRNA datasets in order to calculate a p-value for each pathway
in each study, and then combine these independent p-values. The advantage of this approach
is its flexibility. MetaPath [62] combines p-values in this way, but with the slight difference
that the p-values are combined on both gene and pathway levels. The drawback is that each
of these methods is designed to work with one single matrix of expression values, i.e. one
data type. One can forcefully extend this matrix to include other data types as well but in
order to do this, the data must be sample-matched. In other words, one must perform all
types of assays on every single sample. In addition, since different data types are assayed
on different platforms, the data need to be normalized together, for these approaches to
function properly. However, the correct way to do such a cross-platform normalization
is still an open problem [173]. The same limitations apply for analysis tools dedicated
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to miRNA and mRNA integration[155, 174]. For meta-analysis, these approaches would
require multiple sets of sample-matched data. Performing different assays on one set of
samples is already expensive; asking for many sets of matched samples for the same disease
is even more impractical.
Although primarily designed to overcome the matched-sample bottleneck discussed
above, our proposed framework also aims to address a well-known limitation of p-value-based
meta-analyses. Classical approaches often rely on hypothesis testing to identify differential
expression. This results in critical information loss. While the p-value is partly a function
of effect size, it is also partly a function of sample size [175]. For example, with large sam-
ple size, a statistical test will tend to find differences as significant, unless the effect size
is exactly zero. In reality, any individual study will include some degree of batch effects,
such as sampling/study bias, noise, and measurement errors. Simply combining individual
p-values would not correct such problems. On the contrary, meta-analysis of effect sizes
across all studies would definitely compensate for and eliminate such random effects. This
point is illustrated in the results included here, in particular in the difference between Im-
pactAnalysis_P and ImpactAnalysis_G for both colorectal and pancreatic cancer (Tables
4.2 and 4.3). The former simply combines the p-values, while the later takes into consid-
eration both p-values and effect sizes across different studies. ImpactAnalysis_G offers a
great improvement over ImpactAnalysis_P using the same sets of mRNA data.
However, the approach proposed here is not without limitations. One such limitation
is the computational complexity at both gene and pathway levels. For individual genes and
miRNA molecules, the framework not only calculates p-values, but also iteratively estimates
the effect sizes and variances. In principle, the iterative algorithm requires more computation
than meta-analyses that use closed-form expressions. At pathway-level, Impact Analysis is
a non-parametric approach that constructs an empirical distribution of all measured values
for each pathway. This requires more computation and storage than parametric approaches,
such as the hypergeometric test or Fisher’s exact test. However, this is mitigated by the
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power of modern computers which are able to perform all needed computations in less than
10 minutes, even for datasets with more than 1,000 samples (Table 4.4). In addition, our
framework allows for parallel computing at the gene-level to reduce the time complexity.
However, the time values reported here (in Table 4.4) do not take advantage of the ability
to parallelize the computation in order to be comparable with the results obtained with
MetaPath. All values reported in this table are obtained on a single core for both approaches.
The biological results presented here could be further validated by investigating the
other pathways reported as significant, and identifying the putative mechanisms that could
explain all measured changes. A tool such as iPathway-Guide [176], could be used to provide
more in depth functional analysis, including identification of drugs that are known to act
on the observed signaling cascades. Follow-up experiments in which tumor cell lines, or
samples from xenographs, are treated with those drugs would validate (or not) both the
putative mechanisms investigated, as well as the other significant pathways. If many or
all significant pathways were mechanistically implicated in the respective conditions, the
proposed orthogonal meta-analysis approach would be further validated.
4.5 Summary
We have presented a two-dimensional data integration that is able to combine mRNA
and miRNA expression data obtained from many independent experiments. The framework
first augments pathway knowledge available in pathway databases with miRNA-mRNA in-
teractions from miRNA knowledge bases. It then computes the statistics that are essential
for pathway analysis, i.e. the standardized mean difference (SMD) and p-value for differen-
tial expression. For each entity, these p-values and the SMDs are computed by combining
multiple studies using robust horizontal meta-analysis techniques. Finally, the framework
performs a topology-based pathway analysis to identify pathways that are likely to be im-
pacted under the given condition.
To evaluate the framework, we examine 1,471 samples from 15 mRNA and 14 miRNA
expression datasets related to two human cancers, using 6 different meta-analysis approaches
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(3 MetaPath approaches and 3 meta-analysis approaches that utilize Impact Analysis). We
demonstrate that the correct pathways are identified only when the data are integrated both
horizontally (combining multiple studies using the same data type) and vertically (combining
miRNA with mRNA expression).
This work serves as a bridge between the two orthogonal types of data integration. The
result is to unblock the sample-matched data bottleneck, by successfully integrating mRNA
and miRNA datasets measured from independent laboratories for different sets of patients.
Furthermore, it increases the power of statistical approaches since it allows many studies
to be analyzed together. With vast databases of various data types being made available,
this framework is expected to be widely applicable because of its relaxed restrictions on
the data being integrated. The framework is flexible enough to integrate data types other
than mRNA and miRNA. It can also be modified to suit other purposes besides pathway
analysis.
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CHAPTER 5: CONCLUSIONS AND FUTURE
WORKS
Advanced high-throughput technologies have produced vast amounts of biological data.
However, real progress in understanding disease phenomena still lags far behind the data
gathering. To this end, we presented new integrative techniques to exploit the complemen-
tary information available in multiple data sources in order to gain a more comprehensive
view of biological mechanisms of the underlying diseases.
First, we proposed a new basic formulation of combining p-values. After mathemati-
cally and experimentally proving the impracticality of classical methods, we proposed to use
the average of p-values, which follows a log-transformation of the Irwin-Hall distribution.
When the number of studies is large, we used the Central Limit Theorem to estimate the
distribution to avoid underflow/overflow problem. We demonstrated that the new method
is more reliable than classical methods of combining p-values in terms of both false positive
rate (FPR) and true positive rate (TPR). This method, named add-CLT, is the building
block of more complicated meta-analysis frameworks.
Second, we introduced DANUBE, an unbiased approach to combine statistics computed
from individual studies. DANUBE uses control samples to construct empirical null distri-
butions, from which empirical p-values of individual studies are calculated and combined
using the add-CLT method. We assessed the performance of DANUBE using four different
pathway analysis methods. DANUBE was compared with five meta-analysis approaches,
as well as with a pathway analysis approach that employs multiple datasets (MetaPath).
The 25 approaches were tested on 16 different datasets related to two human diseases,
Alzheimer’s disease (7 datasets) and acute myeloid leukemia (9 datasets). We demonstrated
that DANUBE overcomed bias in order to consistently identify relevant pathways. We also
showed how the framework improved results in more general cases, compared to classical
meta-analysis performed with common experiment-level statistical tests such as Wilcoxon
and t-test.
137
Third, we proposed to boost the power of any meta-analysis by performing a bi-level
meta-analysis combining an intra-experiment analysis, with an inter-experiment analysis.
First, for each individual experiment, the intra-experiment analysis splits the dataset into
smaller datasets, performs a statistical test on each of the newly created small datasets,
then combines the p-values. Next, the inter-experiment analysis combines those processed
p-values, from each of the individual experiments. For comparative analysis, we demon-
strated that the intra-experiment analysis has more power than the equivalent statistical
test performed on a single large experiment. For pathway analysis, we compared the pro-
posed framework versus classical meta-analysis approaches (Fisher’s, Stouffer’s, and the
additive method) as well as against a dedicated pathway meta-analysis package (MetaP-
ath), using 1,252 samples from 21 datasets related to three human diseases, acute myeloid
leukemia (9 datasets), type II diabetes (5 datasets), and Alzheimer’s disease (7 datasets).
Our framework outperformed its competitors to correctly identify pathways relevant to the
phenotypes. The framework is sufficiently general to be applied to any type of statistical
meta-analysis.
Fourth, we developed a new framework for multi-omics data integration and disease
subtyping. Our subtyping approach, named PINS, is based on the observation that small
changes in any kind of quantitative assay will be inherently present between individuals,
even in a truly homogeneous population in the absence of any subtype. Therefore, if well
defined subtypes of a disease do exist, these have to be stable with respect to small changes
in the measured values. Based on this observation, we developed a perturbation clustering
to accurately subtype patients using high-dimensional gene expression data. The algorithm
was also extended to combine complementary information available in multiple data types,
by adapting techniques in graph theory, network partitioning, and cluster ensembles. The
algorithm has been validated on thousands of real cancer samples, using transcriptomics,
epigenomics, and non-coding RNA molecular data available on Gene Expression Omnibus,
the Broad Institute, and the Cancer Genome Atlas. This simultaneous clustering approach
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accurately identifies known cancer subtypes and predicts the survival of novel subgroups of
patients.
Finally, we proposed a two-dimensional data integration that is able to combine mRNA
and miRNA expression data obtained from many independent experiments. This framework
utilizes techniques based on both p-values and effect sizes to identify entities (mRNA and
miRNAs) that are differentially expressed and their expression change on a genome-scale.
The computed statistics allow for topology-aware pathway analysis of the given pheno-
types, where topological information of genes is taken into consideration. To evaluate this
orthogonal meta-analysis, we examined 1,471 samples from 15 mRNA and 14 miRNA ex-
pression datasets related to two human cancers, using 6 different meta-analysis approaches
(3 MetaPath approaches and 3 meta-analysis approaches that utilize Impact Analysis). We
demonstrated that the correct pathways were identified only when the data are integrated
both horizontally (combining multiple studies using the same data type) and vertically
(combining miRNA with mRNA expression). This work serves as a bridge between the two
orthogonal types of data integration. The result is to unblock the sample- matched data
bottleneck, by successfully integrating mRNA and miRNA datasets measured from inde-
pendent laboratories for different sets of patients. Furthermore, it increases the power of
statistical approaches since it allows many studies to be analyzed together.
For future works, we can further upgrade the developed techniques and apply them to
more data types as well as to other phenotypes for new biological discoveries. There are
several projects that are directly downstream of the work described above. These projects
include:
• Inferring condition-specific microRNA activity: MicroRNAs (miRNAs) are small non-
coding RNA molecules whose primary function is to regulate the expression of gene
products via hybridization to mRNA transcripts. Identifying the interaction between
miRNA and gene products often involves expensive wet lab experiments of sample-
matched data. I am working on developing a new protocol to infer condition-specific
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miRNA activity using massive amounts of public data. This project is an extension
of the orthogonal meta-analysis [12], which allows us to integrate all public datasets
of mRNA and miRNA of the same condition without imposing any restriction on the
data. The goal of this project is to identify putative targets of miRNAs from publicly
available data using causal inference techniques [177, 178]. The predicted targets can
be further verified by established gene-specific experimental validation, such as qRT-
PCR, luciferase reporter assays, and western blot [179, 180]. If it succeeds, this work
could strongly influence the way miRNA research is currently conducted.
• Cancer subtypes and biomarker identification: We know that any cancer is not a single
disease, but a multitude of different subtypes. A clinically important challenge is to
discover cancer subtypes and their molecular drivers. In this dissertation, we described
a new framework, named PINS, that reliably identifies known subtypes as well as
novel subgroups of patients with significantly different survival profiles [15, 16]. One
limitation of PINS is that it was designed to integrate only continuous variables, such
as gene expression, methylation, and microRNA. Therefore, PINS is unable to process
important data types with discrete values, such as somatic mutations and SNPs. We
will work on extending PINS to include both continuous and discrete variables to
harness the full potential of large-scale multi-omics datasets. Beside unsupervised
subtyping, we will also work on identifying biomarkers of discovered or known subtypes
in order to efficiently stratify incoming patients.
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APPENDIX
A.1 Fixed-effect model
The general form for the linear model is
y = Xβ + e (A.1)
where y ∈ Rk is a vector of k effect sizes, X is an design matrix, β is a vector of p unknown
fixed effects, and e is a vector of random error, ei ∼ N(0, σ2), so the error are i.i.d. normal
variables.
The likelihood function for (A.1) is given by
L(β, σ2; y) =
k∏
i=1
f(yi;Xiβ, σ
2)
=
k∏
i=1
1√
2piσ2
exp(− 1
2σ2
(yi −Xiβ)2)
where Xi is the i
th row of X, f(y;µ, σ2) is the probability density function for a normal
random variable y with mean µ and variance σ2.
After removing the additive constant −k
2
ln(2pi), the log-likelihood function is then
given by
l(β, σ2; y) = −k
2
ln(σ2)− 1
2σ2
(y −Xβ)T (y = Xβ) (A.2)
and the maximum likelihood estimates of µ and σ2 are those values that maximize L or l.
Note that the ordinary least squares estimator of β is the value that minimize the sum
of squares of the residuals, i.e. the difference between the data (yi) and its estimated value
(Xiµ):
n∑
i=1
(yi −Xiβ)2 (A.3)
This clearly yields the same estimate as the maximum likelihood method. Taking
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differentiation with respect to β and setting the derivative to zero will yield
βˆ = (XTX)−1XTy (A.4)
and for σ2
σˆ2 =
(y −Xβˆ)T (y −Xβˆ)
k
(A.5)
When X is not full column rank, the generalized inverse of A is used, such that
AA−1A = A.
A.2 Random-effects model
More generally, the random-effects model given by Equation (4.6) can be written in
the general linear mixed-effects model as
y = Xβ + Zγ + e (A.6)
where y ∈ Rk are the observed size effects, X ∈ Rk×p is a design matrix for β ∈ Rp (vector of
fixed effects parameters), Z is the design matrix for the γ ∈ Rq (a vector of random effects
parameters), and e ∈ Rk is a vector of random error terms. We note that Equation (A.6)
and Equation (4.6) are identical when y consists of the k effect size estimates, X is a
vector composed entirely of 1’s, β includes only the mean µθ, Z is the identity matrix, γ is
comprised of the τi values at the population level.
As described above, we have E(γ) = E(e) = 0. In addition, from the independency
between the true effect and sampling error, we also have cov(γ, e) = 0. DenotingD = var(γ)
and V = var(y), we have
V = var(Zγ + e) = Zvar(γ)ZT + var(e)
= ZDZT + var(e)
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After assuming normality of the random terms in the model, we have y ∼ N(Xβ, V ).
Denoting the variance components in V by the vector σ2, as described in [159, 167], we can
write the log-likelihood function of β and σ2 as:
l(β, σ2; y) = −1
2
ln |V | − 1
2
(y −Xβ)TV −1(y = Xβ) (A.7)
after removing the additive constant −k
2
ln(2pi). The log-likelihood function of µθ and σ
2
θ
for Equation (4.6) can be written as follows:
l(µθ, σ
2; y) = −1
2
k∑
i=1
ln(σ2θ + σ
2
i
)− 1
2
k∑
k=1
(yi − µθ)2
σ2θ + σ
2
i
(A.8)
Setting partial derivatives with respect to µθ and σ
2
θ equal to zero and solving the
likelihood equations for the two parameter to be estimated, we obtain the mean and variance,
i.e. µˆθ and σˆ
2
θ , of the size effects. Solution for the maximum likelihood (ML) method can
be obtained by iterating between µˆθ and σˆ
2
θ .
However, the maximum-likelihood estimator of σ2θ tend to underestimate the population
heterogeneity in finite samples by failing to account for the loss in degree of freedom that
results from estimating β [159, 167, 168]. The restricted maximum likelihood method is
based on the likelihood of a vector whose components are independent linear combinations
of the observations. The basic idea is to end up with a random vector that contains all
the information on the variance components but no longer contains information of the fixed
effect parameters.
Denoting r = rank(X), r = 1 for meta-analysis random-effects model. Denote K ∈
R(N−r)×n as a matrix of full ranks, and E(Ky) = 0. Since E(Ky) = KXβ and y ∼
N(Xβ, V ), we also have KX = 0 and KY ∼ N(0, KV KT ). For instance, M = I −
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X(XTX)−1XT would be a good example. The log-likelihood function for Ky is given by
l(σ2; y) = −1
2
ln |V | − 1
2
ln |XTV −1X|
− 1
2σ2
(y −Xβˆ)TV −1(y = Xβˆ)
(A.9)
This simplifies to
l(σ2θ ; y) = −
1
2
k∑
i=1
ln(σ2θ + σ
2
i
)− 1
2
ln
k∑
i=1
1
σ2θ + σ
2
i
−1
2
k∑
i=1
(yi − µˆ(ML)θ )2
σ2θ + σ
2
i
(A.10)
The REML estimator of σ2θ is then given by
σˆ2θ =
∑k
i=1w
2
i [(yi − µθ)2 − σ2i ]∑k
i=1w
2
i
+
1∑k
i=1wi
(A.11)
and
wi =
1
σˆ2θ + σ
2
i
µˆθ =
∑k
i=1wiyi∑k
i=1wi
(A.12)
Again, the variance and mean are obtained in the same iterative manner as described
for the regular maximum likelihood estimator.
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Modern biomedical research lies at the crossroads of data gathering, interpretation,
and hypothesis testing. Due to noise, study bias, or too small changes in biological signals
between disease and healthy, individual studies often fail to identify the true phenomenon.
Data integration is the key to obtaining the power needed to pinpoint the biological mech-
anisms of disease states. Given this, we tried to make important contributions in both
horizontal and vertical integration of high-throughput data; the former is meta-analysis of
independent studies, while the latter is the integration of multi-omics data.
For horizontal meta-analysis, we developed two frameworks: DANUBE and the bi-
level meta-analysis. In DANUBE, we pointed out that most pathway analysis approaches
make wrong assumptions of bio-molecular data which leads to non-uniformity of p-values
under the null hypothesis. DANUBE proposed a way to correct the biased p-values before
combining them using the Central Limit Theorem. In the bi-level meta-analysis, we added
another level of meta-analysis to make better use of the available number of samples within
individual studies. Both techniques were validated using thousands of real samples obtained
from independent studies related to three human diseases, Alzheimer’s disease, acute myeloid
leukemia, and type II diabetes mellitus. The frameworks outperformed classical approaches
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to consistently identify pathways that are relevant to the given phenotypes. Via extensive
simulation studies, we also demonstrate that the proposed techniques are sufficiently general
to be applied outside the scope of biomedical research.
For vertical integrative analysis, we integrated transcriptomics, epigenomics, and non-
coding RNA data to identify disease subtypes. Successful subtyping of complex diseases
can lead to identifying biomarkers and targets of new drugs. We developed a perturbation
clustering to accurately subtype patients using high-dimensional gene expression data. The
framework was also extended to combine complementary information available in multi-
omics data, by adapting techniques in network partitioning and cluster ensembles. The
algorithm was validated on thousands of real cancer samples, using mRNA, methylation,
and microRNA data available on Gene Expression Omnibus, the Broad Institute, and the
Cancer Genome Atlas. This simultaneous subtyping approach accurately identifies known
cancer subtypes and predicts the survival of novel subgroups of patients.
We also developed a meta-analysis framework that combines the two orthogonal types
of data integration: horizontal and vertical meta-analysis. Integrative analyses of omics data
often require all data types to be available for each individual patient. This reduces their
practical availability since sample-matched data is relatively rare and difficult or expensive
to obtain. We proposed an orthogonal meta-analysis framework that is able to overcome
the sample-matched data bottleneck, by successfully integrating datasets of different types
generated in independent laboratories from different sets of patients. The proposed frame-
work was validated using 1,471 samples from 15 mRNA and 14 miRNA expression datasets
related to two human cancers, colorectal cancer and pancreatic cancer. The orthogonal ap-
proach reliably identifies signaling pathways that are impacted by the two cancer diseases.
While validated in the context of pathway analysis, the framework can be modified to adapt
to other domains or applications.
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